

Curriculum Vitae: Graham Pawelec

(1st April, 2019)

- Websites:* <http://www.tati-group.de/>
<http://de.linkedin.com/pub/graham-pawelec/7/886/b13>
- E-mail addresses:* graham.pawelec@uni-tuebingen.de
grahampawelec@cantab.net
gpawelec@hsnri.ca
- Education:* University of Cambridge, England: BA (1973); MA (1977); PhD (1982)
- Academic career* “Dr. habil.”, University of Tübingen, Germany, 1987; “Privat Dozent”, University of Tübingen (1991); Professor, University of Tübingen (1997)
- Current positions* Professor of Experimental Immunology, University of Tübingen, Tübingen, Germany
Cancer Solutions Program Member, Health Sciences North Research Institute, Sudbury, ON, Canada
- Honours* Visiting Professor, Nottingham Trent University, UK, 2005 –
Honorary Chair, Manchester University, 2010 –
Member of the Faculty of 1000 Oncology (since 2012)
Fellow of the Gerontological Society of America (elected 2015)
Visiting Professor, King’s College, University of London, 2016 –
- Bibliometrics* Google Scholar: citations, 24648 (since 2014, 11284); h-index, 87 (since 2014, 56);
i10-index, 343 (since 2014, 199); Av. citations per PubMed-listed article, 49.0
- Editor-in-Chief* Cancer Immunology Immunotherapy (Editorial Board member, 1998, Editor-in-Chief, 2003-)
BMC Immunity and Ageing (2019-)
- Deputy Editor* BMC Immunity and Ageing (2004-2018)
BMC J Translational Medicine (2008-),
- Editorial Board Memberships* Mechanisms of Ageing and Development (1996-), Experimental Gerontology (1997-)
Nutrition and Healthy Aging (2011-); Journals of Gerontology Series A (2013-); Age
(2015-), Biogerontology (1999-).
- Society Memberships:* British Society for Immunology, Deutsche Gesellschaft für Gerontologie und Geriatrie,
Deutsche Gesellschaft für Immunologie, European Association for Cancer Research,
Association for Immunotherapy of Cancer, American Association for Cancer Research,
British Association for Research on Ageing, American Association for Clinical Oncology,
Society for the Immunotherapy of Cancer, American Association of Immunologists,
Gerontological Society of America.

Reviewer for Granting Agencies

Deutsche Forschungsgemeinschaft (DFG); Mildred-Scheel-Stiftung; German-Israel Foundation; Danish Council for Independent Research/Medical Sciences; European Research Council; National Institutes of Health; fortune-Programm University of Tübingen; Boehringer Ingelheim Fonds; British Medical Research Council (MRC); British Biotechnology and Biosciences Research Council (BBSRC); The Wellcome Trust (UK); Research into Ageing (UK); SPARC (UK); The National Kidney Research Fund (of Britain); Leukaemia & Lymphoma Research (UK); Dutch Cancer Society; Swiss Cancer Society; Swiss National Research Funds; Israel Science Foundation; Telethon Foundation, Italy; Association for Cancer Research (AIRC), Italy; Fondazione Cariplo, Italy; Austrian Federal Research Ministry (FWF); F.R.S.-FNRS (Belgium); Polish National Centre for Research and Development; EU-Commission (Biomed II, 1996; Marie Curie Fellowship Panel, 1997, 1998; Framework 5, Quality of Life, Generic 7.1, 1999; Mid-term reviewer for project QLG1-1999-00050, 2001; Marie Curie Fellowships 2002, 2003; 6th Framework Consultant on Feasibility of European Cancer Research Networks, 2004; 6th Framework final Call for SME-led STREPs, 2006; 7th FP Health Call on Cell Therapy, 2009-2010

panels); Fondation pour la Recherche Médicale, Paris; National Institutes of Health, USA: NIAID Human Immunology Program, 2015; DFG Collaborative Research Center 1275 review panel, 2016; EU-TransCan2 2015 Call; National Institutes of Health, USA: NIAID Human Immunology Program, 2016; Studienstiftung des deutschen Volkes, 2016.

Other items

EU Framework 5 Expert Advisory Panel for Ageing and Public Health, 1997
Consultant, Unilever Central Research, Sharnbrooke, Bedford (UK), 1999 - 2005
Invivac Advisory Board Member (Solvay Pharmaceuticals, NL), 2004
Member of the Technology Transfer “Task Force”, Tübingen University Medical Faculty, 2006 -
EU 7th FP Expert Consultant for the Workshop ‘Road map for the future of ageing in Europe’, 2007
Sanofi-Pasteur-MSD Member of the Advisory Board on Immunosenescence and Vaccination, 2008-
WHO Initiative for Vaccine Research, Advisory Board member for impact of ageing on vaccination, 2008-
University of Tübingen ERASMUS representative
Scientific Advisory Board Member, Clasado, impact of prebiotics on immunity, 2015
Scientific Advisory Board Member, Pfizer European healthcare landscape in the context of adult vaccines, 2016
Scientific Advisory Board Member, Seqirus, 2019

Supervisor of 32 PhD students (Dr. rer. nat.), 10 MD, PhD students (Dr. med.)

Coordinator of EU project: **1.** Concerted Action on the Molecular Biology of Immunosenescence (EUCAMBIS, BMHI CT94 1209) (1994-1997) – see <http://www.medizin.uni-tuebingen.de/eucambis/home/index.html>
2. Concerted Action on Peptide Sensitization (EUCAPS, BMHI-CT98-3058) (1998-2001) – see <http://www.medizin.uni-tuebingen.de/eucaps/home/>
3. Immunology and Ageing in Europe (ImAginE, QLK6-1999-02031) (2000-2002), Thematic Network – see <http://www.medizin.uni-tuebingen.de/imagine/index.htm>
4. European Searchable Tumour Cell Line Database (ESTDAB, QLRI-CT-2001-01325) (2001-2004), cost-shared RTD project – see <http://www.medizin.uni-tuebingen.de/estdab/>
5. T-Cells in Ageing (T-CIA, QLK6-2001-02283) (2002-2005), cost-shared RTD project – see <http://www.medizin.uni-tuebingen.de/t-cia/>

Member of EU project: **6.** Outcome and Impact of Specific Treatment in European Research on Melanoma (OISTER, QLG1-CT-2002-00668) (2002-2005), 5th FP cost-shared project (member of the steering committee), see <http://www.dkfz.de/oister/OISTERnav.html>
7. Nutritional zinc, oxidative stress and immunosenescence: biochemical, genetic and life style implications for healthy ageing (ZINCAGE, FP6-506850) (2004-2006), 6th FP STREP (member of the steering committee), see <http://www.zincage.org/home.htm>
8. European Network for the identification and validation of Antigens and biomarkers in Cancer and their application in clinical Tumour immunology (ENACT, FP6 503306) (2005-2008), 6th FP STREP (member of the steering committee), see <http://www.enactcancerresearch.org/>
9. Integrating Research into Development and Ageing (LifeSpan, FP6-036894) (2007-2011), 6th FP NoE (responsible for immunity) see <http://www.lifespannetwork.nl/>
10. WhyWeAge (7th FP Coordination and Support Action, # 200970) (2008-2010). Responsible for “immunosenescence and Inflammation Workshop (with C. Franceschi) see www.whyweage.eu
11. Integrated Research on Developmental Determinants of Aging and Longevity (IDEAL, FP7 LIP F2-2011-259679) (2011-2016), see <http://www.ideal-ageing.eu/>

Grants last 10 years:

The role of CD4 T cell immunity to cytomegalovirus in immunosenescence	2008-2010	Pawelec	German Research Foundation, DFG PA361/11
Discrimination between CMV infection and Alzheimer's disease as driving forces for immune senescence	2008-2010	Pawelec, Larbi	Fortüne Foundation, Tübingen Univeristy Klinikum
Relationship between nutritional status and immune function in the elderly population	2008-2011	Pawelec, Alam	German Academic Exchange Program
Berlin longitudinal ageing study II (BASE-II)	2009-2015	Pawelec	German Federal Ministry for Education and Research
Genetic determinants of longevity: role of immunity?	2010-2013	Pawelec	German Research Society, DFG PA361/14
Immune signatures and human longevity	2010-2013	Pawelec, Rubino	German Academic Exchange Program
GerontoShield - Systems biology-driven approach to unravel and revert the mechanisms responsible for poor immune responses in the elderly	2011-2014	Pawelec	German Federal Ministry for Education and Research, 031 5890 A-G
Immune signatures within the tumor and in the peripheral blood as prognostic/predictive biomarkers in breast cancer: ISPEBREAST	2014-2016	Pawelec, Baxevanis	German Federal Ministry for Education and Research, FKZ 01EI1401
An in vitro model for immunomodulation in melanoma	2015-2017	Pawelec	German Research Society, DFG PA361/22

Conferences co-organised since 2006

PIVAC 18, Oslo, Norway, 3-5 October, 2018.
First Summer School on Immuno-Oncology, Nafplion, Greece, 10.-12.6.2018.
Keystone Conference "Aging, Inflammation and Immunity", Austin, TX, 25.2.-1.3.2018.
World Immunotherapy Council 2nd Young Investigators' Day at the SITC annual meeting, National Harbor, MD, 8th November, 2017
PIVAC 17, Loutraki, Corinth, 27-30 September, 2017
 Impact of chronic viral infection in human immunosenescence: a global health problem.
Symposium at the IAGG meeting, San Francisco, 23-27 July, 2017
Aging and Immunity. Satellite Symposium of the AAI Annual Congress, Rockville, MD, 10-11 May, 2017
 Innovative strategies in the immunotherapy of cancer. **Session at the joint Dutch/British Immunology Societies meeting**, Liverpool, UK, 6-9 December, 2016
 Human CMV Infection: Immunosenescence, HIV, and Intervention. **Session at the GSA annual meeting**, New Orleans, LA, 17-20 October, 2016
 Metabolic and Age-Associated Dysregulation of Anti-Cancer Immunity, **Session at SITC 2016**, National Harbor, MD, 9-11 November, 2016
Biology of aging: Paving the way for healthy aging, Montreal, Canada, 19-20 October, 2016
PIVAC 15, Tübingen, 6-8 October, 2015
The challenges of biological research in aging in the 21st century: from cells to clinics, Sherbrooke, Canada, 2-4 November, 2014
PIVAC 14, Rome, 24-26 September, 2014.
 Annual Meeting of the Society for Geriatric Oncology, Copenhagen, October 24, 2013.
PIVAC 13, Amsterdam, 2-4 October, 2013
 SM3 - Aging and the immune system. **Satellite meeting prior to the ICI 2013**, Meliá Milano Hotel, Milan, August 20-21, 2013

Presidential Symposium on “Immune Frailty and Defense against Infections” 20th world Congress of Gerontology & Geriatrics, Seoul, 23-27 June, 2013

4th International CMV and Immunosenescence Workshop, Parma, 25-27 March, 2013

8th European Biogerontology Congress, Beer-Sheva & Dead Sea, 10-13 March, 2013

SIOG Translational Research workshop on Aging and Cancer, Manchester, 25th October, 2012

PIVAC 12, Nottingham, 11-13th September, 2012

Third International Workshop on CMV and Immunosenescence, University Rectorat, Córdoba, 15nd-16th March, 2012

PIVAC 11, Copenhagen, 10-13th October, 2011

Second International Workshop on CMV and Immunosenescence, University Center, Cambridge, 2nd-4th December, 2010.

PIVAC 10, Cambridge, 27-30th September, 2010

Immunosenescence and Inflammation Workshop (WhyWeAge), Bologna, 12,13th February, 2010

First International Workshop on CMV and Immunosenescence, ZMF, Tübingen, 15th-17th December, 2009

PIVAC 9, Sofia, 8-10th October, 2009

Recent Advances in Cancer Immunotherapy, ESCI2/PIVAC8, Athens, 9-11th October, 2008.

Senescence and Cancer: From Cellular Senescence and Cell Death to Cancer and Ageing (SeneCa), EU-SSA, Warsaw, 4-6 October 2007.

Ageing Research in Immunology: the Impact of Genomics (ARIG), EU-SSA, **Satellite Symposium to the ECI**, Paris, 4-5 September, 2006

Publications (*excluding published Abstracts, categorised, oldest first, PubMed-listed*)

1) Original papers

- 1) **Pawelec G**, Bradley BA, Puntis MCA: Is there a significant gene-dose effect in the primed lymphocyte test? *Tissue Antigens* 10:353, 1977
- 2) **Pawelec G**, Brons G: Modification of lymphocyte responsiveness in vitro by lambda-carrageenan compared with colloidal silica and depletion of surface-adherent cells. *Clin Exp Immunol* 31:426, 1978
- 3) **Pawelec G**. Primed lymphocyte testing in pigs: conditions for the generation of primed cells and their response characteristics. *J Immunol Methods* 21:247-59, 1978.
- 4) **Pawelec G**, Davies HffS, Pearson JD, Steele C, Brons G: Stimulation of lymphocyte proliferation by non-lymphoid porcine tissue cells. *Tissue Antigens* 14:367, 1979
- 5) White DJG, Plumb A, **Pawelec G**, Brons G: Cyclosporin A: an immunosuppressive agent preferentially active against proliferating T cells. *Transplantation* 27:55, 1979
- 6) **Pawelec G**, Rehbein A, Alter BJ, Wernet P: Retention of specific proliferative capacity of cloned human T cells alloactivated against HLA-D alleles. *Immunogenetics* 11:527, 1980
- 7) **Pawelec G**, Wernet P: Restimulation properties of human alloreactive cloned T cell lines. Dissection of HLA-D-region alleles in population studies and in family segregation analysis. *Immunogenetics* 11:507, 1980
- 8) **Pawelec G**: The induction of suppressor cells in mixed leucocyte cultures and in mixed leucocyte-non-lymphoid cell cultures. *Immunology* 39:11, 1980
- 9) **Pawelec G**, Kahle P, Müller C, Wernet P. HLA-Dw5 dissected by cloned PLT reagents. *Immunogenetics* 14:549, 1981
- 10) Kahle P, Wernet P, Rehbein A, Kumbier I, **Pawelec G**. Cloning of functional human T lymphocytes by limiting dilution: impact of filler cells and interleukin 2 sources on cloning efficiencies. *Scand J Immunol.* 14:493-502, 1981.

- 11) **Pawelec G**, Rehbein A, Kahle P, Müller C, Wernet P. Restimulation properties of cloned alloactivated lymphocytes: detection of a novel type of HLA-D/DR region determinant and allelic subtypes for HLA-Dw3 using cloned reagents. *Hum Immunol.* 2:315-24, 1981.
- 12) **Pawelec G**, Rehbein A, Müller C, Sonneborn HH, Wernet P. Human T lymphocytes grown in T-cell growth factor: functional attributes in MLC, CML, PLT and allogeneic suppression. *Immunology* 42:529-40, 1981.
- 13) **Pawelec G**, Borowitz A, Krammer P, Wernet P: Constitutive interleukin 2 production by the JURKAT human leukaemic T cell line. *Eur J Immunol* 12:387, 1982
- 14) **Pawelec G**, Shaw S, Wernet P: Analysis of the HLA-linked SB gene system with cloned and uncloned alloreactive T cell lines. *Immunogenetics* 15:187, 1982
- 15) **Pawelec G**, Kahle P, Wernet P: Specificity spectrum and cell surface markers of mono- and multi-functional mixed leukocyte culture-derived T cell clones in man. *Eur J Immunol* 12:607, 1982
- 16) **Pawelec G**, Hadam MR, Ziegler A, Lohmeyer J, Rehbein A, Kumbier I, Wernet P: Long-term culture, cloning and surface markers of mixed leukocyte culture-derived human T lymphocytes with natural killer-like cytotoxicity. *J Immunol* 128:1892, 1982
- 17) **Pawelec G**, Hadam MR, Schneider EM, Wernet P: Clonally restricted natural killer-like cytotoxicity displayed by cloned human T cell lines. *J Immunol* 129:2271, 1982
- 18) **Pawelec G**, Blaurock M, Schneider EM, Shaw S, Wernet P: Alloactivated long-term cultured human T lymphocytes express both HLA-DR and SB antigens but lack lymphocyte stimulation capacity. *Eur J Immunol* 12:967, 1982
- 19) **Pawelec G**, Shaw S, Ziegler A, Müller C, Wernet P: Differential inhibition of HLA-D or SB-directed secondary lymphoproliferative responses with monoclonal antibodies detecting human Ia-like determinants. *J Immunol* 129:1070, 1982
- 20) **Pawelec G**, Shaw S, Schneider M, Blaurock M, Frauer M, Brackertz D, Wernet P. Population studies of HLA-linked SB antigens and their relative importance in primary MLC typing. Analysis of HLA-D homozygous typing cells and normal heterozygous populations. *Hum Immunol.* 5:215-23, 1982.
- 21) **Pawelec G**, Kahle P, Müller C, Rehbein A, Wernet P. Discrete PLT clones detecting HLA-D and new HLA-non-D encoded cell surface determinants. *Tissue Antigens* 19:269-88, 1982.
- 22) **Pawelec G**, Shaw S, Schneider M, Rehbein A, Wernet P: Homogeneity of the HLA-linked SB2 and SB3 specificities demonstrated by cloned alloreactive T cells. *Immunogenetics* 17:179, 1983
- 23) **Pawelec G**, Schneider EM, Rehbein A, Schaa I, Wernet P. Age-related loss of function of alloactivated interleukin 2-propagated human primed lymphocyte typing clones. *Scand J Immunol.* 17:147-53, 1983
- 24) Wernet P, Shaw S, Brautbar C, Westphal E, **Pawelec G**. SB types of HLA-D homozygous typing cells. *Immunogenetics.* 18:547-51, 1983
- 25) **Pawelec G**, Wernet P. Cyclosporin A inhibits interleukin 2-dependent growth of alloactivated cloned human T-lymphocytes. *Int J Immunopharmacol.* 5:315, 1983
- 26) **Pawelec G**, Schneider EM, Wernet P: Cloned human T lymphocytes with lymphostimulatory capacity preferentially activate suppressor cells. *Eur J Immunol* 14:335, 1984
- 27) Schneider EM, **Pawelec G**, Liangru S, Wernet P: A novel type of human T cell clone with highly potent natural killer-like cytotoxicity divorced from large granular lymphocyte morphology. *J Immunol* 133:173, 1984
- 28) **Pawelec G**, Müller C, Rehbein A, Balko I, Schunter F, Wernet P. The new HLA-DRw6- and 8- associated HLA-Dw HAG specificity defined by homozygous typing cell 9W 1802. Analysis with primed lymphocyte typing clones. *Tissue Antigens* 24(5):292-301, 1984
- 29) **Pawelec G**, Wernet P, Rehbein A, Balko I, Schneider EM. Alloproliferative human T cell clones primed and cultured in vitro lose proliferative and gain suppressive activity with age. *Hum Immunol.* 10(2):135-42, 1984
- 30) **Pawelec G**, Schneider EM, Wernet P. Cloned human T lymphocytes with lymphostimulatory capacity preferentially activate suppressor cells. *Eur J Immunol.* 14(4):335-40, 1984
- 31) **Pawelec G**, Wernet P, Rosenlund R, Blaurock M, Schneider EM. Strong lymphoproliferative suppressive function of PLT clones specific for SB-like antigens. *Hum Immunol.* 9(3):145-57, 1984

- 32) Fleischer B, **Pawelec G**, Wernet P: Homozygous typing cell-defined HLA-Dw specificities correlate better than serologically defined HLA-DR specificities with restriction elements for influenza A virus-specific proliferative human T cell clones. *Human Immunology* 14:37, 1985
- 33) **Pawelec G**, Schneider EM, Wernet P: Function of alloproliferative T lymphocyte clones correlates better with their class II recognitive specificity than with their cell surface phenotype. *Eur J Immunol* 15:163, 1985
- 34) **Pawelec G**, Schneider EM, Müller C, Wernet P: HLA-DR-, MB- and novel DC-related determinants restrict purified protein derivative of tuberculin (PPD)-stimulated human T cell proliferation. *Eur J Immunol* 15:12, 1985
- 35) Spring B, Fonatsch C, Müller C, **Pawelec G**, Koempf J, Wernet P, Ziegler A: Refinement of HLA gene mapping with induced B-cell line mutants. *Immunogenetics* 21:277, 1985
- 36) **Pawelec G**, Newman W, Schwulera U, Wernet P. Heterogeneity of human natural killer recognition demonstrated by cloned effector cells and differential blocking of cytotoxicity with monoclonal antibodies. *Cell Immunol.* 92(1):31-40, 1985
- 37) Falcioni F, **Pawelec G**, Brattig N, Schneider EM, Berg P, Wernet P. Functionally distinct human T-lymphocyte clones sharing potent suppressive activity on immunoglobulin secretion. *Immunology* 54(4):685-92, 1985
- 38) Pawelec G, Ziegler A, Wernet P. Dissection of human allostimulatory determinants with cloned T cells: stimulation inhibition by monoclonal antibodies TU22, 34, 35, 36, 37, 39, 43, and 58 against distinct human MHC class II molecules. *Hum Immunol.* 12(3):165-7, 1985
- 39) **Pawelec G**, Schneider EM, Wernet P: Acquisition of suppressive activity and natural killer-like cytotoxicity by human alloproliferative "helper" T cell clones. *J Immunol* 136:402, 1986
- 40) **Pawelec G**, Ehninger G, Schmidt H, Wernet P: HLA-DP matching and graft-versus-host disease in allogeneic bone marrow transplantation. *Transplantation* 42:558, 1986
- 41) Spring B, **Pawelec G**, Ziegler A: Gamma ray-induced mutants as a tool for the production and characterisation of monoclonal antibodies against HLA-alloantigens. *Tissue Antigens* 27(4):201-8, 1986
- 42) Schneider EM, **Pawelec G**, Shi LR, Bühring HJ, Wernet P. Generation of CD4-positive suppressor T cells from mixed lymphocyte cultures in the presence of interleukin 2 receptor antibody TU69. An in vitro model for transplantation tolerance induction. *Transplantation* 44(2):295-302, 1987
- 43) **Pawelec G**, Wernet P. Alloreactive T-lymphocyte clones detecting epitopes uniquely expressed on HLA-D homozygous cells. *Hum Immunol.* 19(4):279-86, 1987
- 44) Tilanus MG, Schreuder GM, **Pawelec G**, Giphart MJ: The HLA-Dw HAG specificity is defined by DR beta cDNA hybridization as a hybrid haplotype carrying DR5 and DRw6 determinants. *Tissue Antigens* 29(3):168-72, 1987
- 45) **Pawelec G**, Wernet P. HLA-DQw3 dissected by cloned alloreactive T cells. *Immunogenetics* 25(5):356-8, 1987
- 46) **Pawelec G**, Schwulera U, Blaurock M, Busch FW, Rehbein A, Balko I, Wernet P. Relative cloning efficiencies and long-term propagation capacity for T cell clones of highly purified natural interleukin 2 compared to recombinant interleukin 2 in man. *Immunobiology* 174(1):67-75, 1987
- 47) **Pawelec G**, Busch F, Reinhold U, Rehbein A, Balko I, Bühring HJ: Division of human helper T cells into two sets on the basis of the induction of anti-tumor cytotoxicity by phorbol ester and calcium ionophore. *Eur J Immunol* 18:1147, 1988
- 48) **Pawelec G**, Rehbein A, Katrilaka K, Balko I, Busch FW. Prevention of human helper T-cell clone activation by cyclosporin A also blocks secretion of granulocyte/macrophage colony stimulating activity. *Immunopharmacology* 16(3):207-16, 1988
- 49) **Pawelec G**, Fernandez N, Brocker T, Schneider EM, Festenstein H, Wernet P: DY determinants, possibly associated with novel class II molecules, stimulate autoreactive CD4⁺ T cells with suppressive activity. *J Exp Med* 167:243, 1988
- 50) Schneider EM, Saal JG, Mann DL, **Pawelec G**, Schneider J, Schlote W, Wernet P: Lymphoma-specific T- and B-cell responses suggest the involvement of HTLV-1 in virus-non-productive lymphomas of a married couple. *Int J Cancer* 41:548, 1988
- 51) **Pawelec GP**, Bühring HJ, Busch FW, Kalthoff F, Wernet P. Different signals for stimulation of proliferation and lymphokine secretion by a CD3⁺ WT31⁻ cloned cytotoxic lymphocyte. *Cell Immunol* 113(2):329-40, 1988
- 52) **Pawelec G**, Reekers P, Brackertz D, Sansom D, Schneider EM, Blaurock M, Müller C, Rehbein A, Balko I, Wernet P. HLA-DP in rheumatoid arthritis. *Tissue Antigens* 31(2):83-9, 1988
- 53) **Pawelec G**, Ehninger G, Müller C, Blaurock M, Schneider EM, Wernet P. Human leukocyte antigen-DP in leukemia. *Cancer* 61(3):475-7, 1988

- 54) Müller-Eckhardt G, **Pawelec G**, Haas R, Otto C, Kiefel V, Odum N, Müller-Eckhardt C: HLA-DP antigens in patients with chronic autoimmune thrombocytopenia (AITP). *Tissue Antigens* 34:121, 1989
- 55) **Pawelec G**, Schaudt K, Rehbein A, Busch FW: Differential secretion of tumor necrosis factor- α and granulocyte/macrophage colony stimulating factors but not interferon- γ from CD4⁺ compared to CD8⁺ human T cell clones. *Eur J Immunol* 19:197, 1989
- 56) **Pawelec G**, Rehbein A, Schaudt K, Busch FW: IL-4-responsive human helper T cell clones are resistant to growth inhibition by tumor necrosis factor- α . *J Immunol* 143:902, 1989
- 57) Pawelec G, Sayers T, Busch FW. Regulation of normal myelopoiesis and chronic myelogenous leukaemia cell proliferation through a non-cytotoxic mechanism by a gamma/delta T cell clone. *Immunol Lett.* 22(3):199-204, 1989
- 58) Pawelec G, Rehbein A, Schaudt K, Busch FW. Frequencies of HLA-DP alleles in the four major types of leukaemia. *Tissue Antigens* 34(2):138-40, 1989
- 59) **Pawelec G**, Schneider E, Ehninger G, Rehbein A, Schmidt H. Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukaemia after in vivo treatment with interferon-alpha (Wellferon). *Cancer Immunol Immunother.* 29(1):63-6, 1989
- 60) **Pawelec G**, Schmidt H, Rehbein A, Busch F. Antitumor activity in vitro in chronic myelogenous leukaemia revealed after treating peripheral cells with cytosine arabinoside. *Cancer Immunol Immunother.* 29(4):242-6, 1989
- 61) **Pawelec G**, Baumgärtner P, Rehbein A, Reusch U, Schaudt K: Cytokine regulation of the balance between alloindifferent and allospecific suppressor induction in mixed lymphocyte cultures. *Transplantation* 49:615, 1990
- 62) Reinhold U, **Pawelec G**, Fratila A, Leippold S, Bauer R, Kreysel HW: Phenotypic and functional characterisation of tumor infiltrating lymphocytes in mycosis fungoides: continuous growth of CD4⁺ CD45R⁺ T-cell clones with suppressor-inducer activity. *J Invest Dermatol* 94:304, 1990
- 63) **Pawelec G**, Schwulera U, Lenz H, Owsianowski M, Bühring HJ, Schlag H, Schneider E, Schaudt K, Ehninger G. Lymphokine release, suppressor cell generation, cell surface markers, and cytotoxic activity in cancer patients receiving natural interleukin-2. *Mol Biother.* 2:44, 1990
- 64) **Pawelec G**, Schaudt K, Rehbein A, Olive D, Bühring HJ. Human T cell clones with gamma/delta and alpha/beta receptors are differently stimulated by monoclonal antibodies to CD2. *Cell Immunol.* 1990 Sep;129(2):385-93.
- 65) **Pawelec G**, Müller CA, Haen M, Ehninger G. Chronic graft-versus-host disease and HLA-DR4 in the southern German population. *Br J Haematol.* 1990 Jun;75(2):295-6.
- 66) **Pawelec G**, Bühring HJ. Expression of MHC class II epitopes on human T lymphocyte clones. *Cell Immunol.* 1990 May;127(2):520-6.
- 67) **Pawelec G**, Bühring HJ, Müller C. Involvement of CD45 in MHC class II-allospecific cytotoxicity. *Cell Immunol.* 1990 May;127(2):514-9.
- 68) **Pawelec G**. CD4⁺ CD45R⁻ suppressor-inducer T-cell clones: requirements for cellular interaction, proliferation and lymphokines for the induction of suppression in peripheral blood mononuclear cells. *Immunology.* 1990 Apr;69(4):536-41.
- 69) **Pawelec G**, Müller CA, Haen M, Schaudt K, Ehninger G: Lack of association between the frequencies of HLA-DR or HLA-DP alleles and the occurrence of chronic graft versus host disease. *Transplantation*, 51:917,1991
- 70) **Pawelec G**: Modulation of interleukin-2 and interleukin-4-induced cytotoxicities in human helper T-lymphocyte clones by tumor necrosis factor- α . *J Immunol*, 146:572, 1991
- 71) Hamann W, Bruserud O, Patel S, Schmidt H, Ehninger G, **Pawelec G**: Cytotoxic and proliferative functions of T lymphocyte clones derived very shortly after allogeneic bone marrow transplantation. *Bone Marrow Transplantation* 8:113, 1991
- 72) **Pawelec G**, Bühring HJ. Monoclonal antibodies to CD6 preferentially stimulate T-cell clones with gamma/delta rather than alpha/beta antigen receptors. *Hum Immunol.* 1991 Jul;31(3):165-9.
- 73) Kahle P, Saal J, **Pawelec G**. Cytokines in rheumatoid arthritis. *Ann Rheum Dis.* 1991 Jun;50(6):405
- 74) Schaudt K, **Pawelec G**. Computerised transfer and processing of data from experiments measuring cellular proliferation by incorporation of tritiated thymidine. *J Immunol Methods.* 1991 Apr 25;138(2):155-64.

- 75) **Pawelec G.** Conditions for the generation of autoreactive human T cell clones: requirement for lymphokines other than interleukin 2 alone. *Cell Immunol.* 1991 May;134(2):265-75.
- 76) **Pawelec G,** Reutter M, Owsianowsky M, Rehbein A, Busch FW Cytotoxic and noncytotoxic mechanisms involved in the in vitro anti-leukaemia effects of T cell clones established from a chronic myelogenous leukaemia patient during treatment in vivo with interferon alpha. *Cancer Immunol Immunother.* 1991;33(1):54-60.
- 77) **Pawelec G,** Müller C, Haen M, Schaudt K, Ehninger G. Lack of association between the frequencies of HLA-DR or HLA-DP alleles and the occurrence of chronic graft-versus-host disease. *Transplantation.* 1991 Apr;51(4):917-8.
- 78) Bruserud O, Hamann W, Patel S, **Pawelec G.** CD4+ TCR alpha beta+ T-cells developing after allogeneic bone marrow transplantation in patients with chronic myelogenous leukaemia. Dipyridamole inhibits functionally heterogeneous T-cell clones. *Int J Immunopharmacol.* 1991;13(8):1127-35.
- 79) **Pawelec G,** Lenz HJ, Schneider E, Bühring HJ, Rehbein A, Baumgärtner P, Ehninger G. Clinical trial of natural human lymphocyte-derived interleukin 2 in cancer patients: effects on cytokine production and suppressor cell status. *Biotherapy.* 1991;3(4):309-18.
- 80) **Pawelec G,** Jaschonek K, Ehninger G. The anti-fungal agent itraconazole exerts immunosuppressive effects on alloreactivity but not on natural immunity in vitro. *Int J Immunopharmacol.* 1991;13(7):875-9.
- 81) **Pawelec G,** Ehninger G, Rehbein A, Schaudt K, Jaschonek K. Comparison of the immunosuppressive activities of the antimycotic agents itraconazole, fluconazole, ketoconazole and miconazole on human T-cells. *Int J Immunopharmacol.* 1991;13(2-3):299-304.
- 82) Bruserud O, Elsayed S, **Pawelec G:** At least five antigenic epitopes on the streptokinase molecule are recognized by human CD4+ TCR α/β^+ T cells. *Mol Immunol* 29:1097, 1992
- 83) Bruserud O, Hamann W, Patel S, **Pawelec G.** CD4+ TCR alpha beta+ T-cell clones derived shortly after allogeneic bone marrow transplantation: theophyllamine and verapamil inhibit proliferation of functionally heterogeneous T-cells. *Int J Immunopharmacol.* 1992 Jul;14(5):783-9.
- 84) Kahle P, Saal JG, Schaudt K, Zacher J, Fritz P, **Pawelec G:** Analysis of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of the synovial tissue. *Ann Rheum Dis,* 51:731, 1992
- 85) Fernandez N, Kurpisz M, Sachs J, Labeta M, **Pawelec G:** A ligand-epitope in vitro analysis of MHC determinants expressed on B and T lymphocytes. *Immunol* 77:116, 1992
- 86) Kahle P, Saal JG, Schaudt K, Zacher J, Fritz P, **Pawelec G.** Determination of cytokines in synovial fluids: correlation with diagnosis and histomorphological characteristics of synovial tissue. *Ann Rheum Dis.* 1992 Jun;51(6):731-4.
- 87) Friccius H, Pohla H, Adibzadeh M, Siegels-Hübenthal P, Schenk A, **Pawelec G.** The effects of the antifungal azoles itraconazole, fluconazole, ketoconazole and miconazole on cytokine gene expression in human lymphoid cells. *Int J Immunopharmacol.* 1992 Jul;14(5):791-9.
- 88) Busch FW, Kunst A, Flehmig B, Mergenthaler HG, **Pawelec G,** Vallbracht A. Myelopoiesis in vitro is suppressed by hepatitis A virus. *Ann Hematol.* 1992 Jun;64 Suppl:A132-6.
- 89) Bruserud O, Hamann W, Patel S, Ehninger G, **Pawelec G.** IL2- and IL4-dependent proliferation of T-cell clones derived early after allogeneic bone marrow transplantation: studies of patients with chronic myelogenous leukaemia. *Eur J Haematol.* 1992 Apr;48(4):221-7.
- 90) Adibzadeh M, Weder HG, Rehbein A, Schwuléra U, Obermeier J, **Pawelec G.** Activity of liposomal interleukin-2 in vitro. *Mol Biother.* 1992 Mar;4(1):24-8.
- 91) Reuss-Borst MA, **Pawelec G,** Saal JG, Horny HP, Müller CA, Waller HD: Sweet's Syndrome associated with myelodysplasia - possible role of cytokines in the pathogenesis of the disease. *B J Haematol* 84:356, 1993
- 92) Friccius H, Siegels-Hübenthal P, Rehbein A, Schlotz E, **Pawelec G:** Induction of hyporesponsiveness in human lymphocytes-T despite their expression of both the coreceptor CD28 and its ligand B7. *Cell Immunol* 151:283, 1993
- 93) Bruserud O, Hamann W, Patel S, Ehninger G, Schmidt H, **Pawelec G.** IFN-gamma and TNF-alpha secretion by CD4+ and CD8+ TCR alpha beta + T-cell clones derived early after allogeneic bone marrow transplantation. *Eur J Haematol.* 1993 Aug;51(2):73-9.
- 94) Schaudt K, Müller C, Einsele H, Schmidt H, Schlotz E, Rehbein A, **Pawelec G.** Relationship between donor alloreactivity and acute GVHD in CML patients transplanted in the first chronic phase with HLA identical sibling marrow. *Bone Marrow Transplant.* 1993 Jul;12(1):93-5.

- 95) Bruserud O, Ehninger G, Hamann W, **Pawelec G**. Secretion of IL-2, IL-3, IL-4, IL-6 and GM-CSF by CD4+ and CD8+ TCR alpha beta+ T-cell clones derived early after allogeneic bone marrow transplantation. *Scand J Immunol*. 1993 Jul;38(1):65-74.
- 96) Wilson KM, Labeta MO, **Pawelec G**, Fernandez N. Cell-surface expression of human histocompatibility leucocyte antigen (HLA) class II-associated invariant chain (CD74) does not always correlate with cell-surface expression of HLA class II molecules. *Immunology*. 1993 Jun;79(2):331-5.
- 97) Bruserud O, **Pawelec G**. Effects of dipyridamole and R-verapamil on in vitro proliferation of blast cells from patients with acute myelogenous leukaemia. *Leuk Res*. 1993 Jun;17(6):507-13.
- 98) Obata F, Tsunoda M, Ito K, Ito I, Kaneko T, **Pawelec G**, Kashiwagi N. A single universal primer for the T-cell receptor (TCR) variable genes enables enzymatic amplification and direct sequencing of TCR beta cDNA of various T-cell clones. *Hum Immunol*. 1993 Mar;36(3):163-7.
- 99) Bruserud O, **Pawelec G**. Cyclosporine A and FK506 show similar immunosuppressive effects on long-term in vitro T-cell proliferation. *Int J Immunopharmacol*. 1993 Feb;15(2):93-7.
- 100) Obata F, Tsunoda M, Kaneko T, Ito K, Ito I, Masewicz S, Mickelson EM, Ollier WE, **Pawelec G**, Cella M, et al. Human T-cell receptor TCRAV, TCRBV, and TCRAJ sequences newly found in T-cell clones reactive with allogeneic HLA class II antigens. *Immunogenetics*. 1993;38(1):67-70.
- 101) Adibzadeh M, Bühring HJ, Daikeler T, Siegels-Hübenthal P, Owsianowsky M, Schenk A, Rehbein A, Schaudt K, Schlotz E, Pohla H, **Pawelec G**: Extrathymic development and function of human T-lymphocytes from bone marrow cells in vitro. *Cell Immunol* 154:25, 1994
- 102) Adibzadeh M, Friccius H, Bornhak S, Max H, Hambrecht A, Sansom D, Kalbacher H, Schenk A, Pohla H, **Pawelec G**: Role of three quantitatively dominant endogenous peptides from HLA-DRB1*0401 molecules in class II-specific alloreactivity. *Transplant Immunol* 2:293, 1994
- 103) **Pawelec G**, Kalbacher H, Pohla H, Boshell M, Max H, Friccius H, Adibzadeh M, Hambrecht A, Sansom D. Requirements for stimulation or anergy induction in alloreactive human T cell clones. *Cell Immunol*. 1994 Oct 1;158(1):241-52
- 104) **Pawelec G**, Friccius H, Boshell M, Rehbein A, Schlotz E, Pohla H, Schaudt K, Sansom D: Human $\gamma\delta$ T cells are resistant to anergy induction but not clonal deletion in vitro. *Cell Immunol* 162:8, 1995
- 105) Bruserud O, Gjertsen BT, Brustugun OT, Bassoe CF, Nesthus I, Akselsen PE, Bühring HJ, **Pawelec G**: Effects of Interleukin 10 on blast cells derived from patients with acute myelogenous leukemia. *Leukemia* 9:1910, 1995
- 106) Adibzadeh M, Pohla H, Rehbein A, **Pawelec G**: Long-term culture of monoclonal human T lymphocytes: models for immunosenescence? *Mech Ageing Dev* 83:171, 1995
- 107) **Pawelec G**, Da Silva P, Max H, Kalbacher H, Schmidt H, Bruserud O, Zügel U, Baier W, Rehbein A, Pohla H. Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha. *Leuk Lymphoma*. 1995 Aug;18(5-6):471-8.
- 108) **Pawelec G**, Pohla H, Schlotz E, Rehbein A, Schaudt K, Hambrecht A, Friccius H. Interleukin 10 is a human T cell growth factor in vitro. *Cytokine*. 1995 May;7(4):355-63.
- 109) **Pawelec G**, Friccius H, Boshell M, Siegels-Hübenthal P, Rehbein A, Schlotz E, Pohla H, Schaudt K, Sansom D. Human gamma delta T cells are resistant to induction of anergy but not to induction of cell death in vitro. *Cell Immunol*. 1995 Apr 15;162(1):8-15.
- 110) Bruserud O, Hamann W, **Pawelec G**. Secretion of leukaemia inhibitory factor after allogeneic bone marrow transplantation: a study of CD4+ and CD8+ TCR alpha beta+ T-cell clones derived from four leukaemia patients. *Eur J Haematol*. 1995 Feb;54(2):106-10.
- 111) Bruserud O, Nesthus I, Bühring HJ, **Pawelec G**. Cytokine modulation of interleukin 1 and tumour necrosis factor-alpha secretion from acute myelogenous leukaemia blast cells in vitro. *Leuk Res*. 1995 Jan;19(1):15-22.
- 112) Bruserud O, Nesthus I, **Pawelec G**. In vitro effect of r-verapamil on acute myelogenous leukemia blast cells: studies of cytokine secretion and cytokine-dependent blast proliferation. *Cancer Chemother Pharmacol*. 1995;37(1-2):70-8.
- 113) **Pawelec G**, Max H, Halder T, Bruserud O, Merl A, Da Silva P, Kalbacher H: BCR/ABL leukemia oncogene fusion peptides selectively bind to certain HLA-DR alleles and can be recognized by T cells found at low frequency in the repertoire of normal donors. *Blood* 88:2118, 1996

- 114) **Pawelec G**, Rehbein A, Schlotz E, Friccius H, Pohla H: Cytokine modulation of Th1/Th2 phenotype differentiation in directly alloresponsive CD4⁺ human T cells. *Transplantation* 62:1095, 1996
- 115) **Pawelec G**, Sansom D, Rehbein A, Adibzadeh M, Beckman I: Decreased proliferative capacity and increased susceptibility to activation-induced cell death in late-passage human CD4⁺ TCR2⁺ cultured T cell clones. *Exp Gerontol.* 31:655, 1996
- 116) **Pawelec G**, Rehbein A, Schlotz E, da Silva P. Cellular immune responses to autologous chronic myelogenous leukaemia cells in vitro. *Cancer Immunol Immunother.* 1996 Mar;42(3):193-9.
- 117) Adibzadeh M, Mariani E, Bartoloni C, Beckman I, Ligthart G, Remarque E, Shall S, Solana R, Taylor GM, Barnett Y, **Pawelec G**: Lifespans of T lymphocytes. *Mech Ageing Dev* 91:145, 1996
- 118) **Pawelec G**, Hambrecht A, Rehbein A, Adibzadeh M: Interleukin 10 protects activated human T lymphocytes against growth factor withdrawal-induced cell death but only anti-fas antibody can prevent activation-induced cell death. *Cytokine* 8:877, 1996
- 119) Bruserud O, **Pawelec G**. Human T lymphocyte activation in the presence of acute myelogenous leukaemia blasts; studies of normal polyclonal T cells and T lymphocyte clones derived early after allogenic bone marrow transplantation. *Cancer Immunol Immunother.* 1996 Mar;42(3):133-40.
- 120) Bruserud O, Mentzoni L, Bühring HJ, **Pawelec G**. Effects of hematopoietic growth factors on interleukin 6 secretion by blast cells derived from acute myelogenous leukemia patients. *Acta Haematol.* 1996;96(3):155-61.
- 121) Bruserud O, **Pawelec G**. Interleukin-13 secretion by normal and posttransplant T lymphocytes; in vitro studies of cellular immune responses in the presence of acute leukaemia blast cells. *Cancer Immunol Immunother.* 1997 Oct;45(1):45-52.
- 122) Halder T, **Pawelec G**, Kirkin AF, Zeuthen J, Meyer HE, Kun L, Kalbacher H. Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3. *Cancer Res.* 1997 Aug 1;57(15):3238-44.
- 123) Li K, Heinzl S, Halder T, Zeuthen J, Müller C, Adibzadeh M, Kalbacher H, **Pawelec G**: Autocrine proliferative responses to native melanoma cells by MHC class II-restricted T cells sensitized in vitro to synthetic peptides of gp100 and Annexin II. *Cancer Immunol Immunother* 47: 32, 1998
- 124) **Pawelec G**, Müller R, Rehbein A, Hähnel, K, Ziegler B: Extrathymic T cell differentiation in vitro from human CD34⁺ stem cells. *J Leuk Biol* 64:733, 1998
- 125) **Pawelec G**, Müller R, Rehbein A, Hähnel, K, Ziegler B: Finite lifespans of T cell clones derived from CD34⁺ human haematopoietic stem cells in vitro. *Exp Gerontol* 34:69, 1999
- 126) Potestio M, **Pawelec G**, DiLorenzo G, Candore G, D'Anna C, Gervasi F, Lio D, Tranchida G, Caruso C, Romano GC: Age-related changes in the expression of CD95 (APO1/FAS) on blood lymphocytes. *Exp Gerontol* 34:659, 1999
- 127) **Pawelec G**, Schlotz E, Rehbein A. IFN-alpha regulates IL 10 production by CML cells in vitro. *Cancer Immunol Immunother.* 1999 Nov;48(8):430-4.
- 128) Halder TM, Blüggel M, Heinzl S, **Pawelec G**, Meyer HE, Kalbacher H: Defensins are Dominant HLA-DR-Associated Self Peptides from CD34-Peripheral Blood Mononuclear Cells of Different Tumor Patients (Plasmacytoma, Chronic Myeloid Leukemia). *Blood* 95:2890, 2000
- 129) **Pawelec G**, Mariani E, Bradley B, Solana R. Longevity in vitro of human CD4⁺ T helper cell clones derived from young donors and elderly donors, or from progenitor cells: age-associated differences in cell surface molecule expression and cytokine secretion. *Biogerontology.* 2000;1(3):247-54.
- 130) Engel A, Adibzadeh M, **Pawelec G**. Identification of differentially expressed genes in young and senescent T cells. *Methods Mol Med.* 2000;38:97-115. doi: 10.1385/1-59259-070-5:97.
- 131) Heinzl S, Rea D, Offringa R, **Pawelec G**: Human CD4⁺ T cells sensitized to Annexin II (208-223) recognize melanoma cells over-expressing the Annexin II protein. *Cancer Immunol Immunother* 49:671, 2001
- 132) Müller L, Provenzani C, Faul C, **Pawelec G**: Recognition of chronic myelogenous leukaemia cells by autologous T lymphocytes primed in vitro against the patient's dendritic cells. *B J Haematol* 112: 740, 2001
- 133) Hyland P, Barnett C, **Pawelec G**, Barnett Y: Increased levels of oxidative DNA damage and alterations in the levels of the mitotic inhibitors p16^{INK4a/CDKN2a}, p21^{WAF1/CIP1/SDI1}, p27^{KIP1} leads to T cell replicative senescence *in vitro*. *Mech Ageing Dev* 122:1151, 2001

- 134) Sotiriadou R, Perez SA, Gritzapis AD, Sotiropoulou PA, Echner H, Heinzel S, Mamalaki A, **Pawelec G**, Voelter W, Baxevanis CN, Papamichail M. Peptide HER2(776-788) represents a naturally processed broad MHC class II-restricted T cell epitope. *Br J Cancer*. 2001 Nov 16;85(10):1527-34.
- 135) Müller L, Provenzani C, **Pawelec G**: Generation of CML-specific T cells in cytokine-modified autologous mixed lymphocyte/tumour cell cultures. *J Immunother* 24:482, 2001
- 136) Ross OA, Hyland P, Curran MD, McIlhatton BP, Wikby A, Johansson B, Tompa A, **Pawelec G**, Barnett CR, Middleton D, Barnett YA: Mitochondrial DNA damage in lymphocytes: a role in immunosenescence? *Exp Gerontol* 37:329, 2002
- 137) **Pawelec G**, Barnett Y, Mariani E, Solana R: Human CD4+ T cell clone longevity in tissue culture: lack of influence of donor age or cell origin. *Exp Gerontol* 37:265, 2002
- 138) Knights AJ, Zaniou A, Rees RC, **Pawelec G**, Müller L: Prediction of an HLA-DR-binding peptide derived from Wilms' tumour1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol. *Cancer Immunol Immunother* 51:271, 2002
- 139) Wagner W, Ouyang Q, **Pawelec G**: Peptides spanning the fusion region of Abl/Bcr are immunogenic and sensitize CD8(+) T lymphocytes to recognize native chronic myelogenous leukemia. *Leukemia* 16:2341, 2002
- 140) Perez SA, Sotiropoulou PA, Sotiriadou NN, Mamalaki A, Gritzapis AD, Echner H, Voelter W, Pawelec G, Papamichail M, Baxevanis CN. HER-2/neu-derived peptide 884-899 is expressed by human breast, colorectal and pancreatic adenocarcinomas and is recognized by in-vitro-induced specific CD4(+) T cell clones. *Cancer Immunol Immunother*. 2002 Jan;50(11):615-24. Epub 2001 Nov 23.
- 141) Knights A, Müller L, **Pawelec G**: Immunogenicity of WT-1 peptides. *Cancer Immunol Immunother* 51:349, 2002
- 142) Müller L, Knights A, **Pawelec G**: Synthetic peptides derived from the Wilms' tumor 1 protein sensitize human T lymphocytes to recognize chronic myelogenous leukemia cells. *Hematol J* 4:57-66, 2003
- 143) Wagner W, Ouyang Q, **Pawelec G**: The abl/bcr gene product as a novel leukemia-specific antigen: peptides spanning the fusion region of abl/bcr can be recognized by both CD4(+) and CD8(+) T lymphocytes. *Cancer Immunol Immunother*. 52:89, 2003
- 144) Ouyang Q, Wagner WM, Walter S, Müller CA, Wikby A, Aubert G, Klatt T, Stevanovic S, Dodi T, **Pawelec G**: The age-related increase in CD8+ T cells carrying receptors for an immunodominant Epstein-Barr virus (EBV) epitope is counterbalanced by decreased antigen-specific responsiveness. *Mech Ageing Dev* 124: 477, 2003
- 145) Ouyang Q, Wagner W, Wikby A, Walter S, Aubert G, Dodi T, Travers P, **Pawelec G**: Large numbers of dysfunctional CD8+ T lymphocytes bearing receptors for a single dominant CMV epitope in the very old. *J Clin Immunol* 23:247-257, 2003
- 146) Ouyang Q, Wagner WM, Voehringer D, Wikby A, Klatt T, Walter S, Müller CA, Pircher H, **Pawelec G**: Age-associated accumulation of CMV-specific CD8+ T cells expressing the inhibitory killer cell lectin-like receptor G1 (KLRG1). *Exp Gerontol* 38:911-920, 2003
- 147) Flad T, Schiestel T, Brunner H, Tolson J, Ouyang Q, **Pawelec G**, Mueller GA, Mueller CA, Tovar GE, Beck H. Development of an MHC-class I peptide selection assay combining nanoparticle technology and matrix-assisted laser desorption/ionisation mass spectrometry. *J Immunol Methods*. 283:205-213, 2003
- 148) Neri S, Cattini L, Facchini A, **Pawelec G**, Mariani E: Microsatellite instability in in vitro ageing of T lymphocyte clones. *Exp Gerontol* 39:499-505, 2004
- 149) Krichevsky S, **Pawelec G**, Gural A, Effros RB, Globerson A, Ben Yehuda D, Ben Yehuda A: Age-related microsatellite instability in T cells from healthy individuals. *Exp Gerontol* 39:507-515, 2004
- 150) Duggan O, Hyland P, Annett K, Freeburn R, Barnett C, **Pawelec G**, Barnett Y: Effects of a reduced oxygen tension culture system on human T cell clones as a function of in vitro age. *Exp Gerontol* 39:525-530, 2004
- 151) Della Valle NS, Bárcia RN, **Pawelec G**, McLeod JD: Activation marker expression and apoptotic susceptibility of T cell clones derived from CD34+, young and SENIEUR donors. *Exp Gerontol* 39:531-538, 2004
- 152) Ouyang Q, Wagner WM, Zheng W, Wikby A, Remarque EJ, **Pawelec G**: Dysfunctional CMV-specific CD8+ T cells accumulate in the elderly. *Exp Gerontol* 39:607-613, 2004
- 153) Schmolz M, Hurst TL, Bailey DM, Powell JR, Forsey RJ, Thompson JM, Williams C, **Pawelec G**: Validation of a new highly standardised, lab-independent whole-blood leukocyte function assay for clinical trials (ILCS®). *Exp Gerontol* 39:667-671, 2004

- 154) Rodriguez T, Mendez R, Roberts CH, Ruiz-Cabello F, Dodi IA, Nevot MA, Paco L, Maleno I, Marsh SG, **Pawelec G**, Garrido F. High frequency of homozygosity of the HLA region in melanoma cell lines reveals a pattern compatible with extensive loss of heterozygosity. *Cancer Immunol Immunother.* 54: 141-148, 2005
- 155) Klatt T, Ouyang Q, Flad T, Koetter I, Buhring HJ, Kalbacher H, Pawelec G, Muller CA. Expansion of peripheral CD8+ CD28- T cells in response to Epstein-Barr virus in patients with rheumatoid arthritis. *J Rheumatol.* 32: 239-251, 2005
- 156) Wikby A, Ferguson F, Forsey R, Thompson J, Strindhall J, Löfgren S, Nilsson B-O, Ernerudh J, **Pawelec G**, Johansson B: An immune risk phenotype, cognitive impairment and survival in very late life: The impact of allostatic load in Swedish Octo- and Nonagenarian humans. *J Gerontol B* 60: 556-565, 2005
- 157) Walter S, Boley G, Bühring H-J, Koch S, Wernet D, Zippelius A, **Pawelec G**, Romero P, Stevanović S, Rammensee H-G, Gouttefangeas C: High frequencies of functionally impaired cytokeratin 18-specific CD8⁺ T cells in healthy HLA-A2⁺ donors. *Eur J Immunol* 35: 2876-2885, 2005.
- 158) Annett K, Duggan O, Freeburn R, Hyland P, **Pawelec G**, Barnett Y. An investigation of DNA mismatch repair capacity under normal culture conditions and under conditions of supra-physiological challenge in human CD4⁺T cell clones from donors of different ages. *Exp Gerontol.* 40:976-981, 2005
- 159) Reker-Hadrup S, Strindhall J, Køllgaard T, Seremet T, Johansson B, **Pawelec G**, thor Straten P, Wikby A. Longitudinal studies of clonally expanded CD8 T cells reveal a repertoire shrinkage predicting mortality and an increased number of dysfunctional CMV specific T cells in the very elderly. *J Immunol* 176:2645-2653, 2006
- 160) **Pawelec G**, Marsh S. ESTDAB: a collection of immunologically-characterised melanoma cell lines and searchable databank. *Cancer Immunol Immunother* 55:623-627. Epub 2006 Jan 19.
- 161) Trougakos IP, **Pawelec G**, Tzavelas C, Ntouroupi T, Gonos ES. Clusterin/Apolipoprotein J up-regulation after zinc exposure, replicative senescence or differentiation of human haematopoietic cells. *Biogerontology.* 2006 Oct-Dec;7(5-6):375-9
- 162) Knights A, Weinzierl A, Flad T, Guinn B, Müller L, Mufti G, Stevanovic S, **Pawelec G**: A novel MHC-associated Proteinase 3 peptide isolated from primary CML cells further supports the significance of this antigen for immunotherapy of myeloid leukaemias. *Leukemia* 20:1067-1072, 2006.
- 163) Wikby A, Nilsson BO, Forsey R, Thompson J, Strindhall J, Lofgren S, Ernerudh J, **Pawelec G**, Ferguson F, Johansson B. The immune risk phenotype is associated with IL-6 in the terminal decline stage: Findings from the Swedish NONA immune longitudinal study of very late life functioning. *Mech Ageing Dev.* 127:695-704, 2006
- 164) Mazzatti DJ, White A, Forsey RJ, Powell JR, **Pawelec G**: Gene expression changes in long-term culture of T-cell clones: Genomic effects of chronic antigenic stress in ageing and immunosenescence. *Aging Cell* 6:155-163, 2007
- 165) Neri S, **Pawelec G**, Facchini A, Mariani E: Microsatellite Instability and compromised Mismatch Repair gene expression during in vitro passaging of monoclonal human T lymphocytes. *Rej Res* 10:145-56, 2007
- 166) Nikolova PN, **Pawelec G**, Mihailova SM, Ivanova MI, Myhailova AP, Baltadjieva DN, Marinova DI, Ivanova SS, Naumova EJ. Association of cytokine gene polymorphisms with malignant melanoma in the Caucasian population. *Cancer Immunol Immunother.* 56:371-379, 2007
- 167) Rodriguez T, Mendez R, Del Campo A, Aptsiauri N, Martin J, Orozco G, **Pawelec G**, Schadendorf D, Ruiz-Cabello F, Garrido F. Patterns of constitutive and IFN-gamma inducible expression of HLA class II molecules in human melanoma cell lines. *Immunogenetics* 59: 123-133, 2007
- 168) Colonna-Romano G, Akbar AN, Aquino A, Bulati M, Candore G, Lio D, Ammatuna P, Fletcher JM, Caruso C, **Pawelec G**. Impact of CMV and EBV seropositivity on CD8 T lymphocytes in an old population from West-Sicily. *Exp Gerontol.* 42: 995-1002, 2007
- 169) Strindhall J, Nilsson BO, Lofgren S, Ernerudh J, **Pawelec G**, Johansson B, Wikby A. No Immune Risk Profile among individuals who reach 100 years of age: findings from the Swedish NONA immune longitudinal study. *Exp Gerontol.* 42: 753-761, 2007
- 170) Larbi A, Kempf J, **Pawelec G**. Oxidative stress modulation and T cell activation. *Exp Gerontol.* 42: 852-858, 2007
- 171) Mathieu MG, Knights AJ, **Pawelec G**, Riley CL, Wernet D, Lemonnier FA, Straten PT, Mueller L, Rees RC, McArdle SE. HAGE, a cancer/testis antigen with potential for melanoma immunotherapy: identification of several MHC class I/II HAGE-derived immunogenic peptides. *Cancer Immunol Immunother.* 56: 1885-1895, 2007

- 172) Mazzatti DJ, **Pawelec G**, Longdin R, Powell JR, Forsey RJ. SELDI-TOF-MS ProteinChip array profiling of T-cell clones propagated in long-term culture identifies human profilin-1 as a potential bio-marker of immunosenescence. *Proteome Sci.* Jun 5;5:7, 2007
- 173) Britten CM, Gouttefangeas C, Welters MJ, Pawelec G, Koch S, Ottensmeier C, Mander A, Walter S, Paschen A, Muller-Berghaus J, Haas I, Mackensen A, Kollgaard T, Thor Straten P, Schmitt M, Giannopoulos K, Maier R, Veelken H, Bertinetti C, Konur A, Huber C, Stevanovic S, Wolfel T, van der Burg SH. The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8(+) T lymphocytes by structural and functional assays. *Cancer Immunol Immunother.* 57: 289-302, 2008
- 174) Méndez R, Rodríguez T, Del Campo A, Monge E, Maleno I, Aptsiauri N, Jiménez P, Pedrinaci S, **Pawelec G**, Ruiz-Cabello F, Garrido F. Characterization of HLA class I altered phenotypes in a panel of human melanoma cell lines. *Cancer Immunol Immunother.* 57: 719-729, 2008
- 175) Neri S, **Pawelec G**, Facchini A, Ferrari C, Mariani E. Altered Expression of Mismatch Repair Proteins Associated with Acquisition of Microsatellite Instability in a Clonal Model of Human T Lymphocyte Aging. *Rejuvenation Res.* 11: 565-572, 2008.
- 176) Koch S, Larbi A, Derhovanessian E, Ozcelik D, Naumova E, **Pawelec G**. Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old people. *Immun Ageing;*5:6, 2008.
- 177) Kuttruff S, Koch S, Kelp A, **Pawelec G**, Rammensee H-G, Steinle A. NKp80 defines and stimulates a reactive subset of CD8 T cells. *Blood* 113:358-369, 2009.
- 178) Larbi A, **Pawelec G**, Witkowski J, Schipper H, Derhovanessian E, Fülöp T. Dramatic shifts in circulating CD4 but not CD8 T cell subsets in mild Alzheimer's disease. *J Alzheimer's Disease* 17:91-103, 2009
- 179) Casado JG, Delarosa O, **Pawelec G**, Peralbo E, Duran E, Barahona F, Solana R, Tarazona R. Correlation of effector function with phenotype and cell division after in vitro differentiation of naive MART-1-specific CD8+ T cells. *Int Immunol.* 21:53-62, 2009.
- 180) Skopeliti M, Iconomidou VA, Derhovanessian E, **Pawelec G**, Voelter W, Kalbacher H, Hamodrakas SJ, Tsitsilonis OE. Prothymosin alpha immunoactive carboxyl-terminal peptide TTKQKTDEDD stimulates lymphocyte reactions, induces dendritic cell maturation and adopts a beta-sheet conformation in a sequence-specific manner. *Mol Immunol.* 46:784-792, 2009
- 181) Robinson J, Roberts CH, Dodi IA, Madrigal JA, **Pawelec G**, Wedel L, Marsh SG. The European searchable tumour line database. *Cancer Immunol Immunother.* 58:1501-1506, 2009
- 182) Derhovanessian E, Adams V, Hähnel K, Groeger A, Pandha H, Ward S, **Pawelec G**. Pre-treatment frequency of circulating IL-17⁺CD4⁺ T-cells, but not Tregs, correlates with clinical response to whole-cell vaccination in prostate cancer patients. *Int J Cancer* 125:1372-1379, 2009
- 183) Casado JG, **Pawelec G**, Morgado S, Sanchez-Correa B, Delgado E, Gayoso I, Duran E, Solana R, Tarazona R. Expression of adhesion molecules and ligands for activating and costimulatory receptors involved in cell-mediated cytotoxicity in a large panel of human melanoma cell lines. *Cancer Immunol Immunother.* 58:1517-1526, 2009.
- 184) Weide B, Pascolo S, Scheel B, Derhovanessian E, Pflugfelder A, Eigentler TK, **Pawelec G**, Hoerr I, Rammensee HG, Garbe C. Direct injection of protamine-protected mRNA: results of a phase 1/2 vaccination trial in metastatic melanoma patients. *J Immunother.* 32:498-507, 2009.
- 185) Attig S, Hennenlotter J, **Pawelec G**, Klein G, Koch S, Pircher H, Feyerabend S, Wernet D, Stenzl A, Rammensee HG, Gouttefangeas C. Simultaneous infiltration of polyfunctional effector and suppressor T cells into renal cell carcinomas. *Cancer Res* 69:8412-8419, 2009.
- 186) Larbi A, Cabreiro F, Zelba H, Marthandan S, Combet E, Friguet B, Petropoulos I, Barnett Y, **Pawelec G**. Reduced oxygen tension results in reduced human T cell proliferation and increased intracellular oxidative damage and susceptibility to apoptosis upon activation. *Free Radic Biol Med.* 48:26, 2010.
- 187) Larbi A, Zelba H, Goldeck D, **Pawelec G**. Induction of HIF-1 α and the glycolytic pathway alters apoptotic and differentiation profiles of activated human T cells. *J. Leuk. Biol.* 87:265, 2010.
- 188) Uddin M, Aiello AE, Wildman DE, Koenen KC, **Pawelec G**, de los Santos R, Goldmann E, Galea S. Epigenetic and immune function profiles associated with post-traumatic stress disorder. *PNAS* 107:9470-9475, 2010.

- 189) Kamphausen E, Kellert C, Abbas T, Akkad N, Tenzer S, **Pawelec G**, Schild H, van Endert P, Seliger B. Distinct molecular mechanisms leading to deficient expression of ER-resident aminopeptidases in melanoma. *Cancer Immunol Immunother.* 59:1273-1284, 2010
- 190) Weide B, Derhovanessian E, Pflugfelder A, Eigentler TK, Radny P, Zelba H, Pföhler C, **Pawelec G**, Garbe C. High response rate and prolonged survival after intratumoral treatment with interleukin-2 – results of a phase II DeCOG-study in 51 metastasized melanoma patients. *Cancer* 116: 4139-4146, 2010.
- 191) Derhovanessian E, Maier AB, Beck R, Jahn G, Hähnel K, Slagboom PE, De Craen AJM, Westendorp RGJ, **Pawelec G**. Hallmark features of immunosenescence are absent in familial longevity. *J Immunol* 185(8):4618-4624, 2010.
- 192) Respa A, Bukur J, Ferrone S, **Pawelec G**, Zhao Y, Wang E, Marincola FM, Seliger B. Association of IFN-gamma signal transduction defects with impaired HLA class I antigen processing in melanoma cell lines. *Clin Cancer Res* 17:2668-2678, 2011.
- 193) Simanek AM, Dowd JB, **Pawelec G**, Melzer D, Dutta A, Aiello A. Seropositivity to Cytomegalovirus, Inflammation, All-Cause and Cardiovascular Disease-Related Mortality in the United States. *PLoS ONE* 6(2): e16103, doi:10.1371/journal.pone.0016103, 2011
- 194) Mortensen LH, Maier AB, Slagboom PE, **Pawelec G**, Derhovanessian E, Petersen I, Jahn G, Westendorp RG, Christensen K. Early-life environment influencing susceptibility to cytomegalovirus infection: evidence from the Leiden Longevity Study and the Longitudinal Study of Aging Danish Twins. *Epidemiol Infect.* 2012 May;140(5):835-41.
- 195) Derhovanessian E, Maier AB, Hähnel K, Beck R, de Craen AJ, Slagboom EP, Westendorp RG, **Pawelec G**. Infection with cytomegalovirus but not herpes simplex virus induces the accumulation of late differentiated CD4+ and CD8+ T-cells in humans. *J Gen Virol.* 2011 Dec;92(Pt 12):2746-56. Epub 2011 Aug 3.
- 196) Pellicanò M, Larbi A, Goldeck D, Colonna-Romano G, Buffa S, Bulati M, Rubino G, Iemolo F, Candore G, Caruso C, Derhovanessian E, **Pawelec G**. Immune profiling of Alzheimer patients. *J Neuroimmunol.* 2012 Jan 18;242(1-2):52-9. Epub 2011 Dec 6.
- 197) Alam I, Larbi A, **Pawelec G**, Paracha PI. Relationship between anthropometric variables and nutrient intake in apparently healthy male elderly individuals: a study from Pakistan. *Nutr J.* 2011 Oct 12;10:111.
- 198) Khalil A, Berrougui H, **Pawelec G**, Fulop T. Impairment of the ABCA1 and SR-BI-mediated cholesterol efflux pathways and HDL anti-inflammatory activity in Alzheimer's disease. *Mech Ageing Dev.* 2012 Jan;133(1):20-9. Epub 2011 Dec 9.
- 199) Alam I, Goldeck D, Larbi A, **Pawelec G**. Flow cytometric lymphocyte subset analysis using material from frozen whole blood. *J Immunoassay Immunochem.* 2012 Apr;33(2):128-39.
- 200) Derhovanessian E, Maier AB, Hähnel K, Zelba H, de Craen AJ, Roelofs H, Slagboom EP, Westendorp RG, **Pawelec G**. Lower proportion of naïve peripheral CD8+ T cells and an unopposed pro-inflammatory response to human Cytomegalovirus proteins in vitro are associated with longer survival in very elderly people. *Age (Dordr).* 2013 Aug;35(4):1387-99. doi: 10.1007/s11357-012-9425-7. Epub 2012 Jun 4.
- 201) Weide B, Zelba H, Derhovanessian E, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries IJ, Sucker A, Schadendorf D, Büttner P, Garbe C, **Pawelec G**. Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis. *J Clin Oncol.* 2012 May 20;30(15):1835-41. Epub 2012 Apr 23.
- 202) Shipp C, Derhovanessian E, **Pawelec G**. Effect of culture at low oxygen tension on the expression of heat shock proteins in a panel of melanoma cell lines. *PLoS One.* 2012;7(6):e37475. Epub 2012 Jun 22.
- 203) Alam I, Goldeck D, Larbi A, **Pawelec G**. Aging affects the proportions of T and B cells in a group of elderly men in a developing country—a pilot study from Pakistan. *Age (Dordr).* 2013 Oct;35(5):1521-30. doi: 10.1007/s11357-012-9455-1. Epub 2012 Jul 19.
- 204) Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, Staehler M, Brugger W, Dietrich PY, Hilf N, Schoor O, Fritsche J, Mahr A, Mendrzyk R, Maurer D, Vass V, Trautwein C, Lewandrowski P, Flohr C, Pohla H, Stanczak JJ, Bronte V, Mandruzzato S, Biedermann T, **Pawelec G**, Derhovanessian E, Yamagishi H, Miki T, Hongo F, Takaha N, Hirakawa K, Tanaka H, Stevanovic S, Rammensee HG, Frisch J, Mayer-Mokler A, Kirner A, Reinhardt C, Singh-Jasuja H. Prolonged survival of patients with advanced renal cancer responding to multi-peptide vaccine IMA901 after single-dose cyclophosphamide. *Nat Med.* 18: 1254-1261, 2012
- 205) Shipp C, Weide B, Derhovanessian E, **Pawelec G**. Hsps are up-regulated in melanoma tissue and correlate with patient clinical parameters. *Cell Stress Chaperones.* 2013 Mar;18(2):145-54. doi: 10.1007/s12192-012-0363-1. Epub 2012 Aug 8.

- 206) Alam I, Larbi A, **Pawelec G**. Nutritional status influences peripheral immune cell phenotypes in healthy men in rural Pakistan. *Immun Ageing*. 2012 Aug 3;9(1):16. doi: 10.1186/1742-4933-9-16.
- 207) Chen S, de Craen A, Raz Y, Derhovanessian E, Vossen Ctm A, Westendorp GJ R, **Pawelec G**, Maier AB. Cytomegalovirus seropositivity is associated with glucose regulation in the oldest old. Results from the Leiden 85-plus Study. *Immun Ageing*. 2012 Aug 28;9(1):18. doi: 10.1186/1742-4933-9-18.
- 208) Passtoors WM, Beekman M, Deelen J, van der Breggen R, Maier AB, Guigas B, Derhovanessian E, van Heemst D, de Craen AJ, Gunn DA, **Pawelec G**, Slagboom PE. Gene expression analysis of mTOR pathway: association with human longevity. *Aging Cell*. 2013 Feb;12(1):24-31. doi: 10.1111/ace.12015. Epub 2012 Nov 23.
- 209) Alam I, Alam I, Paracha PI, **Pawelec G**. Higher estimates of daily dietary net endogenous acid production (NEAP) in the elderly as compared to the young in a healthy, free-living elderly population of Pakistan. *Clin Interv Aging*. 2012;7:565-73. doi: 10.2147/CIA.S37158. Epub 2012 Dec 12.
- 210) Derhovanessian E, Theeten H, Hähnel K, Van Damme P, Cools N, **Pawelec G**. Cytomegalovirus-associated accumulation of late-differentiated CD4 T-cells correlates with poor humoral response to influenza vaccination. *Vaccine*. 2013 Jan 11;31(4):685-90. doi: 10.1016/j.vaccine.2012.11.041. Epub 2012 Nov 26.
- 211) Buffa S, Pellicanò M, Bulati M, Martorana A, Goldeck D, Caruso C, **Pawelec G**, Colonna-Romano G. A novel B cell population revealed by a CD38/CD24 gating strategy: CD38(-)CD24 (-) B cells in centenarian offspring and elderly people. *Age (Dordr)*. 2013 Oct;35(5):2009-24. doi: 10.1007/s11357-012-9488-5. Epub 2012 Nov 7.
- 212) Bertram L, Böckenhoff A, Demuth I, Düzel S, Eckardt R, Li SC, Lindenberg U, Pawelec G, Siedler T, Wagner GG, Steinhagen-Thiessen E. Cohort Profile: The Berlin Aging Study II (BASE-II). 2014 Jun;43(3):703-12. doi: 10.1093/ije/dyt018. Epub 2013 Mar 14.
- 213) Goldeck D, Low I, Shadan NB, Mustafah S, **Pawelec G**, Larbi A. Multi-parametric phospho-flow cytometry: A crucial tool for T lymphocyte signaling studies. *Cytometry A*. 2013 Mar;83(3):265-72. doi: 10.1002/cyto.a.22252. Epub 2013 Jan 28.
- 214) Marthandan S, Hyland P, **Pawelec G**, Barnett Y. An investigation of the effects of the antioxidants, ebselen or N-acetyl cysteine on human peripheral blood mononuclear cells and T cells. *Immun Ageing*. 2013 Feb 21;10(1):7. doi: 10.1186/1742-4933-10-7.
- 215) Goldeck D, Larbi A, Pellicanó M, Alam I, Zerr I, Schmidt C, Fulop T, **Pawelec G**. Enhanced Chemokine Receptor Expression on Leukocytes of Patients with Alzheimer's Disease. *PLoS One*. 2013 Jun 18;8(6):e66664.
- 216) Wistuba-Hamprecht K, Frasca D, Blomberg B, **Pawelec G**, Derhovanessian E. Age-associated alterations in gammadelta T-cells are present predominantly in individuals infected with Cytomegalovirus. *Immun Ageing*. 2013 Jul 3;10(1):26. doi: 10.1186/1742-4933-10-26.
- 217) Turner JE, Campbell JP, Edwards KM, Howarth LJ, **Pawelec G**, Aldred S, Moss P, Drayson MT, Burns VE, Bosch JA. Rudimentary signs of immunosenescence in Cytomegalovirus-seropositive healthy young adults. *Age (Dordr)*. 2014 Feb;36(1):287-97. doi: 10.1007/s11357-013-9557-4. Epub 2013 Jul 12.
- 218) Dahl C, Christensen C, Jonsson G, Lorentzen A, Skjodt ML, Borg A, **Pawelec G**, Guldberg P. Mutual exclusivity analysis of genetic and epigenetic drivers in melanoma identifies a link between p14ARF and retinoic acid receptor β signaling. *Mol Cancer Res*. 2013 Oct;11(10):1166-78. doi: 10.1158/1541-7786.MCR-13-0006. Epub 2013 Jul 12.
- 219) Ioannou K, Derhovanessian E, Tsakiri E, Samara P, Kalbacher H, Voelter W, Trougakos IP, **Pawelec G**, Tsitsilonis OE. Prothymosin alpha and a prothymosin alpha-derived peptide enhance TH1-type immune responses against defined HER-2/neu epitopes. *BMC Immunol*. 2013 Sep 22;14(1):43.
- 220) Pellicanò M, Buffa S, Goldeck D, Bulati M, Martorana A, Caruso C, Colonna-Romano G, **Pawelec G**. Evidence for Less Marked Potential Signs of T-Cell Immunosenescence in Centenarian Offspring Than in the General Age-Matched Population. *J Gerontol A Biol Sci Med Sci*. 69:495-504, 2014 (Editor's Choice).
- 221) Weide B, Martens A, Zelba H, Stutz C, Derhovanessian E, Di Giacomo AM, Maio M, Sucker A, Schilling B, Schadendorf D, Büttner P, Garbe C, **Pawelec G**. Myeloid-derived suppressor cells predict survival of advanced melanoma patients: comparison with regulatory T cells and NY-ESO-1- or Melan-A-specific T cells. *Clin Cancer Res*. 2014 Mar 15;20(6):1601-9. doi: 10.1158/1078-0432.CCR-13-2508. Epub 2013 Dec 9.
- 222) Wistuba-Hamprecht K, **Pawelec G**, Derhovanessian E. OMIP-020: Phenotypic characterization of human $\gamma\delta$ T-cells by multicolor flow cytometry. *Cytometry A*. 2014 Jun;85(6):522-4. doi: 10.1002/cyto.a.22470. Epub 2014 Apr 22

- 223) Adriaenssen W, Derhovanessian E, Vaes B, Van Pottelbergh G, Degryse JM, **Pawelec G**, Hamprecht K, Theeten H, Matheï C. CD4:8 Ratio >5 Is Associated With a Dominant Naive T-Cell Phenotype and Impaired Physical Functioning in CMV-Seropositive Very Elderly People: Results From the BELFRAIL Study. *J Gerontol A Biol Sci Med Sci*. 2015 Feb;70(2):143-54. doi: 10.1093/gerona/glu018. Epub 2014 Feb 25.
- 224) Zelba H, Weide B, Martens A, Derhovanessian E, Kini Bailur J, Kyzirakos C, Pflugfelder A, Eigentler TK, Di Giacomo AM, Maio M, Aarntzen EH, de Vries IJ, Sucker A, Schadendorf D, Buttner P, Garbe C, **Pawelec G**. Circulating CD4+ T-cells that produce IL-4 or IL-17 when stimulated by Melan-A but not by NY-ESO-1 have negative impacts on survival of stage IV melanoma patients. *Clin Cancer Res*. 2014 Aug 15;20(16):4390-9.
- 225) Marthandan S, Freeburn R, Steinbrecht S, Pawelec G, Barnett Y. SENIEUR status of the originating cell donor negates certain 'anti-immunosenesence' effects of ebselen and N-acetyl cysteine in human T cell clone cultures. *Immun Ageing*. 2014 Nov 30;11(1):17. doi: 10.1186/s12979-014-0017-5. eCollection 2014.
- 226) Weide B, Eigentler TK, Pflugfelder A, Zelba H, Martens A, **Pawelec G**, Giovannoni L, Ruffini PA, Elia G, Neri D, Gutzmer R, Becker JC, Garbe C. Intralesional Treatment of Stage III Metastatic Melanoma Patients with L19-IL2 Results in Sustained Clinical and Systemic Immunologic Responses. *Cancer Immunol Res*. 2014 Jul;2(7):668-78. doi: 10.1158/2326-6066.CIR-13-0206. Epub 2014 Apr 4.
- 227) Derhovanessian E, Maier AB, Hähnel K, McElhaney JE, Slagboom EP, **Pawelec G**. Latent infection with Cytomegalovirus 1 is associated with poor memory CD4 responses to Influenza A core proteins in the elderly. *J Immunol*. 2014 Oct 1;193(7):3624-31
- 228) Derhovanessian E, Chen S, Maier AB, Hähnel K, de Craen AJM, Roelofs H, Westendorp R, **Pawelec G**. CCR4+ regulatory T-cells accumulate in the very elderly and correlate with superior 8-year survival. *J Gerontol A Biol Sci Med Sci*. 2015 Aug;70(8):917-23. doi: 10.1093/gerona/glu128. Epub 2015 Apr 7.
- 229) Le Page A, Bourgadea K, Lamoureux J, Frost E, **Pawelec G**, Larbi A, Dupuis G, Fülöp T. NK cells are activated in Amnesic Mild Cognitive Impairment but not in Mild Alzheimer Patients. *J Alzheimers Dis*. 2015;46(1):93-107. doi: 10.3233/JAD-143054.
- 230) Kini Bailur J, Gueckel B, Derhovanessian E, **Pawelec G**. Presence of circulating Her-2-reactive CD8+T-cells is associated with lower frequencies of MDSCs and regulatory T cells, and better survival in elderly breast cancer patients. *Breast Cancer Res*. 2015 Dec;17(1):541. doi: 10.1186/s13058-015-0541-z. Epub 2015 Mar 10.
- 231) Di Benedetto S, Derhovanessian E, Steinhagen-Thiessen E, Goldeck D, Müller L, **Pawelec G**. Impact of age, sex and CMV-infection on peripheral T cell phenotypes: results from the Berlin BASE-II Study. *Biogerontology*. 2015 Oct;16(5):631-43. doi: 10.1007/s10522-015-9563-2. Epub 2015 Mar 3.
- 232) Goldeck D, **Pawelec G**, Norman K, Steinhagen-Thiessen E, Oettinger L, Haehnel K, Demuth I. No strong correlations between serum cytokine levels, CMV serostatus and hand-grip strength in older subjects in the Berlin BASE-II cohort. *Biogerontology* 2016 Feb;17(1):189-98. doi: 10.1007/s10522-015-9577-9. Epub 2015 Apr 24.
- 233) Teteloshvili N, Kluiver J, van der Geest KS, van der Lei RJ, Jellema P, **Pawelec G**, Brouwer E, Kroesen BJ, Boots AM, van den Berg A. Age-Associated Differences in MiRNA Signatures Are Restricted to CD45RO Negative T Cells and Are Associated with Changes in the Cellular Composition, Activation and Cellular Ageing. *PLoS One*. 2015 Sep 11;10(9):e0137556.
- 234) Buchmann N, Kassner U, Norman K, Goldeck D, Eckardt R, **Pawelec G**, Steinhagen-Thiessen E, Demuth I. Higher Lipoprotein (a) Levels Are Associated with Better Pulmonary Function in Community-Dwelling Older People - Data from the Berlin Aging Study II. *PLoS One*. 2015 Sep 30;10(9):e0139040. doi: 10.1371/journal.pone.0139040. eCollection 2015.
- 235) Wistuba-Hamprecht K, Di Benedetto S, Schilling B, Sucker A, Schadendorf D, Garbe C, Weide B, **Pawelec G**. Phenotypic characterization and prognostic impact of circulating $\gamma\delta$ and $\alpha\beta$ T-cells in metastatic malignant melanoma. *Int J Cancer*. 2016 Feb 1;138(3):698-704. doi: 10.1002/ijc.29818. Epub 2015 Sep 18.
- 236) McElhaney JE, Garneau H, Camous X, Dupuis G, **Pawelec G**, Baehl S, Tessier D, Frost EH, Frasca D, Larbi A, Fulop T. Predictors of the antibody response to influenza vaccination in older adults with type 2 diabetes. *BMJ Open Diabetes Res Care*. 2015 Oct 13;3(1):e000140. doi: 10.1136/bmjdr-2015-000140. eCollection 2015.
- 237) Bailur JK, Derhovanessian E, Gueckel B, **Pawelec G**. Prognostic impact of circulating Her-2-reactive T-cells producing pro- and/or anti-inflammatory cytokines in elderly breast cancer patients. *J Immunother Cancer*. 2015 Oct 20;3:45. doi: 10.1186/s40425-015-0090-0. eCollection 2015.
- 238) Tegeler C, O'Sullivan JL, Buchholtz N, Goldeck D, **Pawelec G**, Steinhagen-Thiessen E, Demuth I. The inflammatory markers CRP, IL-6, and IL-10 are associated with cognitive function data from the Berlin Aging Study II. *Neurobiol Aging*. 2016 Feb;38:112-7. doi: 10.1016/j.neurobiolaging.2015.10.039. Epub 2015 Nov 7.

- 239) Goldeck D, Maetzler W, Berg D, Oettinger L, **Pawelec G**. Altered dendritic cell subset distribution in patients with Parkinson's disease: Impact of CMV serostatus. *J Neuroimmunol*. 2016 Jan 15;290:60-5. doi: 10.1016/j.jneuroim.2015.11.008. Epub 2015 Nov 14.
- 240) Goldeck D, Oettinger L, Janssen N, Demuth I, Steinhagen-Thiessen E, **Pawelec G**. Cytomegalovirus Infection Minimally Affects the Frequencies of B-Cell Phenotypes in Peripheral Blood of Younger and Older Adults. *Gerontology*. 2016 Jan 29. [Epub ahead of print]
- 241) Martens A, Wistuba-Hamprecht K, Geukes Foppen MH, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Di Giacomo AM, Maio M, Schilling B, Sucker A, Schadendorf D, Hassel JC, Eigentler TK, Martus P, Wolchok JD, Blank CU, **Pawelec G**, Garbe C, Weide B. Baseline peripheral blood biomarkers associated with clinical outcome of advanced melanoma patients treated with ipilimumab. *Clin Cancer Res*. 2016 Jun 15;22(12):2908-18. doi: 10.1158/1078-0432.CCR-15-2412. Epub 2016 Jan 19.
- 242) Chiu YL, Lin CH, Sung BY, Chuang YF, Schneck JP, Kern F, **Pawelec G**, Wang GC. Cytotoxic polyfunctionality maturation of cytomegalovirus-pp65-specific CD4+ and CD8+ T-cell responses in older adults positively correlates with response size. *Sci Rep*. 2016 Jan 18;6:19227. doi: 10.1038/srep19227.
- 243) Goldeck D, Larsen LA, Christiansen L, Christensen K, Hamprecht K, **Pawelec G**, Derhovannessian E. Genetic Influence on the Peripheral Blood CD4+ T-cell Differentiation Status in CMV Infection. *J Gerontol A Biol Sci Med Sci*. 2016 Dec;71(12):1537-1543. Epub 2016 Jan 11. [PubMed]
- 244) Janssen N, Derhovannessian E, Demuth I, Arnaout F, Steinhagen-Thiessen E, **Pawelec G**. Responses of Dendritic Cells to TLR-4 Stimulation Are Maintained in the Elderly and Resist the Effects of CMV Infection Seen in the Young. *J Gerontol A Biol Sci Med Sci*. 2016 Sep;71(9):1117-23. doi: 10.1093/gerona/glv119.
- 245) Aiello AE, Dowd JB, Jayabalasingham B, Feinstein L, Uddin M, Simanek AM, Cheng CK, Galea S, Wildman DE, Koenen K, **Pawelec G**. PTSD is associated with an increase in aged T cell phenotypes in adults living in Detroit. *Psychoneuroendocrinology*. 2016 Feb 3;67:133-141. doi: 10.1016/j.psyneuen.2016.01.024. [Epub ahead of print]
- 246) Aiello AE, Feinstein L, Dowd JB, **Pawelec G**, Derhovannessian E, Galea S, Uddin M, Wildman DE, Simanek AM. Income and Markers of Immunological Cellular Aging. *Psychosom Med*. 2016 Jul-Aug;78(6):657-66. doi: 10.1097/PSY.0000000000000320.
- 247) Martens A, Wistuba-Hamprecht K, Yuan J, Postow MA, Wong P, Capone M, Madonna G, Khammari A, Schilling B, Sucker A, Schadendorf D, Martus P, Dreno B, Ascierto PA, Wolchok JD, **Pawelec G**, Garbe C, Weide B. Increases in absolute lymphocytes and circulating CD4+ and CD8+ T cells are associated with positive clinical outcome of melanoma patients treated with ipilimumab. *Clin Cancer Res*. 2016 Oct 1;22(19):4848-4858.
- 248) Brouwers B, Hatse S, Dal Lago L, Neven P, Vuylsteke P, Dalmasso B, Debrock G, Van Den Bulck H, Smeets A, Bechter O, Kini Bailur J, Kenis C, Laenen A, Schöffski P, **Pawelec G**, Journe F, Ghanem GE, Wildiers H. The impact of adjuvant chemotherapy in older breast cancer patients on clinical and biological aging parameters. *Oncotarget*. 2016 May 24;7(21):29977-88. doi: 10.18632/oncotarget.8796
- 249) Waaijer ME, Westendorp RG, Goldeck D, Gunn DA, **Pawelec G**, Stijntjes M, Slagboom PE, Maier AB. Assessment of health status by molecular measures in adults ranging from middle-aged to old: Ready for clinical use? *Exp Gerontol*. 2016 Apr 2. pii: S0531-5565(16)30088-2. doi: 10.1016/j.exger.2016.03.020.
- 250) Bailur J, Gueckel B, **Pawelec G**. Prognostic impact of high levels of circulating plasmacytoid dendritic cells in breast cancer. *J Transl Med*. 2016 May 28;14(1):151. doi: 10.1186/s12967-016-0905-x.
- 251) Feinstein L, Douglas CE, Stebbins RC, **Pawelec G**, Simanek AM, Aiello AE. Does Cytomegalovirus Infection Contribute to Socioeconomic Disparities in All-cause Mortality? *Mech Ageing Dev*. 2016 Jun 4. pii: S0047-6374(16)30084-7. doi: 10.1016/j.mad.2016.06.001
- 252) Wistuba-Hamprecht K, Martens A, Haehnel K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Demuth I, Steinhagen-Thiessen E, Larbi A, Schilling B, Schadendorf D, Wolchok JD, Blank CU, **Pawelec G**, Garbe C, Weide B. Proportions of blood-borne Vδ1+ and Vδ2+ T-cells are associated with overall survival of melanoma patients treated with ipilimumab. *Eur J Cancer*. 2016 Sep;64:116-26. doi: 10.1016/j.ejca.2016.06.001.
- 253) Martens A, Wistuba-Hamprecht K, Geukes Foppen M, Yuan J, Postow MA, Wong P, Romano E, Khammari A, Dreno B, Capone M, Ascierto PA, Di Giacomo AM, Maio M, Schilling B, Sucker A, Schadendorf D, Hassel JC, Eigentler TK, Martus P, Wolchok JD, Blank C, **Pawelec G**, Garbe C, Weide B. Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. *Clin Cancer Res*. 2016 Jun 15;22(12):2908-18. doi: 10.1158/1078-0432.CCR-15-2412.

- 254) Tan CT, Wistuba-Hamprecht K, Xu W, Nyunt MS, Vasudev A, Lee BT, **Pawelec G**, Puan KJ, Rotzschke O, Ng TP, Larbi A. $\gamma\delta$ 2+ and α/β T cells show divergent trajectories during human aging. *Oncotarget*. 2016 Jun 15. doi: 10.18632/oncotarget.10096.
- 255) Janssen N, Fortis SP, Speigl L, Haritos C, Sotiriadou NN, Sofopoulos M, Arnogiannaki N, Stavropoulos-Giokas C, Dinou A, Perez S, **Pawelec G**, Baxevanis CN, Shipp C. Peripheral T cell responses to tumour antigens are associated with molecular, immunogenetic and cellular features of breast cancer patients. *Breast Cancer Res Treat*. 2016 Oct 27.
- 256) Adriaansen W, **Pawelec G**, Vaes B, Hamprecht K, Derhovanessian E, van Pottelbergh G, Degryse JM, Mathei C. CD4:8 Ratio Above 5 Is Associated With All-Cause Mortality in CMV-Seronegative Very Old Women: Results From the BELFRAIL Study. *J Gerontol A Biol Sci Med Sci*. 2017 Sep 1;72(9):1155-1162. doi: 10.1093/gerona/glw215.
- 257) Speigl L, Janssen N, Weide B, **Pawelec G**, Shipp C. Prognostic impact of the putative cancer stem cell markers ABCG2, CD133, ALDH1A1 and CD44V7/8 in metastatic melanoma. *Br J Dermatol*. 2016 Nov 21. [Epub ahead of print]
- 258) Wistuba-Hamprecht K, Martens A, Weide B, Teng KW, Zelba H, Guffart E, Chen J, Garbe C, Newell EW, Larbi A, **Pawelec G**. Establishing High Dimensional Immune Signatures from Peripheral Blood via Mass Cytometry in a Discovery Cohort of Stage IV Melanoma Patients. *J Immunol*. 2017 Jan 15;198(2):927-936. doi: 10.4049/jimmunol.1600875. Epub 2016 Dec 16.
- 259) Goldeck D, Larsen LA, Christiansen L, Christensen K, Hamprecht K, **Pawelec G**, Derhovanessian E. Genetic Influence on the Peripheral Blood CD4+ T-cell Differentiation Status in CMV Infection. *J Gerontol A Biol Sci Med Sci*. 2016 Dec;71(12):1537-1543.
- 260) Haq K, Fulop T, Tedder G, Gentleman B, Garneau H, Meneilly GS, Kleppinger A, **Pawelec G**, McElhaney JE. Cytomegalovirus Seropositivity Predicts a Decline in the T Cell But Not the Antibody Response to Influenza in Vaccinated Older Adults Independent of Type 2 Diabetes Status. *J Gerontol A Biol Sci Med Sci*. 2017 Sep 1;72(9):1163-1170. doi: 10.1093/gerona/glw216.
- 261) Bailur JK, **Pawelec G**, Hatse S, Brouwers B, Smeets A, Neven P, Laenen A, Wildiers H, Shipp C. Immune profiles of elderly breast cancer patients are altered by chemotherapy and relate to clinical frailty. *Breast Cancer Res*. 2017 Feb 28;19(1):20. doi: 10.1186/s13058-017-0813-x.
- 261) Wistuba-Hamprecht K, Martens A, Heubach F, Romano E, Geukes Foppen M, Yuan J, Postow M, Wong P, Mallardo D, Schilling B, Di Giacomo AM, Khammari A, Dreno B, Maio M, Schadendorf D, Ascierto PA, Wolchok JD, Blank CU, Garbe C, **Pawelec G**, Weide B. Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. *Eur J Cancer*. 2017 Mar;73:61-70. doi: 10.1016/j.ejca.2016.12.011. Epub 2017 Feb 4.
- 262) Fortis SP, Sofopoulos M, Sotiriadou NN, Haritos C, Vaxevanis CK, Anastasopoulou EA, Janssen N, Arnogiannaki N, Ardavanis A, **Pawelec G**, Perez SA, Baxevanis CN. Differential intratumoral distributions of CD8 and CD163 immune cells as prognostic biomarkers in breast cancer. *J Immunother Cancer*. 2017 Apr 18;5(1):39. doi: 10.1186/s40425-017-0240-7.
- 263) Goldeck D, Theeten H, Hassouneh F, Oettinger L, Wistuba-Hamprecht K, Cools N, Tsitsilonis OE, **Pawelec G**. Frequencies of peripheral immune cells in older adults following seasonal influenza vaccination with an adjuvanted vaccine. *Vaccine*. 2017 Aug 3;35(34):4330-4338. doi: 10.1016/j.vaccine.2017.06.082. Epub 2017 Jul 6.
- 264) Le Page A, Lamoureux J, Bourgade K, Frost EH, **Pawelec G**, Witkowski JM, Larbi A, Dupuis G, Fülöp T. Polymorphonuclear Neutrophil Functions are Differentially Altered in Amnesic Mild Cognitive Impairment and Mild Alzheimer's Disease Patients. *J Alzheimers Dis*. 2017 Jul 29. doi: 10.3233/JAD-170124. [Epub ahead of print]
- 265) Le Page A, Garneau H, Dupuis G, Frost EH, Larbi A, Witkowski JM, **Pawelec G**, Fülöp T. Differential Phenotypes of Myeloid-Derived Suppressor and T Regulatory Cells and Cytokine Levels in Amnesic Mild Cognitive Impairment Subjects Compared to Mild Alzheimer Diseased Patients. *Front Immunol*. 2017 Jul 7;8:783. doi: 10.3389/fimmu.2017.00783. eCollection 2017.
- 266) Speigl L, Burow H, Bailur JK, Janssen N, Walter CB, **Pawelec G**, Shipp C. CD14+ HLA-DR-/low MDSCs are elevated in the periphery of early-stage breast cancer patients and suppress autologous T cell proliferation. *Breast Cancer Res Treat*. 2018 Apr;168(2):401-411. doi: 10.1007/s10549-017-4594-9. Epub 2017 Dec 11.
- 267) Janssen N, Speigl L, **Pawelec G**, Niessner H, Shipp C. Inhibiting HSP90 prevents the induction of myeloid-derived suppressor cells by melanoma cells. *Cell Immunol*. 2018 May;327:68-76. doi: 10.1016/j.cellimm.2018.02.012. Epub 2018 Feb 21
- 268) Speigl L, Grieb A, Janssen N, Hatse S, Brouwers B, Smeets A, Floris G, Bailur JK, Kenis C, Neven P, Wildiers H, **Pawelec G**, Shipp C.) Low levels of intra-tumoural T cells in breast cancer identify clinically frail patients with shorter disease-specific survival. *J Geriatr Oncol*. 2018 Nov;9(6):606-612. doi: 10.1016/j.jgo.2018.03.021. Epub 2018 Apr 21.

269) Alam I, Shivappa N, Hebert JR, **Pawelec G**, Larbi A. Relationships between the inflammatory potential of the diet, aging and anthropometric measurements in a cross-sectional study in Pakistan. *Nutr Healthy Aging*. 2018 Jun 15;4(4):335-343. doi: 10.3233/NHA-180042.

270) Teteloshvili N, Dekkema G, Boots AM, Heeringa P, Jellema P, de Jong D, Terpstra M, Brouwer E, **Pawelec G**, Kok K, van den Berg A, Kluiver J, Kroesen BJ. Involvement of MicroRNAs in the Aging-Related Decline of CD28 Expression by Human T Cells. *Front Immunol*. 2018 Jun 18;9:1400. doi: 10.3389/fimmu.2018.01400. eCollection 2018.

271) Zelba H, Bochem J, **Pawelec G**, Garbe C, Wistuba-Hamprecht K, Weide B. Accurate quantification of T-cells expressing PD-1 in patients on anti-PD-1 immunotherapy. *Cancer Immunol Immunother*. 2018 Sep 14. doi: 10.1007/s00262-018-2244-7. [Epub ahead of print]

2) Reports, Commentaries

1) **Pawelec G**, Schneider EM, Wernet P: Human T-cell clones with multiple and changing functions: indications of unexpected flexibility in immune response networks. *Immunology Today* 4:275, 1983

2) Eckels DD, Zeevi A, Beatty PG, Flomenberg N, Goyert S, Knowles RW, Mickelson E, Nepom GT, Parham P, **Pawelec G**, Reinsmoen N: ASHI Workshop summary report of the science and education subcommittee: structural and functional relationships of human class II MHC molecules. *Human Immunology* 15:68, 1986

3) **Pawelec G**, Adibzadeh M, Pohla H, Schaudt K: Immunosenescence: ageing of the immune system. *Immunol Today* 16:420, 1995

4) **Pawelec G**, Adibzadeh M, Solana R, Beckman I: The T cell in the ageing individual. *Mech Ageing Dev* 93:35, 1997

5) **Pawelec G**, Solana R: Immunosenescence. *Immunol Today* 18:514, 1997

6) Kipling D, Wynford-Thomas D, Jones CJ, Akbar A, Aspinall R, Bacchetti S, Blasco MA, Broccoli D, De Pinho RA, Edwards DR, Effros RB, Harley CB, Lansdorp PM, Linskens MHK, Prowse KR, Newbold RF, Olovnikov AM, Parkinson EK, **Pawelec G**, Ponten J, Shall S, Zijlmans M, Faragher RGA: Telomere-dependent senescence. *Nature Biotech* 17:313, 1999

7) **Pawelec G**, Adibzadeh M, Wagner W, Engel A. T cell immunosenescence in vitro and in vivo. *Exp Gerontol* 34:419, 1999

8) **Pawelec G**: Tumour escape from the immune response: the last great hurdle for successful immunotherapy of cancer? [Introduction to a "Symposium in Writing" edited by GP]. *Cancer Immunol Immunother* 48:343, 1999

9) **Pawelec G**: Prerequisites for the immunotherapy of cancer. Report of the Second EUCAPS Meeting, Blaubeuren, February, 1999. *Cancer Immunol Immunother* 48:214, 1999

10) **Pawelec G**: Immunosenescence: impact in the young as well as the old? *Mech Ageing Dev* 108:1, 1999

11) **Pawelec G**: Meeting report: First conference of the EU-supported Thematic Network on Immunology and Ageing in Europe (ImAginE), Schloß Hohentübingen, April 2000. *Exp Gerontol* 35: 1095, 2000

12) **Pawelec G**: Working Together for Robust Immune Responses in the Elderly. *Nature Immunol* 1:91, 2000

13) **Pawelec G**: New methods to approach immunotherapy of cancer - and strategies of tumours to avoid elimination. Conference report, on behalf of EUCAPS. *Cancer Immunol immunother* 49:276, 2000

14) **Pawelec G**: Hypothesis: Loss of telomerase inducibility and subsequent replicative senescence in cultured human T cells is a result of altered costimulation. *Mech Ageing Dev* 121: 181, 2000

15) Kiessling R, **Pawelec G**, Welsh R, Barry JD, Ferrone S: Have tumor cells learnt from microorganisms how to fool the immune system? Escape from immune surveillance of tumors and microorganisms: emerging mechanisms and shared strategies, Naples, Italy, 23-27 March 2000. *Mol Med Today* 6:344, 2000

16) **Pawelec G**, Wagner W. Is HLA-DR4 or the HLA-DRB1*0402 allele associated with decreased risk for CML? *Leukemia* 15:192, 2001

17) **Pawelec G**, Effros RB, Globerson A: A multidisciplinary approach to immunity and ageing: ImAginEering. *Mech Ageing Dev* 121:1, 2000

18) **Pawelec G**, Ferguson FG, Wikby A: The SENIEUR protocol after 16 years. *Mech Ageing Dev*. 122:132, 2001

19) **Pawelec G**, Müller L, Wagner W: CD4+ T cells and MHC class II-restricted tumour antigens have a role in haematological malignancies as well as solid tumours. *Trends Immunol* 22:422, 2001

- 20) **Pawelec G**, Solana R: Immunoageing: the cause or effect of morbidity? *Trends Immunol* 22:348, 2001
- 21) **Pawelec G**: Meeting report: Progress in vaccination against cancer, PIVAC 2001, July 2001, Cambridge, UK. *Trends Mol Med* 7:486, 2001
- 22) De Grey ADNJ, Baynes JW, Berd D, Heward CB, **Pawelec G**, Stock G: Is human aging still mysterious enough to be left only to scientists? *Bioessays* 24:1, 2002
- 23) **Pawelec G**, Ouyang Q, Colonna-Roman G, Candore G, Lio D, Caruso C: Is human immunosenescence clinically relevant? Looking for "immunological risk phenotypes". *Trends Immunol* 23:330, 2002
- 24) Rees RC, **Pawelec G**, Müller L, Robins A: Progress in vaccination against cancer (PIVAC) 2001, Robinson College, University of Cambridge, UK. *Cancer Immunol Immunother* 51:58-61, 2002
- 25) **Pawelec G**: Senescence: the cost of being young and healthy? *Eur Cytokine Netw.* 13:387, 2002
- 26) **Pawelec G**, Rees RC: Cancer vaccination progress. *Trends Mol Med.* 8:545-6, 2002
- 27) **Pawelec G**: Immunosenescence and human longevity. *Biogerontology* 4: 167-179, 2003
- 28) Hasenmaile S, **Pawelec G**, Wagner W. A lack of telomeric non-reciprocal recombination (TENOR) may account for the premature proliferation blockade of Werner's syndrome fibroblasts. *Biogerontology* 4:253-273, 2003
- 29) **Pawelec G**, Ouyang Q: Immunosenescence in Montecatini. *Biogerontology* 4: 121-123, 2003
- 30) **Pawelec G**, Caruso C: Immunology and ageing in Europe: ImAginE-ation in the EU. *Mech Ageing Dev* 124: 357-360, 2003
- 31) Rees RC, Robbins RA, Pawelec G, Müller L, Li G, Spendlove I. International conference: Progress in vaccination against cancer (PIVAC) 2002, Nottingham, UK. *Cancer Immunol Immunother* 52:403-407, 2003
- 32) **Pawelec G**: Extrathymic T cell differentiation in vitro. *Nature Reviews Immunology*. Published online: 1 April 2004 doi:10.1038/nri1257-c1
- 33) Wagner WM, Ouyang Q, Sekeri-Pataryas K, Sourlingas TG, **Pawelec G**: Basic biology and clinical impact of immunosenescence. *Biogerontology* 5:63-66, 2004
- 34) **Pawelec G**, Gouttefangeas C: Strategies for immune therapy: Wurzburg, Germany, 29 February-3 March 2004. *Cancer Immunol Immunother* 53:755-758, 2004
- 35) Ouyang Q, Wagner WM, **Pawelec G**: Reply to Almanzar's et al. letter to the editor: IFN-gamma production by CMV-specific CD8(+) T cells is high in elderly donors. *Exp Gerontol.* 39:867-868, 2004
- 36) **Pawelec G**: Meeting Report: British Society for Immunology Annual Congress, Harrogate, UK, 2-5 December 2003. *Cancer Immunol Immunother* 53:471-472, 2004
- 37) **Pawelec G**, Forsey R. Immunosenescence: what is it and what can be done about it? Session 20 of the BSI Annual Congress, Harrogate, December, 2003. *Rejuvenation Res* 7:61-4, 2004
- 38) **Pawelec G**, Mariani E, McLeod J, Ben-Yehuda A, Fulop T, Aringer M, Barnett Y. Engineering anticancer T cells for extended functional longevity. *Ann N Y Acad Sci* 1019:178-85, 2004
- 39) **Pawelec G**, Akbar A, Caruso C, Effros R, Grubeck-Loebenstien B, Wikby A: Is immunosenescence infectious? *Trends Immunol.* 25:406-10, 2004
- 40) Britten CM, Mueller L, Knights A, **Pawelec G**. Cancer Immunotherapy 2004: Mainz, Germany, 6-7 May 2004. *Cancer Immunol Immunother.* 53:1153-1158, 2004
- 41) Mocchegiani E, Marcellini F, **Pawelec G**. Nutritional zinc, oxidative stress and immunosenescence: biochemical, genetic, and lifestyle implications for healthy ageing. *Biogerontology* 5:271-3, 2004.
- 42) **PawelecG**. Progress in Vaccination against Cancer 4. *Cancer Immunol Immunother* 55:61-62, 2006.
- 43) Koch S, Kempf J, **Pawelec G**. T-CIA: investigating T cells in aging. *Sci Aging Knowledge Environ.* 2005 Jul 6;2005(27):pe21.

- 44) Hasenmaile S, **Pawelec G**. The concept of telomeric non-reciprocal recombination (TENOR) applied to human fibroblasts grown in serial cultures: concordance with genealogical data. *Rejuvenation Res.* 8:154-171, 2005
- 45) Koch S, Kempf J, **Pawelec G**. T cell immunity and ageing. *Sci Aging Knowledge Environ.* 2005
- 46) **Pawelec G**. When T cells get old. *Sci Aging Knowledge Environ.* 2005 Dec 14;2005(50):pe39.
- 47) **Pawelec G**. Immunosenescence and Vaccination. *Immunity & Ageing* 2005, 2:16 doi:10.1186/1742-4933-2-16
- 48) Solana R, **Pawelec G**, Tarazona R. Aging and Innate Immunity. *Immunity* 24:491-494, 2006
- 49) Naumova E, **Pawelec G**, Ivanova M, Constantinescu I, Boguin-Kubik K, Lange A, Qguz F, Carin M. The Component "Immunogenetics of Aging": Report on the activities of the 14th International HLA and immunogenetics working group. *Tissue Antigens* 69(s1): 304-310, 2007.
- 50) Gouttefangeas C, Britten CM, Badalians ED, **Pawelec G**. IMT meets strategies for immune therapy. Report and abstracts of the 4th International Meeting of the Association for Immunotherapy of Cancer, Mainz, Germany, 4-5 May 2006 *Cancer Immunol Immunother.* 56: 397-427, 2007
- 51) Mocchegiani E, Malavolta M, Marcellini F, **Pawelec G**: Zinc, oxidative stress, genetic background and immunosenescence: implications for healthy ageing. *Immun Ageing* 3:6, 2006
- 52) Larbi A, **Pawelec G**. A satellite symposium of the 1st European Congress of Immunology Paris, France, September 2006, Aging research in immunology: The genomic facet in Paris. *Exp Gerontol.* 42: 379-384, 2007
- 53) **Pawelec G**. Immunosenescence comes of age. Symposium on Aging Research in Immunology: The Impact of Genomics. *EMBO Rep.* 8: 220-223, 2007.
- 54) Malavolta M, Cipriano C, Costarelli L, Giacconi R, Tesei S, Muti E, Piacenza F, Pierpaoli S, Larbi A, **Pawelec G**, Dedoussis G, Herbein G, Monti D, Jajte J, Rink L, Mocchegiani E. Metallothionein downregulation in very old age: a phenomenon associated with cellular senescence? *Rejuvenation Res.* 11:455-9, 2008
- 55) **Pawelec G**, Solana R. Are cancer and ageing different sides of the same coin? Conference on Cancer and Ageing. *EMBO Rep.* 9:234-8, 2008
- 56) **Pawelec G**, Bohr V, Campisi J. Special issue on cancer and ageing. *Mech Ageing Dev* 130:1-2, 2009
- 57) Anisimov VN, Sikora E, **Pawelec G**. Relationships between cancer and aging: a multilevel approach. *Biogerontology.* 10:323-338, 2009
- 58) **Pawelec G**, Lustgarten J, Ruby C, Gravekamp C. Impact of aging on cancer immunity and immunotherapy. *Cancer Immunol Immunother.* 58:1907-1908, 2009
- 59) Caruso C, Buffa S, Candore G, Colonna-Romano G, Dunn-Walters D, Kipling D, **Pawelec G**. Mechanisms of immunosenescence. *Immun Ageing.* 2009 Jul 22;6(1):10.
- 60) **Pawelec G**. Accumulations of KIR+ T cells in the elderly. *Blood* 114:3360-3361, 2009
- 61) Naumova E, McArdle S, **Pawelec G**. Ninth international conference on progress in vaccination against cancer (PIVAC 9), 8-10 October 2009, Sofia, Bulgaria. *Cancer Immunol Immunother.* 59:1569-1572, 2010.
- 62) **Pawelec G**, Akbar A, Beverley P, Caruso C, Derhovanessian E, Fülöp T, Griffiths P, Grubeck-Loebenstien B, Hamprecht K, Jahn G, Kern F, Koch SD, Larbi A, Maier AB, Macallan D, Moss P, Samson S, Strindhall J, Trannoy E, Wills M. Immunosenescence and Cytomegalovirus: where do we stand after a decade? *Immun Ageing.* 2010 Sep 7;7:13.
- 63) Britten CM, Janetzki S, van der Burg SH, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, **Pawelec G**, Roep BO, Romero P, Hoos A, Davis MM. Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond. *Cancer Immunol Immunother.* 60:15-22, 2011.
- 64) Naumova E, Ivanova M, **Pawelec G**, Constantinescu I, Bogunia-Kubik K, Lange A, Qguz F, Carin M, Franceschi C, Caruso C, Middleton D. 'Immunogenetics of Aging': report on the activities of the 15th International HLA and Immunogenetics Working Group and 15th International HLA and Immunogenetics Workshop. *Tissue Antigens* 77:187-192, 2011.
- 65) Butterfield LH, Palucka AK, Britten CM, Dhodapkar MV, Håkansson L, Janetzki S, Kawakami Y, Kleen TO, Lee PP, Maccalli C, Maecker HT, Maino VC, Maio M, Malyguine A, Masucci G, **Pawelec G**, Potter DM, Rivoltini L, Salazar LG, Schendel DJ, Slingluff CL Jr, Song W, Stroncek DF, Tahara H, Thurin M, Trinchieri G, van Der Burg SH, Whiteside TL,

Wigginton JM, Marincola F, Khleif S, Fox BA, Disis ML. Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. *Clin Cancer Res.* 17:3064-3076, 2011.

66) Wills M, Akbar A, Beswick M, Bosch JA, Caruso C, Colonna-Romano G, Dutta A, Franceschi C, Fulop T, Gkrania-Klotsas E, Goronzy J, Griffiths SJ, Henson S, Herndler-Brandstetter D, Hill A, Kern F, Klenerman P, Macallan D, Macalalay R, Maier AB, Mason G, Melzer D, Morgan M, Moss P, Nikolich-Zugich J, Pachnio A, Riddell N, Roberts R, Sansoni P, Sauce D, Sinclair J, Solana R, Strindhall J, Trzonkowski P, van Lier R, Vescovini R, Wang G, Westendorp R, **Pawelec G**. Report from the Second Cytomegalovirus and Immunosenescence Workshop. *Immun Ageing* 2012 Oct 31;9(1):23. doi: 10.1186/1742-4933-9-23.

67) Fox BA, Schendel DJ, Butterfield LH, Aamdal S, Allison JP, Ascierto PA, Atkins MB, Bartunkova J, Bergmann L, Berinstein N, Bonorino CC, Borden E, Bramson JL, Britten CM, Cao X, Carson WE, Chang AE, Characiejus D, Choudhury AR, Coukos G, de Gruijl T, Dillman RO, Dolstra H, Dranoff G, Durrant LG, Finke JH, Galon J, Gollob JA, Gouttefangeas C, Grizzi F, Guida M, Hakansson L, Hege K, Herberman RB, Hodi FS, Hoos A, Huber C, Hwu P, Imai K, Jaffee EM, Janetzki S, June CH, Kalinski P, Kaufman HL, Kawakami K, Kawakami Y, Keilholtz U, Khleif SN, Kiessling R, Kotlan B, Kroemer G, Lapointe R, Levitsky HI, Lotze MT, Maccalli C, Maio M, Marschner JP, Mastrangelo MJ, Masucci G, Melero I, Nelief C, Murphy WJ, Nelson B, Nicolini A, Nishimura MI, Odunsi K, Ohashi PS, O'Donnell-Tormey J, Old LJ, Ottensmeier C, Papamichail M, Parmiani G, **Pawelec G**, Proietti E, Qin S, Rees R, Ribas A, Ridolfi R, Ritter G, Rivoltini L, Romero PJ, Salem ML, Scheper RJ, Seliger B, Sharma P, Shiku H, Singh-Jasuja H, Song W, Straten PT, Tahara H, Tian Z, van Der Burg SH, von Hoegen P, Wang E, Welters MJ, Winter H, Withington T, Wolchok JD, Xiao W, Zitvogel L, Zwierzina H, Marincola FM, Gajewski TF, Wigginton JM, Disis ML. Defining the Critical Hurdles in Cancer Immunotherapy. *J Transl Med.* 2011 Dec 14;9(1):214. doi: 10.1186/1479-5876-9-214.

68) **Pawelec G**: F1000Prime Recommendation of [Provinciali M et al., *Cancer Immunol Immunother* 2012, 61(3):363-71]. In F1000Prime, 16 Mar 2012; DOI: 10.3410/f.14001974.15455082. F1000Prime.com/14001974#eval15455082

69) **Pawelec G**: F1000Prime Recommendation of [Schreiber K et al., *Clin Cancer Res* 2012, 18(9):2526-33]. In F1000Prime, 16 May 2012; DOI: 10.3410/f.715297840.790852858. F1000Prime.com/715297840#eval790852858

70) **Pawelec G**: F1000Prime Recommendation of [Dudakov JA et al., *Science* 2012, 336(6077):91-5]. In F1000Prime, 11 May 2012; DOI: 10.3410/f.14218962.790402834. F1000Prime.com/14218962#eval790402834

71) **Pawelec G**. Hallmarks of human "immunosenescence": adaptation or dysregulation? *Immun Ageing* 2012, 9:15

72) **Pawelec G**: F1000Prime Recommendation of [Topalian SL et al., *N Engl J Med* 2012, 366(26):2443-54]. In F1000Prime, 09 Jul 2012; DOI: 10.3410/f.717548111.793153300. F1000Prime.com/717548111#eval793153300

73) Britten CM, Janetzki S, Butterfield LH, Ferrari G, Gouttefangeas C, Huber C, Kalos M, Levitsky HI, Maecker HT, Melief CJ, O'Donnell-Tormey J, Odunsi K, Old LJ, Ottenhoff TH, Ottensmeier C, **Pawelec G**, Roederer M, Roep BO, Romero P, van der Burg SH, Walter S, Hoos A, Davis MM. T Cell Assays and MIATA: The Essential Minimum for Maximum Impact. *Immunity.* 2012 Jul 27;37(1):1-2.

74) Jensen-Jarolim E, **Pawelec G**. The nascent field of AllergoOncology. *Cancer Immunol Immunother.* 2012 Sep;61(9):1355-7. doi: 10.1007/s00262-012-1315-4. Epub 2012 Aug 22.

75) Galon J, Franck P, Marincola FM, Angell HK, Thurin M, Lugli A, Zlobec I, Berger A, Bifulco C, Botti G, Tatangelo F, Britten CM, Kreiter S, Chouchane L, Delrio P, Hartmann A, Asslaber M, Maio M, Masucci GV, Mihm M, Vidal-Vanaclocha F, Allison JP, Gnjatic S, Hakansson L, Huber C, Singh-Jasuja H, Ottensmeier C, Zwierzina H, Laghi L, Grizzi F, Ohashi PS, Shaw PA, Clarke BA, Wouters BG, Kawakami Y, Hazama S, Okuno K, Wang E, O'Donnell-Tormey J, Lagorce C, **Pawelec G**, Nishimura MI, Hawkins R, Lapointe R, Lundqvist A, Khleif SN, Ogino S, Gibbs P, Waring P, Sato N, Torigoe T, Itoh K, Patel PS, Shukla SN, Palmqvist R, Nagtegaal ID, Wang Y, D'Arrigo C, Kopetz S, Sinicrope FA, Trinchieri G, Gajewski TF, Ascierto PA, Fox BA. Cancer classification using the Immunoscore: a worldwide task force. *J Transl Med.* 2012 Oct 3;10:205. doi: 10.1186/1479-5876-10-205.

76) Solana R, Tarazona R, Aiello AE, Akbar AN, Appay V, Beswick M, Bosch JA, Campos C, Cantisán S, Cicin-Sain L, Derhovannessian E, Ferrando-Martínez S, Frasca D, Fulöp T, Govind S, Grubeck-Loebenstien B, Hill A, Hurme M, Kern F, Larbi A, López-Botet M, Maier AB, McElhaney JE, Moss P, Naumova E, Nikolich-Zugich J, Pera A, Rector JL, Riddell N, Sanchez-Correa B, Sansoni P, Sauce D, van Lier R, Wang GC, Wills MR, Zielinski M, **Pawelec G**. CMV and Immunosenescence: from basics to clinics. *Immun Ageing.* 2012 Oct 31;9(1):23.

77) Calder PC, Ahluwalia N, Albers R, Bosco N, Bourdet-Sicard R, Haller D, Holgate ST, Jönsson LS, Latulippe ME, Marcos A, Moreines J, M'rini C, Müller M, **Pawelec G**, van Neerven RJ, Watzl B, Zhao J. A Consideration of Biomarkers to be Used for Evaluation of Inflammation in Human Nutritional Studies. *Br J Nutr.* 2013 Jan;109 Suppl 1:S1-S34. doi: 10.1017/S0007114512005119.

78) Naumova E, Ivanova M, **Pawelec G**, Constantinescu I, Bogunia-Kubik K, Lange A, Oguz F, Ozdilli K, Franceschi C, Caruso C, Mishra M, Middleton D. 16th IHIW: Immunogenetics of Aging. *Int J Immunogenet.* 2013 Feb;40(1):77-81. doi: 10.1111/iji.12027.

- 79) Bot A, Ahn M, Bosch M, Brockstedt D, Butterfield LH, Cornforth A, Harrop R, Kast WM, Koya R, Marincola F, Margolin K, McCoy C, **Pawelec G**, Rothman J, Ramirez-Montagut T, Schlom J, Srivastava P, Wallis S, Walter S, Wang E, Waslif J. A novel series of conferences tackling the hurdles confronting the translation of novel cancer immunotherapies. *J Transl Med*. 2012 Nov 5;10:218. doi: 10.1186/1479-5876-10-218.
- 80) **Pawelec G**: F1000Prime Recommendation of [Youm Y-H et al., *Cell Rep* 2012, 1(1):56-68]. In F1000Prime, 19 Jun 2012; DOI: 10.3410/f.717047817.792352822. F1000Prime.com/717047817#eval792352822
- 81) **Pawelec G**: F1000Prime Recommendation of [Ye J et al., *J Immunol* 2013, 190(5):2403-14]. In F1000Prime, 11 Jul 2013; DOI: 10.3410/f.717983142.793479914. F1000Prime.com/717983142#eval793479914
- 82) **Pawelec G**: F1000Prime Recommendation of [Savva GM et al., *Aging Cell* 2013, 12(3):381-7]. In F1000Prime, 11 Jul 2013; DOI: 10.3410/f.717982402.793479778. F1000Prime.com/717982402#eval793479778
- 83) **Pawelec G**: F1000Prime Recommendation of [Song G et al., *Cancer Immunol Immunother* 2013, 62(6):1123-30]. In F1000Prime, 18 Jul 2013; DOI: 10.3410/f.718002327.793480047. F1000Prime.com/718002327#eval793480047
- 84) **Pawelec G**: F1000Prime Recommendation of [Atarashi K et al., *Nature* 2013, 500(7461):232-6]. In F1000Prime, 09 Sep 2013; DOI: 10.3410/f.718030143.793483029. F1000Prime.com/718030143#eval793483029
- 85) Kurnick JT, Pandolfi F, **Pawelec G**. Current Challenges in Immunology. *Int Trends Immunol* 2013; 1:5-9.
- 86) Martens A, Zelba H, Garbe C, **Pawelec G**, Weide B. Monocytic myeloid-derived suppressor cells in advanced melanoma patients: Indirect impact on prognosis through inhibition of tumor-specific T-cell responses? *Oncoimmunology*. 2014 Jan 1;3(1):e27845. Epub 2014 Feb 14.
- 87) Fulop T, Witkowski JM, **Pawelec G**, Alan C, Larbi A. On the immunological theory of aging. *Interdiscip Top Gerontol*. 2014;39:163-76. doi: 10.1159/000358904. Epub 2014 May 13.
- 88) **Pawelec G**. T-cell immunity in the aging human. *Haematologica*. 2014 May;99(5):795-7. doi: 10.3324/haematol.2013.094383
- 89) Sansoni P, Vescovini R, Fagnoni FF, Akbar A, Arens R, Chiu YL, Čičin-Šain L, Dechanet-Merville J, Derhovanessian E, Ferrando-Martinez S, Franceschi C, Frasca D, Fulöp T, Furman D, Gkrania-Klotsas E, Goodrum F, Grubeck-Loebenstien B, Hurme M, Kern F, Lilleri D, López-Botet M, Maier AB, Marandu T, Marchant A, Matheï C, Moss P, Muntasell A, Remmerswaal EB, Riddell NE, Rothe K, Sauce D, Shin EC, Simanek AM, Smithey MJ, Söderberg-Nauclér C, Solana R, Thomas PG, van Lier R, **Pawelec G**, Nikolich-Zugich J. New advances in CMV and immunosenescence. *Exp Gerontol*. 2014 Jul;55:54-62. doi: 10.1016/j.exger.2014.03.020. Epub 2014 Apr 3.
- 90) Faragher R, Frasca D, Remarque E, **Pawelec G, for the ImAginE Consortium**. Better immunity in later life: a position paper. *Age (Dordr)*. 2014 Jun;36(3):9619. doi: 10.1007/s11357-014-9619-2. Epub 2014 Feb 16.
- 91) Pallis AG, Hatse S, Brouwers B, **Pawelec G**, Falandry C, Wedding U, Lago LD, Repetto L, Ring A, Wildiers H. Evaluating the physiological reserves of older patients with cancer: the value of potential biomarkers of aging? *J Geriatr Oncol*. 2014 Apr;5(2):204-18. doi: 10.1016/j.jgo.2013.09.001. Epub 2013 Sep 29.
- 92) Bron D, Ades L, Fulop T, Goede V, Stauder R; Elderly Task Force in Hematology EHA SWG. Aging and blood disorders: new perspectives, new challenges. *Haematologica*. 2015 Apr;100(4):415-7. doi: 10.3324/haematol.2015.12677
- 93) Zelba H, Weide B, Martens A, Bailur JK, Garbe C, **Pawelec G**. The prognostic impact of specific CD4 T-cell responses is critically dependent on the target antigen in melanoma. *Oncoimmunology*. 2015 Jan 30;4(1):e955683.
- 94) Pandha H, **Pawelec G**. Immune checkpoint targeting as anti-cancer immunotherapy: promises, questions, challenges and the need for predictive biomarkers at ASCO 2015. *Cancer Immunol Immunother*. 2015 Sep;64(9):1071-4. doi: 10.1007/s00262-015-1748-7. Epub 2015 Aug 13.
- 95) Fulop T, Dupuis G, Baehl S, Le Page A, Bourgade K, Frost E, Witkowski JM, **Pawelec G**, Larbi A, Cunnane S. From inflamm-aging to immune-paralysis: a slippery slope during aging for immune-adaptation. *Biogerontology*. 2015 Oct 15. [Epub ahead of print]
- 96) Gerstorf D, Bertram L, Lindenberger U, **Pawelec G**, Demuth I, Steinhagen-Thiessen E, Wagner GG. Editorial. *Gerontology*. 2016 Jan 29. [Epub ahead of print]
- 97) Wistuba-Hamprecht K, **Pawelec G**. Characterization of $\gamma\delta$ T-cells via flow cytometry. *Age (Dordr)*. 2015 Dec;37(6):123. doi: 10.1007/s11357-015-9861-2. Epub 2015 Dec 4

- 98) Naumova E, **Pawelec G**, Mihaylova A. Natural killer cells, ageing and cancer. *Cancer Immunol Immunother.* 2016 Apr;65(4):367-70. doi: 10.1007/s00262-016-1817-6. Epub 2016 Mar 11.
- 99) Ascierto PA, Ascierto MA, Formenti S, Gnjatic S, Hammers H, Hirsh V, Kiessling R, Melero I, Nanda R, **Pawelec G**, Pignata S, Romero P, Speiser DA, Fox BA, Marincola FM. Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, December 5th 2015. *J Immunother Cancer.* 2016; 4: 62. Published online 2016 Oct 18. doi: 10.1186/s40425-016-0168-3
- 100) **Pawelec G**. Are Lower Antibody Responses to Influenza Vaccination in Cytomegalovirus-Seropositive Older Adults the Result of Beta Adrenergic Blockade? *Brain Behav Immun.* 2016 Nov 16. pii: S0889-1591(16)30518-9. [Epub ahead of print]
- 101) **Pawelec G**. Editorial. *Mech Ageing Dev.* 2016 Sep;158:1-2. doi: 10.1016/j.mad.2016.07.012.
- 102) Shipp C, **Pawelec G**. The fifteenth International Conference on Progress in Vaccination against Cancer (PIVAC-15), 6-8 October 2015, Tübingen, Germany: looking back on 15 years of progress. *Cancer Immunol Immunother.* 2016 Aug 24. [Epub ahead of print]
- 103) **Pawelec G**, Ostrand-Rosenberg S. Professor Enrico Mihich, 1928-2016. *Cancer Immunol Immunother.* 2017 Jul;66(7):955-957. doi: 10.1007/s00262-017-2024-9. Epub 2017 May 29
- 104) Wistuba-Hamprecht K, **Pawelec G**. KEYNOTE-006: a success in melanoma, but a long way to go. *Lancet.* 2017 Oct 21;390(10105):1816-1817. doi: 10.1016/S0140-6736(17)31816-0. Epub 2017 Aug 16
- 105) Samara P, Kotsakis A, Tsitsilonis O, Georgoulas V, **Pawelec G**, Baxevanis CN. 2nd Symposium on Advances in Cancer Immunology and Immunotherapy, December 15-17, 2016, Athens, Greece. *Cancer Immunol Immunother.* 2018 Jan;67(1):153-159. doi: 10.1007/s00262-017-2096-6. Epub 2017 Dec 1.
- 106) **Pawelec G**, McElhaney J. Vaccines for Improved Cellular Immunity to Influenza. *EBioMedicine.* 2018 Mar 5. pii: S2352-3964(18)30085-9. doi: 10.1016/j.ebiom.2018.03.001. [Epub ahead of print]
- 107) **Pawelec G**. Unexpected Benefits of Aging for Favorable Responses to PD-1 Blockade in Melanoma? *Clin Cancer Res.* 2018 Nov 1;24(21):5193-5194. doi: 10.1158/1078-0432.CCR-18-1475. Epub 2018 Jun 15.
- 108) **Pawelec GP**. CASIN the joint: immune aging at the stem cell level. *Blood.* 2018 Aug 9;132(6):553-554. doi: 10.1182/blood-2018-06-858696
- 109) **Pawelec G**. Is There a Positive Side to T Cell Exhaustion? *Front Immunol.* 2019 Jan 29;10:111. doi: 10.3389/fimmu.2019.00111

3) Reviews

- 1) **Pawelec G**: Allogeneically primed T lymphocyte clones in the analysis of lymphocyte stimulatory determinants. *Human Immunology* 8:239, 1983
- 2) Wernet P, Schneider EM, Kalthoff F, **Pawelec G**: Constitutive functional heterogeneity without detectable somatic mutation of antigen receptor genes in helper T cell clones: possible regulation by novel HLA class II "DY" determinants. *Immunol Rev* 96:109, 1987
- 3) **Pawelec G**: Suppressor cells in transplantation immunology. *Transplant Immunol* 1:172, 1993
- 4) **Pawelec G**: MHC-unrestricted surveillance of leukemia. *Cancer Biotherapy* 9:265, 1994
- 5) **Pawelec G**: Molecular and cell biological studies of ageing and their application to considerations of T lymphocyte immunosenescence. *Mech Ageing Dev* 79:1, 1995
- 6) **Pawelec G**, Adibzadeh M, Sansom D, Bornhak S, Friccus H, Halder T, Kalbacher H: The role of endogenous peptides in the direct pathway of alloreactivity to human MHC class II molecules expressed on CHO cells. *Immunol Rev* 154:155, 1996
- 7) Effros R, **Pawelec G**: Replicative senescence of T lymphocytes: does the Hayflick Limit lead to immune exhaustion? *Immunol Today* 18:450, 1997
- 8) **Pawelec G**, Rehbein A, Haehnel K, Merl A, Adibzadeh M: Human T cell clones in long-term culture as a model of immunosenescence. *Immunol. Rev.* 160:31, 1997
- 9) **Pawelec G**, Zeuthen J, Kiessling R: Tumor escape from immunosurveillance. *Crit Rev Oncogen* 8:111, 1997

- 10) Remarque E, **Pawelec G**: T cell immunosenescence and its clinical relevance in man. *Rev Clin Gerontol* 8:5, 1998.
- 11) **Pawelec G**, Solana R, Remarque E, Mariani E: Impact of aging on innate immunity in man. *J Leuk Biol* 64:703, 1998
- 12) **Pawelec G**, Effros RB, Caruso C, Remarque E, Barnett Y, Solana R: T cells and aging. *Frontiers in Bioscience* 4:d216, 1999 (access via <http://www.bioscience.org>)
- 13) **Pawelec G**, Rees RC, Kiessling R, Madrigal A, Dodi A, Baxevanis C, Gambacorti-Passerini C, Masucci G, Zeuthen J: Cells and cytokines in immunotherapy and gene therapy of cancer. *Crit Rev Oncogen* 10:83, 1999
- 14) **Pawelec G**, Rehbein A, Hähnel K, Adibzadeh M, Wagner W, Engel A: In vitro senescence models for human T lymphocytes. *Vaccine* 18: 1666, 2000
- 15) **Pawelec G**, Heinzel S, Kiessling R, Müller L, Ouyang Q, Zeuthen J: Escape mechanisms in tumor immunity: A year 2000 update. *Crit Rev Oncogen* 11:97, 2000
- 16) Ouyang Q, Wagner W, Wikby A, Remarque E, **Pawelec G**: Compromised IFN-gamma production in the elderly leads to both acute and latent viral antigen stimulation: contribution to the immune risk phenotype? *Eur Cytokine Netw* 13:387, 2002
- 17) Müller L, Kiessling R, Rees RC, **Pawelec G**: Escape mechanisms in tumor immunity: an update. *J Environ Pathol Toxicol Oncol.* 21:277, 2002.
- 18) Müller L, **Pawelec G**: Chronic phase CML patients possess T cells capable of recognising autologous tumour cells. *Leuk Lymphoma.* 43:943, 2002
- 19) **Pawelec G**, Barnett Y, Forsey R, Frasca D, Globerson A, McLeod J, Caruso C, Franceschi C, Fulop T, Gupta S, Mariani E, Mocchegiani E, Solana R. T cells and aging, January 2002 update. *Front Biosci.* 7:d1056-183, 2002
- 20) Muller L, **Pawelec G**: Cytokines and antitumor immunity. *Technol Cancer Res Treat.* 2:183-94, 2003.
- 21) Fülöp T, Larbi A, Dupuis G, **Pawelec G**: Ageing, autoimmunity and arthritis: Perturbations of TCR signal transduction pathways with ageing – a biochemical paradigm for the ageing immune system. *Arthritis Res Ther* 5: 290-302, 2003
- 22) **Pawelec G**. Tumour escape: antitumour effectors too much of a good thing? *Cancer Immunol Immunother.* 53: 262-274, 2004
- 23) **Pawelec G**. Immunotherapy and immunoselection – tumour escape as the final hurdle. Minireview. *FEBS Letters* 567: 63-66, 2004
- 24) **Pawelec G**. Tumour escape from the immune response. *Cancer Immunol Immunother.* 53:843, 2004
- 25) **Pawelec G**, Akbar A, Caruso C, Solana R, Grubeck-Loebenstein B, Wikby A. Human immunosenescence. Is it infectious? *Immunol. Rev.* 205:257-268, 2005
- 26) Fulop T, Larbi A, Wikby A, Mocchegiani E, Hirokawa H, and **Pawelec G**. Dysregulation of T-cell function in the elderly: scientific basis and clinical implications. *Drugs Aging* 22: 589-603, 2005
- 27) **Pawelec G**, Gouttefangeas C. T cell dysregulation caused by chronic antigenic stress: role of CMV in immunosenescence? *Aging Clin Exp Res* 18: 171-173, 2006
- 28) Koch S, Solana R, Dela Rosa O, **Pawelec G**. Human Cytomegalovirus infection and T cell immunosenescence: a Minireview. *Mech Ageing Dev* 127: 538-43, 2006
- 29) Solana R, Casado JG, Delgado E, Delarosa O, Marin J, Duran E, **Pawelec G**, Tarazona R. Lymphocyte activation in response to melanoma: interaction of NK-associated receptors and their ligands. *Cancer Immunol Immunother.* 56:101-109, 2007.
- 30) **Pawelec G**, Koch S, Griessemann H, Rehbein A, Hähnel K, Gouttefangeas C. Immunosenescence, suppression and tumour progression. *Cancer Immunol Immunother* 55: 981-986, 2006
- 31) **Pawelec G**, Koch S, Gouttefangeas C, Wikby A. Immunorejuvenation in the elderly. *Rejuvenation Res.* 9:111-116, 2006.
- 32) Capri M, Salvioli S, Sevini F, Valensin S, Celani L, Monti D, **Pawelec G**, De Benedictis G, Gonos ES, Franceschi C. The Genetics of Human Longevity. *Ann NY Acad Sci* 1067: 252-263, 2006
- 33) **Pawelec G**, Koch S, Franceschi C, Wikby A. Human Immunosenescence. Does it have an infectious component? *Ann NY Acad Sci* 1067: 56-65, 2006

- 36) Larbi A, Kempf J, Wistuba-Hamprecht K, Haug C, **Pawelec G**. The heat shock proteins in cellular aging: is zinc the missing link? *Biogerontol* 7: 399-408, 2006.
- 37) Delarosa O, **Pawelec G**, Peralbo E, Wikby A, Mariani E, Mocchegiani E, Tarazona R, Solana R: Immunological biomarkers of ageing in man: changes in both innate and adaptive immunity are associated with health and longevity. *Biogerontology* 7:471-481, 2006.
- 38) **Pawelec G**. Immunity and ageing in man. *Exp Gerontol*. 41: 1239-1242, 2006
- 39) Vasto S, Colonna-Romano G, Larbi A, Wikby A, Caruso C, **Pawelec G**. Role of persistent CMV infection in configuring T cell immunity in the elderly. *Immun Ageing*. 4:2, 2007
- 40) Fülöp T, Larbi A, Hirokawa K, Mocchegiani E, Lesourd B, Castle S, Wikby A, Franceschi C, **Pawelec G**. Immunosupportive therapies in aging. *Clin Interventions Aging* 2:1-22, 2007
- 41) Koch S, Larbi A, Ozcelik D, Solana R, Gouttefangeas C, Attig S, Wikby A, Strindhall J, Franceschi C, **Pawelec G**. Cytomegalovirus infection: a driving force in human T cell immunosenescence. *Ann N Y Acad Sci*. 1114:23-35, 2007
- 42) **Pawelec G**, Larbi A. Immunity and ageing in man: Annual review 2006/2007. *Exp Gerontol*. 2007 Oct 1; [Epub ahead of print]
- 43) Larbi A, Franceschi C, Mazzatti D, Solana R, Wikby A, **Pawelec G**. Aging of the immune system as a prognostic factor for human longevity. *Physiology* 23:64-74, 2008
- 44) Derhovanessian E, Solana R, Larbi A, **Pawelec G**. Immunity, ageing and cancer. *Immun Ageing*. 2008 Sep 24;5(1):11
- 45) Trzonkowski P, Myśliwska J, **Pawelec G**, Myśliwski A. From bench to bedside and back: the SENIEUR Protocol and the efficacy of influenza vaccination in the elderly. *Biogerontology* 10: 83-94, 2009.
- 46) **Pawelec G**, Derhovanessian E, Larbi A, Strindhall J, Wikby A. Cytomegalovirus and human immunosenescence. *Rev Med Virol*. 19:47-56, 2009
- 48) Fulop T, **Pawelec G**, Castle S, Loeb M. Immunosenescence and Vaccination in Nursing Home Residents. *Clin Infect Dis*. 48:443-448, 2009
- 49) Grubeck-Loebenstien B, Della Bella S, Iorio AM, Michel JP, **Pawelec G**, Solana R. Immunosenescence and vaccine failure in the elderly. *Aging Clin Exp Res*. 21:201-209, 2009.
- 50) Weksler ME, **Pawelec G**, Franceschi C. Immune therapy for age-related diseases. *Trends Immunol*. 30:344-350, 2009
- 51) Derhovanessian E, Larbi A, **Pawelec G**. Biomarkers of human immunosenescence: impact of Cytomegalovirus infection. *Curr Op Immunol* 21:440-445, 2009.
- 52) **Pawelec G**, Larbi A, Derhovanessian E. Senescence of the Human Immune System. *J Comp Pathol* 142 Suppl 1:S39-44, 2010.
- 53) Fulop T, Kotb R, Fortin CF, **Pawelec G**, de Angelis F, Larbi A. Potential role of immunosenescence in cancer development. *Ann N Y Acad Sci*. 1197:158-165, 2010.
- 54) Fulop T, Larbi A, Witkowski JM, McElhaney J, Loeb M, Mitnitski A, **Pawelec G**. Aging, frailty and age-related diseases. *Biogerontology*. 11:547-563, 2010.
- 55) **Pawelec G**, Derhovanessian E, Larbi A. Immunosenescence and cancer. *Crit Rev Oncol Hematol* 75:165-172, 2010
- 56) **Pawelec G**, Derhovanessian E, Larbi A. Immunosenescence and cancer. *J Geriatric Oncol* 1:20-26, 2010
- 57) **Pawelec G**, Derhovanessian E. Role of CMV in immune senescence. *Virus Res* 157:175-179, 2011
- 58) Larbi A, **Pawelec G**, Wong SC, Goldeck D, Tai JJ, Fulop T. Impact of age on T cell signalling. *Ageing Res Rev* 10:370-378, 2011
- 59) Fulop T, Larbi A, Kotb R, de Angelis F, **Pawelec G**. Aging, immunity, and cancer. *Discov Med*. 11:537-550, 2011.
- 60) Naumova E, Ivanova M, **Pawelec G**. Immunogenetics of ageing. *Int J Immunogenet*. 38: 373-381, 2011.
- 61) Derhovanessian E, **Pawelec G**. Vaccination in the elderly. *Microb Biotechnol*. 2012 Mar;5(2):226-32. doi: 10.1111/j.1751-7915.2011.00283.x. Epub 2011 Aug 31.

- 62) McElhaney JE, Zhou X, Talbot HK, Soethout E, Bleackley RC, Granville DJ, **Pawelec G**. The unmet need in the elderly: How immunosenescence, CMV infection, co-morbidities and frailty are a challenge for the development of more effective influenza vaccines. *Vaccine* 2012 Mar 9;30(12):2060-7. Epub 2012 Jan 27.
- 63) **Pawelec G**, McElhaney JE, Aiello AE, Derhovanessian E. The impact of CMV infection on survival in older humans. *Curr Opin Immunol.* 24: 507-511, 2012
- 64) Fulop T, Larbi A, Kotb R, **Pawelec G**. Immunology of aging and cancer development. *Interdiscip Top Gerontol.* 2013;38:38-48. doi: 10.1159/000343599. Epub 2013 Jan 17.
- 65) Fulop T, Lacombe G, Cunnane S, Le Page A, Dupuis G, Frost EH, Bourgade-Navarro K, Goldeck D, Larbi A, **Pawelec G**. Elusive Alzheimer's disease: can immune signatures help our understanding of this challenging disease? Part 1: clinical and historical background. *Discov Med.* 2013 Jan;15(80):23-32.
- 66) Fulop T, Lacombe G, Cunnane S, Le Page A, Dupuis G, Frost EH, Bourgade-Navarro K, Goldeck D, Larbi A, **Pawelec G**. Elusive Alzheimer's disease: can immune signatures help our understanding of this challenging disease? Part 2: new immune paradigm. *Discov Med.* 2013 Jan;15(80):33-42.
- 67) Müller L, Fülöp T, **Pawelec G**. Immunosenescence in vertebrates and invertebrates. *Immun Ageing.* 2013 Apr 2;10(1):12. doi: 10.1186/1742-4933-10-12.
- 68) Müller L, **Pawelec G**. Aging and immunity - Impact of behavioral intervention. *Brain Behav Immun.* 2014 Jul;39:8-22. doi: 10.1016/j.bbi.2013.11.015. Epub 2013 Dec 4.
- 69) Fülöp T, Larbi A, **Pawelec G**. Human T Cell Aging and the Impact of Persistent Viral Infections. *Front Immunol.* 2013 Sep 13;4:271.
- 70) **Pawelec G**. Immunosenescence: Role of cytomegalovirus. *Exp Gerontol.* 2014 Jun;54:1-5.
- 71) **Pawelec G**, Goldeck D, Derhovanessian E. Inflammation, ageing and chronic disease. *Curr Opin Immunol.* 2014 Aug;29:23-8. doi: 10.1016/j.coi.2014.03.007. Epub 2014 Apr 2
- 72) Müller L, **Pawelec G**. As we age: Does slippage of quality control in the immune system lead to collateral damage? *Ageing Res Rev.* 2015 Sep;23(Pt A):116-23. doi: 10.1016/j.arr.2015.01.005. Epub 2015 Feb 9
- 73) Vinay DS, Ryan EP, **Pawelec G**, Talib WH, Stagg J, Elkord E, Lichtor T, Decker WK, Whelan RL, Kumara HM, Signori E, Honoki K, Georgakilas AG, Amin A, Helferich WG, Boosani CS, Guha G, Ciriolo MR, Chen S, Mohammed SI, Azmi AS, Keith WN, Bilsland A, Bhakta D, Halicka D, Fujii H, Aquilano K, Ashraf SS, Newsheen S, Yang X, Choi BK, Kwon BS. Immune evasion in cancer: Mechanistic basis and therapeutic strategies. *Semin Cancer Biol.* 2015 Dec;35 Suppl:S185-98. doi: 10.1016/j.semcancer.2015.03.004. Epub 2015 Mar 25.
- 74) Fulop T, McElhaney J, Pawelec G, Cohen AA, Morais JA, Dupuis G, Baehl S, Camous X, Witkowski JM, Larbi A. Frailty, Inflammation and Immunosenescence. *Interdiscip Top Gerontol Geriatr.* 2015;41:26-40. doi: 10.1159/000381134. Epub 2015 Jul 17.
- 75) Block KI, Gyllenhaal C, Lowe L, Amedei A, Amin AR, Amin A, Aquilano K, Arbiser J, Arreola A, Arzumanyan A, Ashraf SS, Azmi AS, Benencia F, Bhakta D, Bilsland A, Bishayee A, Blain SW, Block PB, Boosani CS, Carey TE, Carnero A, Carotenuto M, Casey SC, Chakrabarti M, Chaturvedi R, Chen GZ, Chen H, Chen S, Chen YC, Choi BK, Ciriolo MR, Coley HM, Collins AR, Connell M, Crawford S, Curran CS, Dabrosin C, Damia G, Dasgupta S, DeBerardinis RJ, Decker WK, Dhawan P, Diehl AM, Dong JT, Dou QP, Drew JE, Elkord E, El-Rayes B, Feitelson MA, Felsher DW, Ferguson LR, Fimognari C, Firestone GL, Frezza C, Fujii H, Fuster MM, Generali D, Georgakilas AG, Gieseler F, Gilbertson M, Green MF, Grue B, Guha G, Halicka D, Helferich WG, Heneberg P, Hentosh P, Hirschey MD, Hofseth LJ, Holcombe RF, Honoki K, Hsu HY, Huang GS, Jensen LD, Jiang WG, Jones LW, Karpowicz PA, Keith WN, Kerkar SP, Khan GN, Khatami M, Ko YH, Kucuk O, Kulathinal RJ, Kumar NB, Kwon BS, Le A, Lea MA, Lee HY, Lichtor T, Lin LT, Locasale JW, Lokeshwar BL, Longo VD, Lyssiotis CA, MacKenzie KL, Malhotra M, Marino M, Martinez-Chantar ML, Matheu A, Maxwell C, McDonnell E, Meeker AK, Mehrmohamadi M, Mehta K, Michelotti GA, Mohammad RM, Mohammed SI, Morre DJ, Muralidhar V, Muqbil I, Murphy MP, Nagaraju GP, Nahta R, Niccolai E, Newsheen S, Panis C, Pantano F, Parslow VR, **Pawelec G**, Pedersen PL, Poore B, Poudyal D, Prakash S, Prince M, Raffaghello L, Rathmell JC, Rathmell WK, Ray SK, Reichrath J, Rezazadeh S, Ribatti D, Ricciardiello L, Robey RB, Rodier F, Rupasinghe HP, Russo GL, Ryan EP, Samadi AK, Sanchez-Garcia I, Sanders AJ, Santini D, Sarkar M, Sasada T, Saxena NK, Shackelford RE, Shantha Kumara HM, Sharma D, Shin DM, Sidransky D, Siegelin MD, Signori E, Singh N, Sivanand S, Sliva D, Smythe C, Spagnuolo C, Stafforini DM, Stagg J, Subbarayan PR, Sundin T, Talib WH, Thompson SK, Tran PT, Ungefroren H, Vander Heiden MG, Venkateswaran V, Vinay DS, Vlachostergios PJ, Wang Z, Wellen KE, Whelan RL, Yang ES, Yang H, Yang X, Yaswen P, Yedjou C, Yin X, Zhu J, Zollo M. Designing a broad-spectrum integrative approach for cancer prevention and treatment. *Semin Cancer Biol.* 2015 Dec;35 Suppl:S276-304. doi: 10.1016/j.semcancer.2015.09.007.

- 76) Goldeck D, Witkowski JM, Fülöp T, **Pawelec G**. Peripheral immune signatures in Alzheimer Disease. *Curr Alzheimer Res*. 2016 Feb 21. [Epub ahead of print]
- 77) Fulop T, Dupuis G, Baehl S, Le Page A, Bourgade K, Frost E, Witkowski JM, **Pawelec G**, Larbi A, Cunnane S. From inflamm-aging to immune-paralysis: a slippery slope during aging for immune-adaptation. *Biogerontology*. 2016 Feb;17(1):147-57.
- 78) Shipp C, Speigl L, Janssen N, Martens A, **Pawelec G**. A clinical and biological perspective of human myeloid-derived suppressor cells in cancer. *Cell Mol Life Sci*. 2016 Nov;73(21):4043-61. doi: 10.1007/s00018-016-2278-y.
- 79) Fulop T, Witkowski JM, Le Page A, Fortin C, **Pawelec G**, Larbi A. Intracellular signaling pathways: Targets to reverse immunosenescence. *Clin Exp Immunol*. 2016 Jul 1. doi: 10.1111/cei.12836. [Epub ahead of print]
- 80) Fülöp T, Herbein G, Cossarizza A, Witkowski JM, Frost E, Dupuis G, **Pawelec G**, Larbi A. Cellular Senescence, Immunosenescence and HIV. *Interdiscip Top Gerontol Geriatr*. 2017;42:28-46. [Epub 2016 Nov 22]
- 81) **Pawelec G**. Immunosenescence and cancer. *Biogerontology*. 2017 Aug;18(4):717-721. doi: 10.1007/s10522-017-9682-z. Epub 2017 Feb 20.
- 82) Di Benedetto S, Müller L, Wenger E, Düzel S, **Pawelec G**. Contribution of neuroinflammation and immunity to brain aging and the mitigating effects of physical and cognitive interventions. *Neurosci Biobehav Rev*. 2017 Apr;75:114-128. doi: 10.1016/j.neubiorev.2017.01.044. Epub 2017 Feb 1.
- 83) **Pawelec G**. Does the human immune system ever really become “senescent”? [version 1; referees: 5 approved]. *F1000Research* 2017, 6(F1000 Faculty Rev):1323 (doi: 10.12688/f1000research.11297.1)
- 84) Merani S, **Pawelec G**, Kuchel GA, McElhaney JE. Impact of Aging and Cytomegalovirus on Immunological Response to Influenza Vaccination and Infection. *Front Immunol*. 2017 Jul 17;8:784. doi: 10.3389/fimmu.2017.00784. eCollection 2017
- 85) **Pawelec G**. Age and immunity: What is "immunosenescence"? *Exp Gerontol*. 2018 May;105:4-9. doi: 10.1016/j.exger.2017.10.024. Epub 2017 Oct 27
- 86) **Pawelec G**. Immune correlates of clinical outcome in melanoma. *Immunology*. 2018 Apr;153(4):415-422. doi: 10.1111/imm.12870. Epub 2017 Dec 20
- 87) Le Page A, Dupuis G, Frost EH, Larbi A, **Pawelec G**, Witkowski JM, Fulop T. Role of the peripheral innate immune system in the development of Alzheimer's disease. *Exp Gerontol*. 2017 Dec 21. pii: S0531-5565(17)30541-7. doi: 10.1016/j.exger.2017.12.019. [Epub ahead of print]
- 88) **Pawelec G**. Immune parameters associated with mortality in the elderly are context-dependent: lessons from Sweden, Holland and Belgium. *Biogerontology*. 2018 Dec;19(6):537-545. doi: 10.1007/s10522-017-9739-z. Epub 2017 Nov 28.
- 89) **Pawelec G**. Immune signatures predicting responses to immunomodulatory antibody therapy. *Curr Opin Immunol*. 2018 Mar 15;51:91-96. doi: 10.1016/j.coi.2018.03.003. [Epub ahead of print]
- 90) **Pawelec G**. Immune signatures associated with mortality differ in elderly populations from different birth cohorts and countries even within northern Europe. *Mech Ageing Dev*. 2018 Apr 11. pii: S0047-6374(18)30054-X. doi: 10.1016/j.mad.2018.04.005. [Epub ahead of print]
- 91) Le Page A, Dupuis G, Frost EH, Larbi A, **Pawelec G**, Witkowski JM, Fulop T. Role of the peripheral innate immune system in the development of Alzheimer's disease. *Exp Gerontol*. 2018 Jul 1;107:59-66. doi: 10.1016/j.exger.2017.12.019. Epub 2017 Dec 21.
- 92) **Pawelec G**. Does patient age influence anti-cancer immunity? *Semin Immunopathol*. 2018 Jul 13. doi: 10.1007/s00281-018-0697-6. [Epub ahead of print]
- 93) Fulop T, Witkowski JM, Bourgade K, Khalil A, Zerif E, Larbi A, Hirokawa K, **Pawelec G**, Bocti C, Lacombe G, Dupuis G, Frost EH. Can an Infection Hypothesis Explain the Beta Amyloid Hypothesis of Alzheimer's Disease? *Front Aging Neurosci*. 2018 Jul 24;10:224. doi: 10.3389/fnagi.2018.00224. eCollection 2018.
- 94) Andrew MK, Bowles SK, **Pawelec G**, Haynes L, Kuchel GA, McNeil SA, McElhaney JE. Influenza Vaccination in Older Adults: Recent Innovations and Practical Applications. *Drugs Aging*. 2018 Nov 9. doi: 10.1007/s40266-018-0597-4. [Epub ahead of print] Review.
- 95) Martens A, **Pawelec G**, Shipp C. Expansion and Determination of Antigen-Reactive T Cells by Flow Cytometry. *Methods Mol Biol*. 2019;1913:141-151. doi: 10.1007/978-1-4939-8979-9_10.

96) Müller L, Di Benedetto S, **Pawelec G**. The Immune System and Its Dysregulation with Aging. *Subcell Biochem.* 2019;91:21-43. doi: 10.1007/978-981-13-3681-2_2.

4) Book contributions

1) Sachs J, Duquesnoy R, Hansen J, Amos B, Carbonara A, Fradelizi D, Grosse-Wilde H, Hartzmen R, Jaraquemada D, Jorgensen F, Kaneoka H, Kashiwagi N, Layrisse Z, Mickelson E, Nousiainen H, **Pawelec G**, Reinsmoen N, Sasportes M, Schendel D, Suci-Foca N, Termijtelen A, Thomsen M, Tsuji K, Wank R: Joint report. HLA-D specificities evaluated by participating laboratories. In: Terasaki PI (ed): *Histocompatibility Testing 1980*. Los Angeles, UCLA Press, 1981, p 268

2) Wernet P, Hadam M, Ziegler A, **Pawelec G**: Cloned human T cells with natural killer activity: specificity, cell surface markers, and relationship to graft-versus-host reactivity. In: Baum SJ, Ledney GD, Thierfelder S (eds): *Experimental Hematology Today 1982*. Basel, S. Karger, 1982, p 219

3) Fleischer B, Blaurock M, Wernet P, **Pawelec G**: Restriction of human Influenza A virus-specific T cell clones by HTC-defined subtypes of HLA-Dw6. *Histocompatibility Testing 1984*, Springer-Verlag, Berlin, p. 623, 1984.

4) Müller C, Spring B, Ziegler A, **Pawelec G**, Fonatsch C, Wernet P: Mutant cell lines as a means of resolving HLA gene products. In: Albert ED, Baur MP, Mayr WR (eds): *Histocompatibility Testing 1984*. Berlin, Heidelberg, Springer-Verlag, 1984, p 483

5) **Pawelec G**, Ziegler A, Blaurock M, Wernet P: Stimulation of secondary lymphoproliferative responses inhibited by monoclonal antibodies specific for human MHC class II molecules. In: Steel M (ed): *Disease Markers, Special Issue*. Chichester, John Wiley & Sons, 1984, p 341

6) **Pawelec G**: Functions and changing activities of interleukin 2-dependent human T lymphocyte clones derived from sensitization in mixed leukocyte cultures. In: Boehmer H von, Haas W (eds): *T cell clones*. Amsterdam, Elsevier Biomedical Press, 1985, p 311

7) **Pawelec G**, Wernet P, Newman W: Recognitive heterogeneity of NK cells. In: Herberman RB, Callewaert DM (eds): *Mechanisms of cytotoxicity by NK cells*. Orlando, Academic Press, 1985, p 655

8) Schneider EM, Wernet P, **Pawelec G**, Busch FW: Granulocyte-macrophage colony formation by normal bone marrow is suppressed by T cell clones with natural killer-like activity. In: Urbanitz D, Haubeck F (eds): *Aktuelle Aspekte der Tumor-Immunologie*. Berlin, Heidelberg, Springer-Verlag, 1985, p 1

9) **Pawelec G**, Busch FW, Schneider EM, Rehbein A, Balko I, Wernet P: Acquisition of suppressive and natural killer-like activities associated with loss of alloreactivity in human "helper" T lymphocyte clones. In: Fleischer B, Reimann J, Wagner H (eds): *Current Topics in Microbiology and Immunology. Specificity and function of clonally developing T cells*. Berlin, Heidelberg, Springer-Verlag, 1986, p 121

10) Wernet P, **Pawelec G**, Schneider EM: Cellular detection of human class II antigens: delineation of a novel HLA-DP-like suppressor restriction system, DY, the sequential expression of class II antigens, and a pronounced functional flexibility of class II alloproliferative T cell clones. In: Solheim BG, Moller E, Ferrone S (eds): *HLA class II antigens. A comprehensive review of structure and function*. Berlin, Heidelberg, Springer Verlag, 1986, p 281

11) Rehbein A, Schlotz E, Vöhringer D, Schaudt K, **Pawelec G**: Cellular reactivity to the DRB1* 1303 allele-associated Dw"HAG" specificity. In: *HLA 1991*, eds. Tsuji K et al, Oxford University Press, p. 914, 1992.

12) **Pawelec G**: Cloning and propagation of human T lymphocytes. In: *Tumour Immunology: A practical approach*, eds. Gallagher G, Rees RC, Reynolds CW, Oxford University Press, pp. 131-141, 1992.

13) **Pawelec G**, Friccius H, Schlotz E, Rehbein A: Expression of CD28 and B7 on T cell clones: relevance for anergy. In *Leukocyte Typing V*. Eds. S. Schlossman et al., Oxford University Press, p. 372, 1995.

14) **Pawelec G**, Schlotz E, Rehbein A: Cytokine receptors on lymphocytes activated in MLC: effects of exogenous cytokines on receptor expression and function. In *Leukocyte Typing V*. Eds. S. Schlossman et al., Oxford University Press, p. 1959, 1995.

15) Bühring HJ, Burkhardt M, Ning Y, Zhu X, Volkmann R, Müller CA, **Pawelec G**, Bruserud O: Reactivity of cytokine panel antibodies with immature hematopoietic cells and cell lines. In *Leukocyte Typing V*. Eds. S. Schlossman et al., Oxford University Press, p. 1945, 1995.

16) Merl A, Pohla H, Adibzadeh M, **Pawelec G**: Expression of cytokine receptors on anergic CD4+ TCR2+ Th0 cell clones. In: *Leukocyte Typing VI*, eds. T. Kishimoto et al. p. 873, 1997.

17) **Pawelec G**, Mariani E, Offringa R, Melief CJM, Solana R: Generation and characterization of killer cells. In: *Immunological Methods in Microbiology* (eds. SHE Kaufmann, D Kabelitz), series "Methods in Microbiology", Academic Press, London, pp. 605-619, 1998.

- 18) **Pawelec G**, Obata F, Sansom D, Friccius H, Daikeler T, Adibzadeh M, Schaudt K, Pohla H: Analysis of MHC class II-specific T cell clones. In: MHC cellular and molecular genetics: A practical approach, Eds. N. Fernandez & G. Butcher, IRL Press at Oxford University Press, pp. 71-89, 1997.
- 19) Barnett Y, King C, Bristow-Craig H, Warnock C, Hyland P, Gillespie E, Rea M, Middleton D, Curran D, **Pawelec G**, Barnett C: Age-related increases in DNA damage and mutations in T cells in vivo and in vitro: contributors to alterations in T cell-mediated immune responses? In **Pawelec G** (ed) EUCAMBIS: Immunology and Ageing in Europe, IOS Press, ISBN 90 5199 434 6, p. 54, 2000
- 20) **Pawelec G**: The European Union Concerted Action on the Molecular Biology of Immunosenescence (EUCAMBIS). In **Pawelec G** (ed) EUCAMBIS: Immunology and Ageing in Europe, IOS Press, ISBN 90 5199 434 6, p. 1, 2000
- 21) **Pawelec G**: T cell clones. In: Methods in Molecular Medicine : Aging Methods and Protocols (Eds. C. Barnett & Y. Barnett), Humana Press. Vol 38, p. 53, 2000
- 22) Engel A, Adibzadeh M, **Pawelec G**: DDRT-PCR. In: Methods in Molecular Medicine : Aging Methods and Protocols (Eds. C. Barnett & Y. Barnett), Humana Press. Vol 38, p. 97, 2000
- 23) **Pawelec G**: Escape Mechanisms in Tumour Immunity. In: Immunology in Medicine Series: Cancer Immunology (eds. RA Robins & RC Rees), Kluwer. Vol 30, p. 219, 2001.
- 24) **Pawelec G**: Impact of Immunosenescence on Disease and Aging: Role of Telomere Attrition, Telomerase and Oxidative Damage as Factors controlling Human T Lymphocyte Clonal Expansion Ability. In: Aging: Morphological, Biochemical, Molecular and Social Aspects (eds. M Oehmichen, S Ritz-Timmer, C Meissner), Schmid-Römhild, Lübeck, pp.343-352, 2002.
- 25) **Pawelec G**, Mariani E, Offringa R, Melief CJM, Solana R: Generation and characterization of killer cells. In: Immunology of Infection, 2nd Edition (eds SHE Kaufmann, D Kabelitz), series "Methods in Microbiology", Vol. 32, Academic Press, London, pp. 693-706, 2002.
- 26) **Pawelec G**, Ouyang Q, Wagner W, Wikby A: Pathways to a robust immune response in the elderly. In: Impact of immune senescence on human aging (eds JD Mountz, H-C Hsu), series Immunol Allergy Clin N America, Vol. 23, WB Saunders Co, Philadelphia, pp. 1-13, 2003
- 27) **Pawelec G**: T cell Immunosenescence. In: Aging of cells in and outside the body, Chapter 6 (eds SC Kaul, R Wadhwa), Vol. 1 of the series "Biology of Aging and its Modulation", series editor Suresh Rattan, Kluwer, pp. 85-100, 2003.
- 28) Solana R, **Pawelec G**: Immunosenescence. In: Neuroimmune Biology Vol 9: The neuroendocrine immune network in ageing (Eds. R. Straub & E. Mocchegiani), Elsevier, Amsterdam, 2004
- 29) Müller L, **Pawelec G**: Chronic Myelogenous Leukemia. In: Horizons in Cancer Research: Vol. 5. Focus on Leukemia Research. Nova Science Publishers, New York, pp. 1-26, 2005
- 30) **Pawelec G**, Mariani E, Solana R, Forsey R, Larbi A, Neri S, Dela Rosa O, Barnett Y, Tolson J, Fülöp T: Human T cell clones in long-term culture as models for the impact of chronic antigenic stress in ageing. In: Handbook of Models of Human Aging ed. Michael Conn, Oregon National Primate Research Center, Elsevier, pp. 781-792, 2006.
- 31) Müller L, McArdle S, Derhovanessian E, Flad T, Knights A, Rees R, **Pawelec G**: Current strategies for the identification of immunogenic epitopes of tumor antigens. In: Immunotherapy of Cancer. Ed. M.L. Disis, Humana Press, Totowa, NJ, pp. 21-44, 2006.
- 32) Fülöp T, Hirokawa H, Mocchegiani E, Witkowski JM, Larbi A, Wikby A, **Pawelec G**. The immune system in the elderly. Chapter VIII in: Aging and Age-Related Diseases: The Basics (Ed., M. Karasek), Nova Science Publishers, pp.173-196, 2007.
- 33) Larbi A, Fülöp T, **Pawelec G**. Immune receptor signalling, aging and autoimmunity. In: Multichain immune recognition receptor signalling: from spatiotemporal organisation to human disease (Ed. A.B. Sigalov), Landes Bioscience, pp781-792, 2007.
- 34) **Pawelec G**, Kempf, J, Larbi A. Clonal culture models of immunosenescence. In: Handbook on immunosenescence (Eds. T. Fülöp, C. Franceschi, H. Hirokawa, G. Pawelec). Springer, pp.107-116, 2009.
- 35) Forsey RJ, Thomson JM, **Pawelec G**, Powell JR. Healthy Ageing: The Immune System. In: Healthy Ageing: The Role of Lifestyle and Nutrition. (Eds. S. Stanner, R. Thompson, JL Buttriss). Wiley Blackwell, pp. 191-207, 2009.
- 36) Müller L, **Pawelec G**. Introduction to Ageing of the Adaptive Immune System. In: Immunosenescence. Psychosocial and Behavioral Determinants. (Eds. JA Bosch, AC Phillips, JM Lord). Springer, pp.17-34, 2013.

- 37) Fülöp T, Larbi A, Extermann M, Solana R, Dupuis G, Kotb R, Derhovanessian E, **Pawelec G**. Aging, Immunosenescence, and Cancer. In: *Inflammation, Advancing Age and Nutrition: Research and Clinical Interventions 1st edn.* (Eds I Rahman, D Bagchi). Academic Press, Oct 17 2013, p 55-69
- 38) Müller, L., **Pawelec, G.**, & Derhovanessian, E. (2013). The immune system during aging. In P. Calder & P. Yagoob (Ed.), *Diet, immunity and inflammation* (pp. 631-651). Cambridge, UK: Woodhead Publishing.
- 39) Müller L., **Pawelec G** (2014) Immune escape and ageing of the immune system compromises the immune response to tumor antigens. In RC Rees (ed) *Tumor Immunology and Immunotherapy*, Oxford University Press.
- 40) Fulop T, **Pawelec G**, Dupuis G, Kotb R, Friguet B, Larbi A (2015). Immunosenescence, Oxidative Stress, and Cancers. In N. Rezaei (ed) *Cancer Immunology: A Translational Medicine Context*. Springer Verlag.
- 41) Müller L, **Pawelec G** (2016). The Aging Immune System: Dysregulation, Compensatory Mechanisms, and Prospects for Intervention. In MR Kaeberlein and G. Martin (Eds) *Handbook of the Biology of Aging*, 8th Edition, Academic Press
- 42) **Pawelec G**, Barnett Y (2016). Ageing and senescence in immune cells in vitro and in vivo. In: SIS Rattan and L Hayflick (Eds) *Cellular Ageing and Replicative Senescence (Healthy Ageing and Longevity, Vol. 4)*. Springer International Publishing Switzerland, pp85-95
- 43) Müller L, Hamprecht K, **Pawelec G**. The role of CMV in immunosenescence (2017). In V. Bueno, JM. Lord and TA. Jackson (Eds). *The Ageing Immune System and Health*, Springer International Publishing Switzerland.
- 44) **Pawelec G**. Age-related immune function changes as they relate to cancer immunotherapy. In: *Cancer Immunotherapy: Principles and Practice* (Eds. LH Butterfield, HL Kaufman, FM Marincola). SITC/Demos Medical, New York, 2017, pp 587-591.

5) Books edited

- Pawelec G** (ed) *EUCAMBIS: Immunology and Ageing in Europe*. IOS Press, Amsterdam, ISBN 90 5199 434 6, 2000
- Pawelec G** (ed) *Advances in Cell Ageing and Gerontology: Basic Biology and Clinical Impact of Immunosenescence*. Elsevier, Amsterdam, ISBN 0-444-51316-7, 2003.
- Pawelec G** (ed) *Immunosenescence*. Landes Bioscience/Springer Medical Intelligence Unit, NY, 2007. ISBN 978-0-387-76840-3
- Fülöp T, Franceschi C, Hirokawa H, **Pawelec G** (eds.). *Handbook on immunosenescence*. Springer, 2009. ISBN 978-1-4020-9062-2
- Fülöp T, Franceschi C, Hirokawa H, **Pawelec G** (eds.). *Handbook on immunosenescence*. Second Edition. Springer, 2019. ISBN 978-3-319-99373-7, ISBN 978-3-319-99375-1 (eBook), ISBN 978-3-319-99374-4 (print and electronic bundle)

Invited presentations

- Ageing and the human immune system. Lecture at Undoing Aging 2019, Berlin, 28th March, 2019 (invited by Dr. A. de Grey)
- Ageing and the human immune system in the era of immunomodulatory antibody therapy for cancer: is it all downhill? Lecture at Cambridge Healthtech IO-Summit Europe 2019, London, UK, 19th March, 2019 (invited by Mr. J. Hornby)
- Influenza in older adults. Presentation at the Sequirus Advisory Board meeting, Barcelona, 14th March, 2019 (invited by Dr. S. Rajaram)
- Immunotherapy of cancer: triumphs and challenges, and the impact of immunosenescence in humans. Lecture at the EACR IO conference, Barcelona, 12th March, 2019 (invited by Prof. J. Seoane)
- Peripheral blood immune signatures predicting response to immunomodulatory antibody therapy in melanoma. Lecture at the 14th Oxford Global Annual Biomarkers Congress, Manchester, 21st February, 2019 (invited by Dr. K. Landschulz).
- Ageing and the human immune system in the era of immunomodulatory antibody therapy for cancer: is it all downhill? Plenary lecture at the 47th Annual Scientific Meeting of the Australasian Society for Immunology, Perth, 5th December, 2018 (invited by Prof. D. Nelson).
- Immune Signatures Predicting Response To Immunomodulatory Antibody Therapy. Presentation at the Tumour

Immunology Special Interest Group Workshop, Australasian Society for Immunology meeting, Perth, 2nd December, 2018 (invited by Prof. D. Nelson).

Interplay between age, immunity, cancer and CMV. Charles Easton Gould Seminar, Dept Immunology, University of Toronto, 5th November, 2018 (invited by Prof. T. Watts).

Interplay between age, immunity, cancer and CMV. Keynote at the 5th National Congress of Immunology, Plovdiv, Bulgaria, 25th October, 2018 (invited by Prof. E. Naumova).

Vaccination in the elderly. Lecture at the 2nd Eur Hematol Soc SWG on Ageing, Warsaw, Poland, 12th October, 2018 (invited by Prof. D. Bron).

CMV infection, cancer and survival in the elderly. Lecture at PIVAC 18, Oslo, Norway, 5th October, 2018 (invited by Dr. E-M. Sso-Inderberg)

Immunotherapy of cancer: triumphs and challenges, and the impact of immunosenescence in humans. Lecture at CRT 2018, London, UK, 7th August, 2018 (session organized by self)

Impact of immunosenescence on immunomodulatory antibody therapy. Lecture at the Frontiers in Immunomodulation and Cancer Therapy Conference, Madrid, 10th July, 2018 (invited by Prof. M. Soengas)

Human Immunosenescence. Lecture at the American Aging Association annual meeting, Philadelphia, 30th June, 2018 (invited by Prof. C. Sell)

Immune monitoring of melanoma patients using peripheral blood. Lecture at the 1st ImmunoOncology meeting, Nafplion, Greece, 10th June, 2018 (invited by Prof. C. Baxevanis)

Immunity and ageing: causes and consequences of immunosenescence in humans. Lecture at the 31st Annual Meeting of the Canadian Immunology Society, London, ON, 2nd June, 2018 (invited by Prof. M. Haeryfar)

Immune signatures predicting response to immunomodulatory antibody therapy. Lecture at Loyola School of Medicine, Chicago, 9th May, 2018 (invited by Prof. M. Nishimura)

Interplay between age, immunity, cancer and CMV. Visiting Prof lecture at King's College London, 16th March, 2018 (invited by Prof. F. Farzaneh)

Immune signatures predicting response to immunomodulatory antibody therapy. Lecture at the 2nd Annual Next Gen Immuno-Oncology Congress, London, UK, 13th March, 2018 (invited by Dr. K. Hollevoet)

Immune Parameters Associated with Mortality in the Elderly Are Context-Dependent: Lessons from Sweden, Holland, and Belgium. Lecture at the Keystone Meeting Aging, Inflammation and Immunity, Austin, TX, 26th February, 2018 (invited by Prof. B. Blomberg)

Interplay between age, immunity, cancer and CMV. Murray Seminar Series Lecture, Western University, London, ON, Canada, 14th December, 2017 (invited by Prof. S.M. Haeryfar).

Interplay between age, immunity, cancer and CMV. Lecture for the Master's Course in Immune Defence and Cancer, Copenhagen, 5th December, 2017 (invited by Prof. P. thor Straten)

Interplay between cancer and ageing. Lecture at the 3rd Symposium on Advances in Cancer Immunology and Immunotherapy, Athens, Greece, 3rd November, 2017 (invited by Prof. O. Tsitsilonis)

Immune Parameters Associated with Mortality in the Elderly are Context-Dependent: Lessons from Sweden, Holland and Belgium. Lecture at the IUBMB Focused Meeting on Molecular aspects of aging and longevity, Athens, Greece, 18th October, 2017 (invited by Prof. E. Gonos)

CMV and Immunosenescence. Lecture at Infectious Disease Week, San Diego, 6th October, 2017 (invited by Prof. P. Griffiths)

Immunotherapy of Cancer: triumphs and challenges, and the impact of immunosenescence. Lecture at PIVAC 17, Lutraki, Greece, 29th September, 2017 (invited by Prof. C. Baxevanis).

Immunosenescence. Lecture at IAGG San Francisco, 26th July, 2017 (invited by Prof. T. Fülöp)

Immune Parameters Associated with Mortality in the Elderly are Context-Dependent: Lessons from Sweden, Holland and Belgium. Lecture at the BSRA annual meeting, Exeter, UK, 12th July, 2017 (invited by Prof. L. Harries)

A clinical and biological perspective of human myeloid-derived suppressor cells in cancer. Lecture at European Hematology

Association 22, 23rd June, 2017 (invited by Prof. S. Izraeli)

Immunosenescence. Lecture at Neuroscience in Intensive Care International Symposium (NICIS):Critical Illness : Ageing, Frailty and Resilience. Institute Pasteur, Paris, 8th June, 2017 (invited by Prof RD Stevens)

CMV infection, cancer and survival in the elderly. Lecture at the AAI Satellite Symposium Rockville, MD, 11th May, 2017 (invited by Profs. B. Blomberg and D. Frasca)

The immune system in the elderly. Lecture at Hematological diseases in the elderly, Rome, 29th April, 2017 (invited by Profs. P. Zinzani and L. Balducci)

Immune signatures predicting response to immunomodulatory antibody therapy. Keynote lecture at CITIM 5, Prague, 26th April, 2017 (invited by Profs. M. Shurin and V. Umansky)

Immunization in the elderly. Lecture at WHO consultation on immunization in the elderly, Geneva, 22nd March, 2017 (invited by Dr. M. Friede)

Immunity and ageing: causes and consequences of immunosenescence in humans. Presentation at SFB-TR36, Munich, 9th March, 2017 (invited by Prof. E. Nössner)

Discussant, Oral Abstract Section C at the 1st ASCO/SITC conference, Orlando, 25th February, 2017 (invited by Dr. M. Disis)

Immunity and ageing: causes and consequences of immunosenescence in humans. Presentation at Novartis, Dept. of Autoimmunity, Transplantation and Inflammation, Basel, 9th February, 2017 (invited by Dr. C. Burkhardt)

Influence of chronic CMV infection on peripheral immune cell phenotypes, frailty and mortality. Departmental seminar, Virology Tübingen, 25th January, 2017 (invited by Prof. K. Hamprecht)

Influence of chronic CMV infection on peripheral immune cell phenotypes, frailty and mortality. Lecture at the GSA Annual Meeting, New Orleans, 20th November, 2016 (invited by Prof. S. Leng)

Immunity and ageing: causes and consequences of immunosenescence in humans. Departmental Seminar, Center for Aging, Tulane University, New Orleans, 14th November, 2016 (invited by Prof. M. Jaswinski)

Immune Parameters Associated with Mortality in the Elderly are Context-Dependent: Lessons from Sweden, Holland and Belgium. Lecture at the Biology of Aging: Paving the way for healthy aging conference, Montreal, 19th October, 2016 (invited by Prof. T. Fülöp)

Clonal T cell cultures as models of immune cell ageing. Lecture at the Cell Fates and Aging Conference, Dubrovnik-Cavtat, 26th September, 2016 (invited by Profs. J. Campisi and J. Vijg)

Immunosenescence and cancer. Lecture at the 10th European Biogerontology Congress, Warsaw, 23rd September, 2016 (invited by Prof. E. Sikora)

Immunotherapy of Cancer: Triumphs and Challenges. Visiting Professor Lecture at Nottingham Trent University, Nottingham, 16th September, 2016 (invited by Prof. G. Pockley)

Immunosenescence and Cancer: is there an “Immune Risk Profile” in cancer and ageing? Lecture at Health Sciences North Research Institute, Sudbury, ON, Canada, 11th August, 2016 (invited by Dr J. McElhaney)

Immunosenescence and Cancer: is there an “Immune Risk Profile” in cancer and ageing? Seminar at IMIBIC, Cordoba, 29th June, 2016 (invited by Prof. R. Solana).

Antigen-specific T cells, MDSCs and survival in melanoma and breast cancer. Lecture at Regulatory Myeloid Suppressor Cells, Wistar Institute, Philadelphia, 18th June, 2016 (invited by Prof. D. Gabrilovich).

Immunity and ageing: causes and consequences of immunosenescence in humans. Lecture at ABC 5 Summer School on Autoimmunity, Tartu, Estonia, 8th June 2016 (invited by Prof. K. Kisand).

Immunosenescence and Cancer. Lecture at the 45th Meeting of the American Aging Association, Seattle, 3rd June, 2016 (invited by Prof. M. Kaeberlein)

Immunosenescence and Cancer: is there an “Immune Risk Profile” in cancer and ageing? Inaugural Visiting Professor lecture, King’s College, London, 27th May, 2016 (invited by Prof. F. Farzaneh).

The Impact of CMV Infection on Immunity and Survival in Older Humans. Lecture at the 100th AAI congress, Seattle, 15th May, 2016 (invited by Dr. R. Fuldner).

Immunity and ageing: causes and consequences of immunosenescence in humans. Lecture at the International Conference on Aging and Hematological malignancies, Athens, 11th March, 2016 (invited by Prof. L. Balducci).

Immunosenescence and Cancer: is there an “Immune Risk Profile” in cancer and ageing? Lecture at the Manchester Immunology Group, Manchester, 3rd March, 2016 (invited by Prof. M. Exley)

Immunity and ageing: causes and consequences of immunosenescence in humans. Lecture at Age 2016, O2 Arena, London, 10th February 2016 (invited by Prof. A. Saccho)

The Clinical Impact of Immunosenescence on Kidney Transplantation. Lecture at the 16th Canadian Kidney Transplant Forum. Montreal, 29th January, 2016 (invited by Prof. J. Shapiro)

Immunity and ageing: causes and consequences of immunosenescence in humans. Departmental Seminar, University of Groningen, 18th January, 2016 (invited by Prof. A. van den Berg).

Why do we age? Departmental seminar, University of Athens, 14th December 2015 (invited by Prof. O. Tsitsilonis)

Antigen-specific T cells, MDSCs and survival in melanoma and breast cancer. Presentation at the Immunotherapy Bridge, Naples, Italy, 5th December, 2015 (invited by Prof. P. Ascierto).

Immune status of BASE-II donors: associations with socioeconomic score. Symposium presentation at the GSA Annual Meeting, Orlando, 21st November, 2015 (invited by Dr. C. Krekel).

Immunity and ageing: causes and consequences of immunosenescence in humans. Johns Hopkins Seminar, Baltimore, 5th November, 2015 (invited by Prof. S Leng).

Antigen-specific T cells, MDSCs and survival in melanoma and breast cancer. Presentation at Advances in Cancer Immunology and Immunotherapy, Athens, 30th October, 2015 (invited by Prof. O. Tsitsilonis).

Immunosenescence and Cancer: is there an “Immune Risk Profile” in cancer and ageing? Keynote Lecture at Advances in cancer Immunology and immunotherapy, Athens, 30th October, 2015 (invited by Prof. O. Tsitsilonis).

Why do we age? Presentation at the Biology of Aging Conference, Singapore, 23rd October, 2015 (invited by Dr. A. Larbi).

In vitro models of human T cell senescence. Presentation at Immunosenescence Satellite Symposium, Vienna, 5th September 2015 (invited by Dr. B. Weinberger)

Senescence, Immunosenescence and Cancer. Visiting Prof lecture, Nottingham Trent University, Nottingham, UK, 19th August, 2015 (invited by Prof. Y. Barnett)

The ageing immune system: how can it be assessed? Presentation at the FASEB Conference “Nutritional Immunology: Role in Health and Disease” Lisbon, 28th July, 2015 (invited by Profs. R. Montgomery and P. Calder)

Immunosenescence and Cancer: is there an “Immune Risk Profile” in cancer and ageing? Departmental Seminar, University of Essex, Colchester, UK, 30th June, 2015 (invited by Prof. N. Fernandez)

Immunosenescence. Presentation at EHA-SWG Scientific Meeting “Aging and Hematology: the Next Questions”, Lisbon, 8th May, 2015 (invited by Prof. D. Bron)

Antigen-specific T cells, MDSCs and survival in melanoma and breast cancer. Presentation at CITIM 2015, Ljubljana, 27th April, 2015 (invited by Drs M. Shurin & V. Umansky)

Immunosenescence and Cancer: is there an “Immune Risk Profile” in cancer and ageing? A*SIgN Network Seminar, Singapore, 5th February, 2015 (invited by Dr. A. Larbi)

Immunosenescence and Cancer: is there an “Immune Risk Profile” in cancer and ageing? Departmental lecture, Dept for Health, University of Bath, 10th December, 2014 (invited by Dr. J. Turner)

The Impact of CMV Infection on Immunity and Survival in Older Humans. Lecture at the BSI Symposium “Immune Frailty and Defence against Infections”, Brighton, 4th December, 2014 (organised by self)

Why do we age? Extrinsic Determinants. Lecture at the Italia Longeva conference “Determinants of active and healthy aging: A strategy for the EU”, Rome, 15th November, 2014 (invited by Prof. R. Bernabei)

Immune status of BASE-II donors: associations with socioeconomic score and impact of CMV infection. Lecture at the GSA Annual Congress, Washington DC, 7th November, 2014 (invited by Prof. E. Steinhagen-Thiessen)

The Impact of CMV Infection on Immunity and Survival in Older Humans. □Lecture at the GSA Annual Congress, Washington DC, 5th November, 2014 (invited by Dr B. Zaniello)

Immune frailty: role of viral infection and impact on vaccination in the elderly. Lecture t the Symposium "The challenges of the biological research in aging in the 21st century: from the cells to the clinics", Sherbrooke, Canada, 3rd November, 2014 (invited by Prof. T. Fülöp).

Immunity and ageing: causes and consequences of immunosenescence in humans. Lecture at the 9th European Biogerontology Congress, Sevilla, 17th October, 2014 (invited by Prof. G. Lopez-LLuch)

Immunity and ageing: causes and consequences of immunosenescence in humans. Lecture at the 4th National Congress of Immunology, Varna, Bulgaria, 4th October, 2014 (invited by Prof. E. Naumova)

Immunity and ageing: causes and consequences of immunosenescence in humans. Lecture at the 2nd Eurosymposium on Healthy Ageing, Brussels, 1st October, 2014 (invited by S. Bulterijs)

Cancer vaccination in the era of immunomodulatory immunotherapy. Lecture at the SMi conference Cancer Vaccines, London, 15th September, 2014 (invited by SMi)

Immunity and ageing: causes and consequences of immunosenescence in humans. Lecture at the Center for Regenerative Therapies, Charité, Berlin, 26th August, 2014 (invited by Prof. A. Thiel).

Immunological biomarkers predicting survival in late-stage melanoma patients. Lecture at the Czech Academy of Sciences, Prague, 22nd May, 2014 (invited by Dr. L. Vannucci).

Peripheral immune signatures and survival in stage IV melanoma. Lecture at the International Conference Challenges and Solutions in Cancer Research and Treatment, Rio das Pedras, 28th April, 2014 (invited by Prof. C. Bonorino).

How to get your paper published. Lecture at Athens University for the EU □INtegrating the emerging research Potential of the University of Athens Cancer Research Group in the European research area (INsPiRE) project, Athens, 17th December, 2013 (invited by Prof. O. Tsitsiloni)

Immunological biomarkers predicting survival in late-stage melanoma patients. Lecture at the Hellenic Society for Immunology Triennial Meeting, Athens, 14th December, 2013 (invited by Prof. C. Baxevanis).

Health, demographic change and wellbeing. Lecture at the 66th Annual Congress of the Gerontological Society of America, New Orleans, 23rd November, 2013 (invited by Prof. L. Gavrilov)

An exceptional degree of cellular and humoral immune commitment to controlling the persistent β -herpesvirus HHV5 (CMV) underlines the importance of maintaining defenses against this “innocuous” virus in the elderly – no matter what the cost! Lecture at the 66th Annual Congress of the Gerontological Society of America, New Orleans, 22nd November, 2013 (invited by Prof. I. Rubinstein)

Immunosenescence and cancer. Departmental seminar, Dept. Hematological Medicine, King’s College London, 8th November 2013 (invited by Prof. F. Farzaneh)

Immunosenescence and cancer. Lecture at the Cold Spring Harbor Asia conference “Tumor Immunology & Immunotherapy” Suzhou, 29th October, 2013 (invited by Prof. O. Finn)

Immunosenescence and cancer. Round Table at the SIOG Annual conference 2013, Copenhagen, 24th October, 2013 (invited by Prof.M. Extermann)

Antigen-specific T-cells and survival in melanoma. Lecture at the 11th NIBIT Congress, Siena, 19th October, 2013 (invited by Prof. M. Maio).

Immunological biomarkers predicting survival in late-stage melanoma patients. Lecure at PIVAC 13, Amsterdam, 3rd October, 2013 (last-minute stand-in for Luca Gattinoni who could not attend)

Understanding the link between ageing and infection. Lecture at the BioRN Annual Conference, Heidelberg, 27th September, 2013 (invited by Ms Y. Steinrock).

Immunological biomarkers predicting survival in late-stage melanoma patients. Lecture at the Danish Cancer Society Symposium on Immunotherapy of Cancer: Prewsent Status and Future Promise, Copenhagen, 24th September 2013 (invited by Prof. P. thor Straten)

Immunological biomarkers predicting survival in late-stage melanoma patients. Lecture at the SMi conference Cancer Vacines, London, 19th September, 2013 (invited by SMi)

An exceptional degree of cellular and humoral immune commitment to controlling the persistent β -herpesvirus HHV5 (CMV) underlines the importance of maintaining defenses against this “innocuous” virus in the elderly – no matter what the cost! Lecture at the IUSI-ICI Satellite Symposium “SM3 - Aging and the immune system”, Milan, 20th August, 2013 (invited by Prof. D. Frasca)

Immunosenescence and Immune Escape: impact of chronic antigenic stress. Lecture at the International Workshop on Ageing and Cancer, Athens, 29th June, 2013 (invited by Dr. I. Trougakos)

Immunological correlates of long-term survival in advanced cancer patients. Lecture at the National Cancer Center, Seoul, 25th June, 2013 (invited by Prof. B. Kwon)

A high degree of immune commitment to controlling the persistent β -herpesvirus HHV5 (CMV) underlines the importance of maintaining defences against this “innocuous” virus in the elderly. Lecture at the Workshop Recent Updates in Immunosenescence, Yonsei University, Seoul, 24th June, 2013 (invited by Dr. Eui-Cheol Shin)

Understanding the link between ageing and infection. Lecture at the 20th IAGG World Congress, Seoul, 24th June, 2013 (invited by Dr. D. Coles)

The impact of CMV infection on immunity and survival in older humans. Lecture at the Marie Curie NINA Network final meeting, Amsterdam, 14th June 2013 (invited by Ptof. J. Lord)

Immune frailty: role of viral infection and impact on vaccination in the elderly. Departmental Seminar, Biomedical Research Institute, Hasselt University, Belgium, 21st May, 2013 (invited by Prof. N. Hellings)

Is there an “Immune Risk Profile” in cancer and ageing? Chair and presentation at the Centennial Congress of the AAI, Honolulu, 6th May, 2013 (invited by Dr. R. Fuldner)

Immunological correlates of advanced stage melanoma survivorship. Lecture at CITIM 3, Krakow, 24th April, 2013 (invited by Prof. M. Shurin)

Immunological correlates of long-term survival in advanced cancer patients. Lecture at Nottingham Trent University, 22nd March, 2013 (invited by Prof. G. Pockley)

Immunity, ageing and viral infection. Presentation at the 8th European Biogerontology Congress, Dead Sea, 13th March, 2013 (invited by Prof. V. Fraifeld)

Immunity and ageing: causes and impact of immunosenescence in humans. Keynote lecture at the First Workshop on HealthyAging, 14th December, 2012, Belo Horizonte (invited by Prof. A Caetano Faria)

Immune surveillance in cancer. Lecture at the Progress in combination therapy of cancer using novel immunomodulators conference, 2nd November 2012, Athens (invited by Dr. O. Tsitsilonis)

Immunosenescence and Cancer. Session introductory lecture, Int Soc for Geriatric Oncology meeting, Manchester, 25th October 2012 (invited by Prof. M. Extermann)

Inflamm-ageing and Lifelong Antigenic Load as Major Determinants of Human Longevity. Keynote lecture at the Japanese Society for Food Immunology, Tokyo, 16th October, 2012 (invited by Dr. S. Fujisawa)

Monitoring immunotherapy outcomes. Lecture at SMi Cancer Vaccines Conference London, 19th September, 2012 (invited by K. Prior).

Immunological correlates of long-term survival in melanoma patients. Keynote at the Dutrch Tumour Immunology Society meeting, Breukelen, 7th June, 2012 (invited by Dr. T. de Gruijl)

Immunity and Ageing: Causes and impact of immunosenescence in humans. Departmental seminar, Department of Physiology, Anatomy and Cell Biology, Universidad Pablo de Olavide, Sevilla, 16th May, 2012 (invited by Prof. G. Lopez-Lluch)

Immune frailty: role of viral infection and impact on vaccination in the elderly. Seminar at the Department of Microbiology and Immunology, University of Miami, 27th February, 2012 (invited by Prof. B. Blomberg)

Immunological correlates of long-term survival in melanoma patients. Lecture at the World Immunotherapy Council Inaugural Summit, Curacao, 22nd February, 2012 (invited by Prof. B. Fox)

Immunosenescence and its impact on vaccination: influence of CMV infection. Lecture at the Department of Virology, UCL, London, 16th February, 2012 (invited by Prof. P. Griffiths)

Immunosenescence and its impact on vaccination: influence of CMV infection. Lecture at the Division of Biological Sciences, UCSD, La Jolla, 27th January, 2012 (invited by Prof. S. Hedrick)

Immunological correlates of long-term survival in melanoma patients. Lecture at the “World Cancer Immunotherapy Conference”, San Diego, 26th January, 2012 (invited by Dr. A. Bot)

Immune frailty: role of viral infection and impact on vaccination in the elderly. Lecture at the Norwegian Immunology Society, Rikshospitalet, Oslo, 15th December, 2011 (invited by Prof. G. Gaudernack)

Immune frailty: role of viral infection and impact on vaccination in the elderly. Seminar at the Dept. Pathophysiology, Medical University of Gdansk, 24th November, 2011 (invited by Prof. J. Witkowski)

Immunological correlates of long-term survival in melanoma patients. Lecture at the 26th Annual Meeting of the Society for the Immunotherapy of Cancer, N. Bethesda, 5th November, 2011 (invited by Prof. T. Gajewsky)

Immunological correlates of long-term survival in melanoma patients. Lecture at “New perspectives in the immunotherapy of cancer”, ESCII/NIBIT meeting, Siena, 19th October, 2011 (invited by Prof. M. Maio)

Prospective studies of immune correlates of long-term survivorship in melanoma patients under immunotherapy. Lecture at “Immunotherapy – The Future is Now”, Prague, 18th October, 2011 (invited by Prof. J. Bartunkova)

Immunological correlates of long-term survival in melanoma patients. Lecture at PIVAC 11, Copenhagen, 11th October, 2001 (invited by Prof. P. thor Straten)

Immunosenescence and immune escape: impact of chronic antigenic stress. Lecture at the International Conference “Cancer Immune Escape”, Dilar-Granada, 3rd October, 2011 (invited by Prof. F. Garrido)

Immune frailty: role of viral infection and impact on vaccination in the elderly. Lecture at the 11th annual Meeting of the Safety Pharmacology Society, Innsbruck, 22nd September, 2011 (invited by Dr. Dany Salvail)

Mechanisms and models of human T cell senescence. Lecture at the Banbury Conference, Cold Spring Harbor Laboratory, “Translation of Cellular and Molecular Mechanisms of Aging to Geriatric Disorders”, Lloyd Harbor, NY, 12th September, 2001 (invited by Dr. Cecilia Marta)

The immune system in ageing. Keynote lecture at the First Joint BSRA/IABG Congress, Brighton, 13th July, 2011 (invited by Prof. R. Faragher)

Road-Mapping European Aging Research: The Next Decade of EAR. Presentation at the 40th Annual Meeting of the American Aging Association, Raleigh, NC, 4th June, 2001 (invited by Prof. H. Brown-Borg)

Immune signatures in long-term melanoma survivors. Keynote lecture at CITIM 2, Budapest, 4th May, 2011 (invited by Dr. M. Shurin)

Physiological Changes in T Cells with Increasing Age: The Role of Infections. Plenary lecture at the American Transplant Congress, Philadelphia, 1st May, 2001 (invited by Prof. M. Sester)

Human Immunosenescence. Departmental Seminar at UC Louvain, Brussels, 24th March 2011 (invited by Prof. J. de Gryse).

Immunosenescence and its impact on vaccination. Lecture at the Consultation on Ageing and Immunization, WHO, Geneva, 22nd March 2011 (invited by Dr. M.T. Aguado).

Does CMV contribute to immunosenescence and mortality? Departmental Seminar at UCL, London, 15th March, 2011 (invited by Prof. A. Akbar).

Is there an “Immune Risk Profile” in cancer and ageing? Departmental seminar at the Rayne Institute, King’s College, London, 10th March, 2011 (invited by Prof. F. Farzaneh).

Immunology and Ageing: Infectious senescence? Faculty Keynote address, Postgraduate Medical School, University of Surrey, Guildford, 24th February, 2011 (invited by Prof. H. Pandha).

Is there an “Immune Risk Profile” in cancer and ageing? Departmental seminar at the Van Geest Cancer Research Center, Nottingham Trent University, Nottingham, 23rd February, 2011 (invited by Prof. R.C. Rees).

Ageing of the Immune System. Lecture at The Future of Ageing Research in Europe: A FutureAge and WhyWeAge European Conference, Brussels, 15th December 2010 (invited by Dr. O. Toussaint).

Role of immune/inflammatory responses in the development and progression of Alzheimer Disease. Lecture at the Annual Meeting of the GSA, New Orleans, 21st November, 2010 (invited by Prof. T. Fülöp).

Role of CMV infection in human immunosenescence. Keynote lecture at the the 35th Annual Congress of the Brazilian Society for Immunology, Porto Alegre, 5th November, 2010 (invited by Prof. M. Bauer).

The immune system in old age. Lecture at the French Office of Science and Technology Workshop on Immune System and Aging, Sophia-Antipolis, 22nd October, 2010 (invited by Dr. M. Guyader).

The “Immune Risk Profile”. :Lecture at the 7th Eur Biogerontol Congress, Palermo, 15th October, 2010 (invited by Prof. C. Caruso).

Is there an “Immune Risk Profile” in cancer and ageing? Departmental seminar at the Center for Cancer Immunotherapy, University of Copenhagen, Herlev, 23rd August, 2010 (invited by Prof. P. thor Straten)

Infectious immunosenescence? Keynote lecture at the LifeSpan Young Investigators´ Workshop, London, 12th August, 2010 (invited by Dr. C. Burnett)

Immunosenescence and its impact on vaccination. Departmental seminar, Centre for the Evaluation of Vaccination, Vaccine & Infectious Disease Institute, University of Antwerp, 29th July, 2010 (invited by Prof. P can Damme)

Infectious immunosenescence? Departmental Seminar, School of Cancer Studies, University of Birmingham, 29th June, 2010 (invited by Prof. P. Moss).

Infectious immunosenescence. Lecture at the 39th Annual Meeting of the American Aging Association, Portland, OR, 5th June, 2010 (invited by Prof. J. Nikolich-Zugic).

Infectious immunosenescence. Research Seminar, School of Bioscience, NTU, Nottingham, 21st May, 2010 (invited by Dr. E. Verderio-Edwards).

Infectious immunosenescence. Lecture at the 3rd CIE Symposium Immunopathology & Immunosenescence – An Evolutionary Perspective, University of Edinburgh, 28th April, 2010 (invited by Dr. D. Nussey).

Human immunosenescence. Lecture at the School of Public Health, Dept. Epidemiology, University of Michigan, Ann Arbor, 14th April, 2010 (invited by Prof. A. Aiello).

Immunosenescence: Ageing of the Immune System, role of CMV. Keynote at the Annual Congress of the European Group for Blood and Marrow Transplantation (EBMT), Vienna, 22nd March, 2010 (invited by Prof. H. Greinix).

Human immunosenescence. Lecture at the Pathobiology of Ageing Symposium, Palermo, 15th March, 2010 (invited by Prof. C. Caruso).

Human immunosenescence. Seminar at the UMCG in “Molecular Medicine, Groningen, 11th March, 2010 (invited by Dr. B.J. Kroesen).

Human immunosenescence. Seminar at the Dept Pathology, Bologna University, 15th February, 2010 (invited by Prof. C. Franceschi).

Human immunosenescence. Kiel Institute for Immunology Seminar series lecture, Kiel, 28th January, 2010 (invited by Prof. D. Kabelitz).

Human immunosenescence. Presentation at the BASE-II Workshop, Berlin, 23rd January, 2010 (invited by Dr. L. Müller)

Immune signatures for human ageing: impact of Cytomegalovirus, Keynote lecture at the Final LinkAge Conference, Brussels, 1st December, 2009 (invited by Dr. O. Toussaint)

Immunosenescence, cancer, and Cytomegalovirus, Lecture at PIVAC 9, Sofia, 8th October, 2009 (invited by self)

Ageing, cancer and the immune response. Lecture at the 9th European Conference on Clinical Cell Analysis, St. Etienne, 12th September, 2009 (invited by Prof. J. Gratama)

Persisting immune stimulation as a driving force for human T cell immunosenescence. Lecture at SENS4, Cambridge, 5th September, 2009 (invited by Dr. A. de Grey)

Persisting immune stimulation as a driving force for T cell immunosenescence. Lecture at the 19th Int Assoc Geriatr Gerontol, Paris, 6th July, 2009 (invited by Prof. T. Fülöp)

Herpes viruses and immunosenescence. Lecture at the Royal Society of Medicine, London, 12th June, 2009 (invited by Dr. R. Patel).

Immunosenescence: ageing of the immune system. Lecture at the 28th Congress of the European Academy of Allergy and Clinical Immunology, Warsaw, Poland, 10th June, 2009 (invited by Prof. M. Kowalski).

Immunosenescence and its impact on vaccination. Lecture to the Nencki Institute, Warsaw, Poland, 9th June, 2009 (invited by Prof. E. Sikora)

Immunosenescence of the human immune system: Impact of Cytomegalovirus. Lecture at the meeting Vaccination in Ageing populations, Prague, Czech Republic, 14th May, 2009 (invited by Dr. J-C Thibault).

Immunosenescence and its impact on vaccination. Lecture at the Intanza Master Class, Cannes, France, 30th April, 2009 (invited by Dr. S. Sansom).

Mechanisms and models of immunosenescence in man: role of Cytomegalovirus. Lecture at the meeting Pathophysiology of successful and unsuccessful ageing, Palermo, Italy, 7th April, 2009 (invited by Prof. C. Caruso).

Immunosenescence, ageing of the immune system: role of CMV infection. Lecture at Sanofi-Pasteur, Marcy d'Etoile, France, 19th March, 2009 (invited by Dr. M. Denis).

Ageing of the immune system: prospects for immunosupportive therapies. Lecture at the 10th Intervention on Ageing Conference, Volterra, Italy, 7th March 2009 (invited by Prof. E. Bergamini).

Impact of immunosenescence on human life histories. Lecture at the 3rd Annual LifeSpan meeting. Leiden, The Netherlands, 15th January 2009 (invited by Prof. R. Westendorp)

Immunity, CMV and mortality. Seminar at the School of Public Health, University of Michigan, Ann Arbor, MI (26th November, 2008 (invited by Prof. A. Aeillo)

Changes to Immunity in Alzheimer's Disease. Lecture at the 61st Congress of the Gerontological Society of America, National Harbor, MD, 24th November, 2008 (invited by Prof. P. Larsen)

Immunosenescence and cancer: tumour escape, impact not only for immunotherapy? Lecture at the Herlev Tumor Immunology Postgraduate School, Herlev, Denmark, 17th November, 2008 (invited by Prof. P. thor Straten)

CMV in the Elderly: Impact of CMV Infection on Senescence of the Immune System. Lecture in the session "CMV: not only in Transplantation, ICAAC conference, Washington DC, 26th October, 2008 (invited by Prof P. Ljungman)

Immunosenescence and cancer: Impact not only for immunotherapy? Keynote lecture, 9th meeting of the International Society for Geriatric Oncology, Montreal, Canada, 18th October, 2008 (invited by Prof. T. Fülöp).

Mechanisms and models of human immunosenescence. Institute seminar, Research Center on Aging, University of Sherbrooke, Canada, 17th October, 2008 (invited by Prof. T. Fülöp)

Dysregulation of T cell function in the elderly: scientific basis and clinical implications. Lecture at the Graduate School of Immunology, Danish Immunological Society meeting on Ageing and Immunity, Copenhagen, 9th October, 2008 (invited by Prof. M.H. Nissen)

Interim immunological and virological data from the Leiden Longevity Study. Workshop presentation at the CISBAN/LifeSpan meeting, Newcastle, 1st October, 2008 (invited by Prof. T. Kirkwood)

Mechanisms and models of human immunosenescence. Seminar at Pfizer Global Research, Groton, CT, USA, 24th September, 2008 (invited by Dr. T. Paradis).

Mechanisms and models of human immunosenescence. Seminar at the Helmholtz Institute for Infection Biology, Braunschweig, 18th September, 2008 (invited by Dr. T. Ebensen)

Models and Mechanisms of Human T Cell Senescence. Seminar at the Dept. Hematology, Hopital St. Louis, Paris, 30th June, 2008 (invited by Prof. D. Charron).

Immunosenescence. Ageing of the immune system: impact on vaccination & role of CMV infection. Keynote lecture at the WHO Initiative for vaccine research (IVR) Workshop on ageing and immunity, Paris, 29th June, 2008 (invited by Dr. M. Friede)

Models and Mechanisms of Human T Cell Senescence. Keynote lecture at the Polish Immunology Society Congress, Krakow, 17th May, 2008 (invited by Prof. J. Witkowski)

Models and Mechanisms of Human T Cell Senescence. Keynote lecture at the 3rd Annual Meeting of the Bulgarian Society for Immunology, Varna, 9th May, 2008 (invited by Prof. E. Naumova)

Models and Mechanisms of Human T Cell Senescence. Seminar at the Buck Institute for Aging Research, 10th April, 2008 (invited by Dr. G. Lithgow)

Models and Mechanisms of Human T Cell Senescence. Keynote lecture, Symposium Klinische Immunologie, 20th March, 2008 Amsterdam (invited by Prof. I. ten Berge)

Models and Mechanisms of Human T Cell Senescence. Seminar at IUF Düsseldorf, 28th February, 2008 (invited by Prof. C. Esser)

Models and Mechanisms of Human Immunosenescence. Polish Gerontology Society Seminar at the Medical University, Gdansk, 21st February, 2008 (invited by Prof. J. Witkowski)

Models and Mechanisms of Human Immunosenescence. Seminar at the Biochemistry Department, Nencki Institute, Warsaw, 28th January, 2008 (invited by Prof. E. Sikora)

Models and Mechanisms of Human Immunosenescence. Keynote at the IBMC Fall Symposium, Oporto, 1st December, 2007 (invited by Prof. P. Moradas-Ferreira)

Emerging scientific rationale for the pursuit of immunomodulating therapies against cancer. Keynote at the Celgene Immunomodulatory Drug meeting, Milan, 5th November, 2007 (invited by Dr. B. Bartlett)

Impact of herpesvirus infection on senescence of the immune system. Keynote at the 14th International Herpes Management Forum, Dubrovnik, 9th October, 2007 (invited by Prof. P. Griffiths)

Immunosenescence, immunotherapy, suppression and tumour progression. Lecture at the European Conference on Cancer and Ageing, SeneCa 2007, Warsaw, 6th October, 2007 (invited by Prof. E. Sikora)

Human immunosenescence. Lecture at the Gordon Research Conference on the Biology of Aging, Les Diablerets, Switzerland, 25th September, 2007 (invited by chairs H. Brown-Borg, L. Thompson & A. Bürkle)

Human T cell senescence. Lecture at the 12th International Association of Biogerontology conference, Spetses Island, Greece, 22nd May, 2007 (invited by Prof. E. Gonos)

Cancer Immunotherapy: is there a right way – or any way? Lecture at the Norwegian Radium Hospital, Oslo, 13th February, 2007 (invited by Prof. G. Gaudernack)

Human immunosenescence: can an aspect of ageing be infectious? Norwegian Immunology Society lecture, Oslo, 13th February, 2007 (invited by Prof. A. Spurkland)

Chronic antigenic stress contributing to the immune risk profile: in vitro monitoring and in vivo impact. Lecture at the Final ZINCAGE Conference, Ancona, 16th January, 2007 (invited by Dr. E. Mocchegiani)

Chronic antigenic stress contributing to the immune risk profile: in vitro monitoring and in vivo impact. Lecture at the European Conference on Ageing, ECONAG, Innsbruck, 29th November, 2006 (invited by Dr. P. Jansen-Dürr)

Immunology and ageing. Lecture at the 6th Annual Congress of the Greek Society for Clinical Chemistry, Athens, 11th November, 2006 (invited by Dr. S. Gonos)

Immunotherapy, suppression and tumour progression. ASI-Lecture, Centenary Institute, University of Sydney, 27th Oct., 2006 (invited by Dr. B. Saunders)

Immunotherapy, suppression and tumour progression. ASI-Lecture, Queensland Institute for Medical Research, Brisbane, 25th Oct., 2006 (invited by Dr. C. Schmidt)

Immunosenescence. Seminar, Flinders Medical Center, Adelaide, 24th Oct., 2006 (invited by Dr. S. Heinzel)

Immunotherapy, suppression and tumour progression. ASI-Lecture, University of Adelaide, 23rd October, 2006 (invited by Dr. L. Dent)

Immunosenescence. Seminar, Monash Immunology and Stem Cell Lab, Monash Univ., Melbourne, 18th October, 2006 (invited by Prof. R. Boyd)

Human Immunosenescence: Is it Infectious? Lecture at the 3rd IRCHAL Conference, Melbourne, 14th October, 2006 (invited by Prof. S. Rattan)

Human Immunosenescence: Is it Infectious? Lecture at the Third Extramural R&D Symposium of GlaxoSmithKline Biologicals, Rixensart, 9th October, 2006 (invited by Dr. M. Chevalier)

Is it still worthwhile seeking individual tumour antigens for use in cancer immunotherapy? Lecture at PIVAC 6, Granada, 28th September, 2006 (invited by Prof. F. Garrido)

Biomarkers of Immune Ageing: the Immune Risk Profile. Lecture at the 5th Eur. Congress of Biogerontology, Istanbul, 18th September, 2006 (invited by Prof. S. Akman).

Impact of CMV on Immunosenescence and Human Longevity. Lecture at the ARIG Conference, Paris, 4th September, 2006 (invited by Prof. B. Grubeck-Loebenstein)

The immune risk profile in the very elderly. Lecture, Human Immunology Grand Rounds, Emory University, Atlanta, 21st July (invited by Prof. C. Weyand).

Longitudinal studies implicate CMV in accelerating human immunosenescence. "Immunology Forum Seminar", UCLA, 20th July, 2006 (invited by Prof. R. Effros)

Immunosenescence. Lecture at the FNRS Contact Group on Human Vaccines, Liège, 16th June, 2006 (invited by Prof. M. Goldman)

Immunotherapy, immunosenescence, suppression and tumour progression. Seminar at the Dept. Biochemistry, Jagellonian University, Krakow, 19th May, 2006 (invited by Prof. P. Laidler)

The Immune Risk Profile in the very Elderly. Lecture at the Session on Immunosenescence of the AAI Annual Meeting. Boston, 13th May, 2006 (invited by Prof. S. Swain)

Age and Immunity. Lecture to the IFIB, Tübingen, 24th April, 2006 (invited by Prof. W. Voelter)

Is it still worthwhile seeking individual tumour antigens for use in cancer immunotherapy? Lecture at the NCI, NIH, Frederick, 7th April 2006 (invited by Dr. T. Sayers)

Longitudinal studies of free-living elderly reveal an immune risk profile associated with decreased remaining survival. Lecture at the NIA, NIH, Bethesda, 6th April 2006 (invited by Dr. E. Hadley)

Immunotherapy, immunosenescence, suppression and tumour progression. Lecture at Nottingham Trent University, 6th March, 2006 (invited by Dr. M. Ahmad)

Human T cell clones as models for Immunosenescence: Effect of supplementary zinc. Lecture at the 2nd ZINCAGE Symposium, Madrid, 12th February, 2006 (invited by Dr. E. Mocchegiani)

Immunosenescence, suppression and tumour progression. Lecture at the BSI Annual Congress, Harrogate, 8th December, 2005 (invited by Dr. D.L. Morgan)

Is immunosenescence infectious? Lecture at the Annual meeting of the German Society for Gerontology and Geriatrics, Lübeck, 13th October, 2005 (invited by PD Dr. C. Meissner)

Immunity and Ageing. Lecture to the Graduierten Kolleg, Greifswald, 11th October, 2005 (invited by Prof. B. Bröcker)

CMV and the Immune Risk Profile. Lecture at the International Workshop on Differentiation and Immunosenescence in the Immune System, Compton, 7th October, 2005 (invited by Prof. P. Beverley)

Immunosenescence: a disease of chronic antigenic stimulation? Lecture at the "Successful Aging" Symposium, Warsaw, 3rd October, 2005 (invited by Prof. E. Sikora)

Age & Immunity. Seminar at the National Hellenic Research Foundation, Athens, 22nd September 2005 (invited by Prof. E. Gonos).

Immunorejuvenation in the elderly. Lecture at the 2nd Strategies for Engineering Negligible Senescence conference, Cambridge, 9th September, 2005 (invited by Dr. A. de Grey)

Is immunosenescence infectious? Lecture at the 11th Congress of the Int Assoc for Biomedical Gerontology, Aarhus, 15th August 2005 (invited by Prof. S. Rattan)

Immunosenescence, suppression and tumour progression. Lecture at the Bob Baldwin 50th Anniversary Symposium, Nottingham, 30th June, 2005 (invited by Prof. L. Durrant)

Inaugural lecture as Visiting Professor, Nottingham Trent University, 8th June, 2005 (invited by Prof. E. Billett).

Is Immunosenescence Contagious? Seminar at the GBF, Braunschweig, 4th May, 2005 (invited by Dr. E. Wollscheid-Lengeling)

Is Immunosenescence Contagious? Lecture at the Immunology and Alzheimer's conference, Montreal, 17th March, 2005 (invited by Prof. T. Fülöp)

Human immunosenescence: is it contagious? Lecture at the Immunity and Ageing session of the BSI Annual Congress, Harrogate, 10th December, 2004 (invited by Dr. R. Aspinall and Prof. A. Akbar)

The role of CMV in human immunosenescence. Chair's introductory lecture at the 4th European Biogerontology Congress, Newcastle, 8th November, 2004 (invited by Prof. T. Kirkwood)

The tumor milieu as a hostile environment for immune cells. Lecture at the Conference Tumour escape and its determinants, Salzburg, 11th October, 2004 (invited by Prof. K. Zänker)

Age and Immunity. Lectures at the Trudeau Institute Workshop on Immunosenescence, Saranac Lake, 3rd-5th October, 2004 (invited by Dr. S. Swain)

Age and Immunity in Man. Lecture at the Conference The Ageing People, Pavia, 9th September, 2004 (invited by Prof. E. Ferrari)

Tumour Escape from Immunosurveillance. Lecture at the Annual FEBS Conference, Warsaw, 30th June, 2004 (invited by Prof. P. Laidler)

Is Immunosenescence Contagious? Lecture at the 27th Annual Meeting of the Japanese Society for Biogerontology, Tokyo, 17th June, 2004 (invited by Prof. K. Hirokawa)

Brief Biosketch

Graham Pawelec received an MA in Natural Sciences and a PhD in Transplantation Immunology from the University of Cambridge, UK. He is currently Professor of Experimental Immunology at the Center for Medical Research, Second Department of Internal Medicine, University of Tübingen Medical School, Tübingen, Germany. He is a Visiting Professor, Nottingham Trent University, UK and at King's College London, holds an Honorary Chair at Manchester University, UK and a member of the Cancer Solutions Program at the Health Sciences North Research Institute of Canada, Sudbury, ON, Canada. He is Co-Editor-in-Chief of "Cancer Immunology Immunotherapy" and Deputy Editor of the "Journal of Translational Medicine" and "Immunity and Aging". Research interests are currently centered on alterations to immunity, especially T cell-mediated immunity, in ageing and cancer in man, and the influence these have on the outcome of vaccination and immunomodulatory antibody therapies. The impact of polypathogenicity (including multiple infections, cancer, Alzheimer's, diabetes, autoimmunity) as well as stress (psychological, nutritional) on immune signatures reflecting individual immune status is of particular interest in the clinical context.

Contact details:

Graham Pawelec, MA, PhD,
University of Tuebingen Center for Medical Research (ZMF),
Waldhoernlestr. 22,
D-72072 Tuebingen,
Germany.

Tel. +49 7071 298 2805

Fax +49 7071 294677

graham.pawelec@uni-tuebingen.de,

grahampawelec@cantab.net

gpawelec@hsnri.ca

<http://www.tati-group.de/>

<http://de.linkedin.com/pub/graham-pawelec/7/886/b13>

